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Abstract 
 
Cerebral palsy (CP) affects around every one in 500 children born. It isn’t a 
particular illness or disease, but an umbrella term used to describe a physical 
condition that affects movement as a result of injury to the brain. There are several 
types of CP, the main ones being spastic, athetoid and ataxic. Despite medical 
advances, there is no cure for CP but there are ranges of treatments from drugs to 
Botulinum toxin type A injections, massage therapy to surgery. The aim of this 
study is to look at two of these treatments, namely Botulinum toxin type A 
injections and physiotherapy to treat spastic CP. 
Botulinum toxin is widely used to reduce muscle tone in the treatment of spasticity 
in children with cerebral palsy. The aim of the study is to compare the effects 
treatment with Botulinum toxin type A and Botulinum toxin type A with 
additional physical therapy in the management of a group of children with cerebral 
palsy. 
 
Experiments were done at The Prince Sultan Hospital and Al-Hada Armed Forces 
Hospital in Saudi Arabia. The local Ethics Committee approved the protocol. 47 
children were recruited. All had cerebral palsy, diplegia, spasticity of the ankle 
planter flexors and significant gait abnormalities due to dynamic equinus foot 
deformity. They were divided into two groups. Both groups had their Gross Motor 
Function assessed one week before injection and at 4 and 6 weeks after injection. 
Additional measurements of range of movement and stiffness at the ankle and 
soleus electromyograms were recorded 
The soleus EMG was silent during ankle dorsiflexion in 20 children four weeks 
after injection of Botox. The EMG had returned six weeks after injection in every 
child. The Gross Motor Function Measurements were not significantly different in 
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the two groups before the injection (p=0.23). The measurements improved 
significantly over the next six weeks in both groups (p<0.001). The magnitude of 
the improvement was greater in the group, which received Botulinum toxin type A 
and physical therapy (means 57.2 + 8.90 before, 64.9 + 9.78 after. Mean + SD) 
than in the group which received Botulinum toxin type A alone (59.5 + 11.0 
before, 62.4 + 11.3 after Mean + SD). 
 
Conclusions 
 
1. . The Treatment allocation provided groups, which were comparable pre-
treatment in terms of baseline GMFM. 
 
2. . Both treatments showed evidence of improvement in GMFM over the 
period of the study and particularly at 52 weeks. 
 
3. . Treatment 2 showed a significant average advantage in GMFM over 
Treatment 1 at all times in the study. 
 
4. . This advantage in average GMFM increased from 4 through to 52 weeks 
with a clear and significant difference between 4 and 52 weeks. 
 
5. . This average advantage appeared to increase the higher the child’s 
baseline GMFM. 
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Chapter 1 
Introduction 
 
1. Introduction and Rationale 
Cerebral Palsy is and will remain a significant problem.  In developed 
countries, cerebral palsy is the most common cause of physical disability in 
childhood. Its incidence is about 2 to 2.5 per 1000 live births (Pharoah, 
Cooke, Johnson, King and Mutch, 1998). One of the most disabling aspects 
of cerebral palsy is the development of spastic hypertonia. Estimates suggest 
the incidence of spastic hypertonia is as high as 60% in those who suffer 
from cerebral palsy (Levitt, 1995). There are many ways of classifying 
cerebral palsy. The simplest is according to distribution and number of 
affected limbs. Spastic diplegia is the most common type of juvenile 
cerebral palsy; hemiplegia and quadriplegia are less common (Levitt, 1995). 
Neuromuscular deficits found in cases of cerebral palsy include: a loss of 
selective motor control, abnormal muscle tone leading to an imbalance 
between agonist and antagonists muscles, impaired coordination, sensory 
deficits and weakness.  The ability to maintain postural control is critical for 
the activities of daily life. Control of posture and balance is automatic in 
healthy subjects; it is often a challenging goal for children with cerebral 
palsy. 
Researchers have shown that children with cerebral palsy have a reduced 
ability to adapt their postural control to changing task and environment 
demands (Butler, 1998). These postural impairments affect the ability to 
respond to challenges to balance efficiently and effectively. There are four 
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principal contributing factors: these include velocity dependent increases in 
tonic stretch reflexes, muscle weakness, excessive co activation of 
antagonist muscles and increased stiffness around joints (Gage, 1991). 
The increased muscle tone in cerebral palsy not only produces dynamic 
deformities with a risk of subsequent fixation, but also leads to relative 
failure of longitudinal muscle growth. In the long term, this may result in 
increased disability. An example of this is the equinus foot position 
secondary to spasticity in young children.  Eighty per cent of these children 
have problems with walking as a result of lower limb spasticity, which can 
lead to severe contractures and limb deformity (Gage, 1991).  Calf muscle 
spasticity is one major factor that can interfere with normal walking by 
preventing heel strike.  
A common goal of treatment of children who have cerebral palsy is to 
increase the functional capacity and relieve discomfort.  The approach to 
treating spasticity is usually multi-modal.  Physical therapy is a component 
of anti-spasticity regimens. It is usually combined with surgical 
interventions and pharmaceutical treatments.  It is open to debate which of 
these is most effective either alone or in combination. This study will 
examine the effectiveness of combining physical therapy with botulinum 
toxin A in the treatment of spasticity 
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1.1. Characteristics of Cerebral Palsy 
Cerebral palsy is a disorder of movement and posture caused by a non-
progressive abnormality of the immature brain. The brain damage that 
causes cerebral palsy also may produce a number of other disabilities 
(Kurtz, 1992). It is a commonly used name for a group of conditions 
characterized by motor dysfunction due to brain damage early in life. It is 
due to abnormal development of the brain, anoxia, intra-cranial bleeding, 
trauma and infection (Levitt, 1995).  Although the brain continues to grow 
into early adulthood, the crucial events of its development occur during 
intrauterine life and early childhood (Kurtz, 1992). The key stages in brain 
development are illustrated in figure 1.1 
 
 
Figure 1.1  
Brain development during gestation and early postnatal life. Injuries between 15–22 weeks 
gestation result in neuronal migration defects. After about 22 weeks gestation, the 
oligodendrocytes are vulnerable to injury and white matter wasting periventricular 
leucomalacia with associated expansion of the lateral ventricles is the dominant clinical 
pattern. Adapted from Lin, 2003. 
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A recent consensus definition of cerebral palsy is: “an umbrella term 
covering a group of non-progressive, but often changing, motor impairment 
syndromes secondary to lesions or anomalies of the brain arising in the early 
stages of its development (Mutch, Alberman and Hagberg, 1992). This 
definition will be used throughout this thesis.  
In some cases the cause of the brain damage is known, but in many others it 
is not.  However varied the aetiological factors may be the resulting 
abnormality of the central nervous system is not progressive. The clinical 
features appear to progress but this apparent progression is due to the effects 
of the child’s development (Davis and Barnes, 2000). 
1.2. The prevalence of cerebral palsy 
Worldwide, the prevalence of cerebral palsy is reported to be between 2 – 
2.5 per 1000 live births according to many studies (Kuban and Levition, 
1994, SCPE, 2002). The incidence of cerebral palsy in United Kingdom is 
2.4 per 1000 (SCPE, 2002). It varies between 1.5 and 1.8 per 1000 in the 
USA (UCP, 2002). It is 1 per 1000 in France and 1.7 per 1000 in Sweden. 
The literature available on CNS diseases of children in Saudi Arabia is 
limited to papers by Al-Naquib (1988), Al-Asmari, Al Moutaery, Akhdar 
and Al Jadid (2006). A population survey on the prevalence of child 
disability in Saudi Arabia found the rate to be 1.2 per 1000 and this accounts 
for 0.04% of the total population (Ansari, Sheikh, Akhdar and Moutaery, 
2001). 
Pharoah et al (1998) reported on the epidemiology of cerebral palsy in 
England and Scotland. They found 1649 cases of cerebral palsy in 789,411 
live births, a cerebral palsy prevalence of 2.1 per 1000 neonatal survivors. 
All cases of cerebral palsy born between 1984 and 1989, to mothers resident 
in the area, were included. 
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1.3. Aetiology 
 
50% of children with cerebral palsy are born prematurely. Premature babies 
have a higher risk in part because their organs are not yet fully developed. 
This increases the risk of cerebral palsy. The occurrence of cerebral palsy is 
much more common in premature infants with a birth weight below 1.5 
kilograms. Twins and small for gestational age infants also have a higher 
than normal risk of cerebral palsy (Hagberg, Hagberg and Olow, 1982). 
The aetiologies of cerebral palsy are varied and can occur either pre-natally 
or post-natally (Koman, Mooney, Smith, Goodman and Mulvaney, 1993). 
The causes of cerebral palsy during the first trimester of pregnancy include 
developmental brain abnormalities, intrauterine infections, exposure to 
radiation, exposure to drugs, and chromosomal abnormalities. In later 
pregnancy, placenta abruption and other abnormalities in the fetal-placental 
unit place the child at risk. Later still, complications during labour and 
delivery also are risk factors. In early childhood neonatal illness such as 
meningitis, head trauma, and poisonings become important causes (Paneth, 
1986). 
The most common causes of cerebral palsy are listed in table 1.1. (Kurtz, 
1992). 
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Causes of cerebral palsy 
Labour and delivery  Pre-eclampsia 
Complications of labour and delivery 
Prenatal  
1st trimester: 
 
Genetic syndromes  
Chromosomal abnormalities e.g. Down’s 
Syndrome 
Brain malformations 
2nd-3rd trimester: 
 
Intrauterine infections 
Problems in fetal/placental functioning  
Perinatal: Sepsis/central nervous system infection  
Asphyxia 
Prematurity 
Childhood 
 
 
Meningitis 
Traumatic brain injury 
Toxins 
Table 1.1.  
The most common causes of cerebral palsy adapted from Hagberg and Hagberg 
(1984). 
 
1.4. Classification 
Many classification system of cerebral palsy exist. A simplified three-group 
model: Pyramidal, Extrapyramidal and Mixed Type was suggested by 
(Kurtz, 1992).  
1.4.1. Pyramidal. 
Children with the pyramidal form of cerebral palsy have experienced 
damage to their motor cortex or to the pyramidal tract. Damage to any part 
of this pathway leads to spasticity (Kurtz, 1992). 
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1.4.2. Extrapyramidal.  
In this type, the damage occurs to the pathways outside the pyramidal tract.  
These extra-pyramidal tracts pass through the basal ganglia or emanate from 
the cerebellum.  The most common type of extrapyramidal cerebral palsy is 
called athetoid cerebral palsy.  The clearest clinical sign of extrapyramidal 
cerebral palsy is variable resistance to imposed movement. The limb 
initially appears rigid but this disappears with pressure. Muscle tone may 
vary from one time to another (Denhoff & Robinault, 1960). 
1.4.3. Mixed-type cerebral palsy:  
The mixed-type of cerebral palsy includes elements of both the pyramidal 
and extrapyramidal forms. The most common types of mixed cerebral palsy 
are athetoid and spastic hemiplegic and athetoid and spastic-diplegic (Whyte 
and Glenn, 1990). 
 
1.5. Topographical classifications 
In addition, topographical classifications are frequently used.  
Quadriplegia indicates involvement of the four limbs. It has the worst 
prognosis. The patients are much more likely to suffer from mental 
retardation and to be affected by seizures. They commonly suffer from 
visual or auditory deficits (Eiben and Crocker, 1983). 
Triplegia involves three limbs.  
   
Abeer Felmban 2008  8 
Diplegia involves all four limbs but the legs are more affected than the arms. 
Diplegic patients resemble quadriplegic patients but the important difference 
is that diplegic children can walk with assistance (Levitt, 1995).  
Paraplegia: involves both legs but the arms are unaffected. 
Hemiplegia: involves one side of the body. In general, the arm is more 
severely involved than the leg. 
Monoplegia: Affects one limb.  
This classification is illustrated in Figure 1.2. 
 
1.6. Dyskinetic Cerebral Palsy 
Dyskinetic cerebral palsy is characterized by abnormalities in muscle tone 
that involve the whole body.  Usually the patterns of muscle tone change 
from hour to hour and day to day.  These children will often exhibit normal 
muscle tone or decreased tone while asleep and rigid tone while awake 
(Levitt, 1995). 
 
1.7. Ataxic Cerebral Palsy 
Ataxic Cerebral Palsy is characterized by a lack of coordination and balance 
due to damage to the cerebellum (Whyte and Glenn, 1990). Its main motor 
characteristics are: poor fixation of the head, trunk, shoulder and pelvic 
girdles, disturbances of balance (Levitt, 1995). 
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                                      Spastic                    Dyskinetic                            Ataxic 
       Diplegia        Hemiplegia            Quadriplegia        Athetoid          Dystonic       Ataxic 
                                          Pyramidal                                                    Extrapyramidal 
 
Figure 1.2. 
Different regions of the brain are affected in various forms of cerebral palsy.  The darker the 
shading, the more severe the involvement. (Adapted from Children with disabilities.  By Mark 
L.  Batshaw, M.D.1992) 
 
1.9. Spasticity  
Spasticity in patients can arise from a multitude of lesions that may include 
the sensorimotor cortical areas and their descending tracts, motor centres in 
the brainstem and their descending pathways, and finally the spinal cord 
itself.  The severity of spasticity, its distribution and the magnitude and type 
of reflex responses depend heavily on the precise localization and 
combination of lesions as well as on the time since the lesion developed. In 
the large majority of cases, spasticity develops gradually within months 
after a lesion; less frequently, muscular hypertonia is present immediately as 
in the human cases of deceleration (Walshe, 1923).  
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Spasticity has been defined as a motor disorder characterized by a velocity-
dependent increase in tonic-stretch reflexes with exaggerated tendon 
reflexes. This results from hyperexcitability of the stretch reflex and is one 
component of the upper motor neuron syndrome (Lance, 1980).  
Electromyography has been used successfully to give objective and 
quantitative assessment of reflex excitability and to study the efficacy of 
drugs used to reduce spasticity (Delwaide et al., 1985), (Basmajian, 1974). 
Spasticity can lead to significant physical problems including spasms, 
restricted range of movement, pain and contractures, as well as functional 
difficulties including the maintenance of personal hygiene (Davis and 
Barnes, 2000). 
Clinicians tend to concentrate on positive features of the upper motor 
neurone syndrome like spasticity, clonus, hyper-reflexia and co-contraction. 
However, negative features such as weakness, loss of selective motor 
control and sensory impairment can cause more disability (Graham, Aoki, 
Autti-Rämö, Boyd, Delgado, Gaebler-Spira, Gormley, Guyer, Heinen, 
Holton, Matthews, Molenaers, Motta, Garcia Ruiz and Wissel, 2000). Flett 
concurs with this view, suggesting that eliminating spasticity enables the 
cerebral palsy child to utilise their selective motor control more effectively 
and functionally (Flett, 2003). 
In 2004 Lieber et al acknowledged that the basic mechanisms underlying the 
functional deficits that occur after the development of spasticity are not well 
understood and that with a few notable exceptions, the properties of skeletal 
muscle have largely been ignored.  However it is becoming increasingly 
clear that there are dramatic changes within skeletal muscle as well as in the 
nervous system.  Although our current understanding of spasticity is 
incomplete, it is now acknowledged that spasticity has both 
neurophysiological and musculoskeletal components (Lieber, Steinman, 
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Barash and Chambers, 2004). They suggest that this is why therapeutic 
interventions involving stretching, casting, splinting, neurectomy, 
intrathecal baclofen, botulinum toxin A and electrical stimulation have 
proved to be only partially effective.  
Even less clear are the mechanisms, which lead to a slowly developing 
spasticity.  In view of the heterogeneity of the ‘spastic’ condition in man, it 
is not surprising to note that there is no unique model, which would satisfy 
all clinical signs and symptoms. The problem of late changes typically 
found in patients with human spasticity is a key issue in future studies of 
spasticity.  
After Botulinum toxin-A injection the nerve sprouting and muscle re-
innervations lead to functional recovery within 2 to 4 months (Rosales, 
1996). There is evidence that partially functional neuromuscular junctions 
are re-established within 4 weeks (Angaut-Petit, Molgo, Comella, Faille and 
Tabit, 1990).  The periods of clinically useful muscle relaxation is usually 
12-16 weeks (Graham et al, 2000, Duchen and Strich, 1968). The nature and 
the precise role of the mechanisms which have been discussed in previous 
studies sprouting and hypersensitivity of denervate structures – are still 
poorly understood (Wiesendanger, 1985). 
Spasticity has been defined as follows: “spasticity is a motor characterized 
by a velocity-dependent increase in tonic stretch reflexes (muscle tone) with 
exaggerated tendon jerks, resulting from hyperexcitability of the stretch 
reflex, as one component of the upper motor neuron syndrome” (Lance, 
1981). In the clinical diagnosis of spastic syndromes, reflexes evoked from 
the skin play an important role.  One of them, the sign of Babinski, is 
undoubtedly the most reliable and sensitive indicator of a descending tract 
lesion.  Surprisingly enough, the significance of such a first rank sign for the 
pathophysiology of spasticity is still obscure: probably most neurologists 
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understand spasticity as a state of exaggerated stretch reflex (Meinck, et 
al.1985). 
1.9.1 Spastic Diplegia  
This study will focus on spastic diplegia.  Severe spasticity can interfere 
with a child's normal functioning, motor and speech development, and 
comfort. Spasticity can be painful, especially if joints are pulled into 
abnormal positions or if range of motion is limited (Whyte and Glenn, 
1990). 
It primarily affects the legs, although there may be considerable asymmetry 
between the two sides.  The tension in the spastic muscles during 
development often leads to bony deformities. The most significant problem 
in spastic diplegia is a lack of stability in standing and walking. Even after 
surgical treatments to correct the muscle imbalances, children with this 
condition need walking aids to correct deficiencies in balance. 
1.9.2. Mechanical Changes in Spastic Muscle 
There is no clear consensus regarding whether muscle cells from patients 
with spasticity have normal properties.  This lack of consensus is due to the 
paucity of objective data regarding the mechanical, physiological or 
biochemical properties of spastic muscle (Frieden and Lieber, 2003).  
Foran, Steinman, Barash, Chambers and Lieber (2005) assert that ‘spastic’ 
muscles are altered in a way that is unique among muscle plasticity models 
and inconsistent with simple transformation due to chronic stimulation or 
use. 
They make the case for the following alterations in spastic muscle: 
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Figure 1.3  
Comparison spastic muscle and control –altered proportions of muscle fibre type 
 
Skeletal muscle stained with ATPase, pH 9.4.  Type 2 fibres are dark.  (a) Biopsy of the peroneus 
brevis muscle (x50) from a 7-year-old control subject.  (b) Biopsy of the lateral gastroenemius 
muscle (x50) from a 5-year-old subject with cerebral palsy.  Adapted from Rose J, 1994  
b a 
1) Altered muscle fibre size and fibre type. 
2) Proliferation of extra-cellular matrix. 
3) Increased spastic muscle cell stiffness, and to a lesser extent spastic 
muscle tissue. 
4) Inferior mechanical properties of extra-cellular material, compared to 
normal muscle 
Examples of these changes are shown in figure 1.3. the figure on the left 
(a) shows normal muscle fibers for a child, it shows light stained type 
fibers, tightly packed fibers .  
 
 
These authors suggest that collagen may be involved in increases in the 
muscle stiffness observed in spasticity and that its accumulation contributes 
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either directly or indirectly to the development of contractures and 
secondary bony abnormalities thus playing a major role in mobility 
problems observed in cerebral palsy.   
Other studies have shown that although spastic muscle contains a larger 
amount of extracellular matrix within it, the mechanical strength of that 
material is poor compared with that of normal muscle (Lieber et al, 2004).  
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1.9.3. Spastic muscle Response to Stretch 
More recently it has been shown that only part of the resistance of spastic 
muscles to stretching can be attributed to increase a reflex contraction; much 
is due to the intrinsic stiffness of the muscle itself.  This resistance has three 
components: passive muscle stiffness, neurally mediated reflex stiffness, 
and active muscle stiffness.  Of these, increased passive mechanical stiffness 
accounts for nearly all of the increase in limb stiffness (Lieber et al, 2004). 
 
1.10. The methods of measurement of spasticity 
A number of assessment scales are used to assist the diagnosis of spasticity 
and to measure its severity. The scales measure the resistance to passive 
muscle stretch or the joint range of motion. These clinical rating scales all 
suffer from a subjective component of the assessment of spasticity. There is 
no absolute standard of measurement.  
1.10.1. The Ashworth Scale  
The original Ashworth scale and it is modified version (Bohanon and Smith, 
1987) both attempt to measure the severity of muscle hypertonia using 
clinical assessment scales. The modified Ashworth scale has 6 grades: see 
table 1.2. 
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Grade 0 = no increase in muscle tone. 
Grade 1 = slight increase in muscle tone, manifested by a catch and release or by minimal 
resistance at the end range of motion (ROM) when the affected part is moved in flexion or 
extension/abduction or adduction. 
Grade 1+ = slight increase in muscle tone, manifested by a catch, followed by minimal 
resistance throughout the reminder (less than half) range of motion (ROM)  
Grade 2=more marked increase in muscle tone through must of ROM, but affected part 
easily flexed  
Grade 3=considerable increase in muscle tone, passive movement is difficult. 
Grade 4=affected part rigid in flexion and extension, abduction or adduction. 
Table 1.2.  
The modified Ashworth scale (Bohanon & Smith, 1987) 
 
1.10.2. Pendulum test  
The pendulum test is a biomechanical method of evaluating muscle tone by 
using gravity to provoke muscle stretch reflexes during passive swinging of 
the lower limb (Fowler, Nwigwe and Wong, 2000). The oscillations of the 
knee are affected by spasticity of the quadriceps and hamstring muscles and 
this effect can be seen with the naked eye (Graham, 2000). The pendulum 
test was described almost 50 years ago but has not been assessed as a 
clinical tool in children who have spastic CP. 
1.10.3. Spasm score  
Spasm score is a simple scale for recording the frequency of muscle spasms 
(Middel, Kuipers-Upmeijer, Bouma, Staal, Oenema, Postma, Terpstra and 
Stewart, 1997). See table 1.3. 
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The Spasm Scale 
0 = no spasms. 
1 = mild spasms induced by stimulation. 
2 = infrequent spasms occurring less than once per hour. 
3 = spasms occurring more than once per hour 
4 = spasms occurring more than 10 times per hour. 
 
Table 1.3. 
Spasm scale Evaluates the frequency of spasms with scores listed (Berrie Middel 1997) 
 
1.10.4. The modified Tardieu scale 
The Tardieu scale is a recent introduction to clinical practice (Boyed, 
Barwood, Baillieu and Graham, 1998). It assesses the range of motion of the 
ankle and knee: The dynamic component, R1 or angle of the overactive 
stretch reflex is defined at Tardieu velocity of stretch V3 and the slow 
PROM or degree of muscle contracture R2 is graded as the angle at V1. The 
score is recorded as R1/R2. Boyd found that a large difference between the 
two measures characterises a large dynamic component, which is likely to 
respond to BTX-A injections, whereas a small difference between R2 minus 
R1 means that there is predominantly fixed muscle contracture present. It 
does not seem to have been adopted widely. 
1.10.5. Goniometry 
Spasticity decreases the range of motion at joints.  In more recent studies 
electrogoniometers make continuous measurements of the angle of a joint.  
The output of an electrogoniometer is usually plotted as a chart of joint 
angle against time (Whittle, 1996).  
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1.10.6. Neurophysiological Investigations 
Electromyography (EMG) is the measurement of the electrical activity of a 
contracting muscle- the muscle action potential. One of the most useful 
textbooks on EMG is that by Basmajian (1974) Electromyography is 
sometimes used to distinguish muscle spasticity from a fixed contracture. 
1.10.7. Gross Motor Function Measurement (GMFM) 
The GMFM is commonly used to establish a baseline gross motor level and 
to detect change after interventions (Russell, Rosenbaum, Cadman, 
Gowland, Hardy and Jarvis, (1989), Leach, (1997), Yang, Chan, Chuang, 
Liu and Chiu, (1999), Russell, Avery, Rosenbaum, Raina, Walter and 
Palisano, (2000), Ubhi, Bhakata, Ives, Allgar and Roussounis, (2000), 
Linder, Schindler, Michaelis, Stein, Kirschner, Mall, Berweck, 
Korinthenberg and Heinen, (2001), Russell, Rosenbaum, Avery and Lane, 
(2002). It is a standardised observational instrument designed and validated 
to measure the change in gross motor function over time in children with 
cerebral palsy.  The scoring key gives a general guideline. However, most of 
the items have specific descriptors for each score. 
Scoring is based on a four- point scale for each item using the following 
key:  
0 = does not initiate  
1 = initiates  
2 = partially completes  
3 = completes  
NT = not tested 
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“Does not initiate” is applied when the child is unable to begin any part of 
the activity. “Initiates” is applied when less than 10% of the task is 
completed. “Completes,” is applied when the task is completed fully. “Not 
tested” is used when an item has not been administrated or when a child 
refused to attempt it. 
The test includes 88 items grouped in five dimensions: (A) Lying and 
Rolling; (B) Sitting; (C) Crawling and Kneeling; (D) Standing; (E) Walking, 
Running, and Jumping.  Each item of the test is scored on a 4-point scale 
and percentage score is calculated for each dimension.  The total score is 
obtained by calculating the mean of the five dimension scores.  The total 
GMFM score and dimension scores collected at each evaluation was used in 
the analysis.  See appendix number 4  
The GMFM is used ever more frequently as an outcome measure to 
investigate functional benefit of various treatment regimes (Russell et al, 
(1989) Leach, (1997) Yang et al, (1999) Flett, Stern, Waddy, Connell, 
Seeger and Gibson, (1999) Russell et al, (2000) Ubhi et al, (2000) Boyd, 
Dobson, Parrott, Love, Oates, Larson, Burchall, Chondros, Carlin, Nattrass 
and Graham, (2001) Linder et al, (2001) Russell et al, (2002) Reddihough, 
King, Coleman, Fosang, McCoy, Thomason and Graham, (2002) Bottos, 
Azienda, Benedetti, Salucci, Gasparroni and Giannini, (2003) Mall, Heimen, 
Siebel, Bertram and Hafkemeyer, (2006)). 
In this study I used goniometry, electromyography and GMFM but not the 
pendulum test or Ashworth scale because both spasticity and fixed 
contractures dampen the limb swing and the pendulum test, like the 
Modified Ashworth scale does not distinguish between reversible muscle 
spasticity and fixed contractures. (Bakheit, Pittock, Moore, Wurker, Otto, 
Erbguth and Coxon, 2001) The Modified Ashworth scale has a good 
reliability when used to measure upper limb spasticity but it is less reliable 
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when used for the measurement of spasticity in the lower limb (Sloan, 
Sinclair, Thompson, Taylor and Pentland, 1992). 
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Literature Review 
 
 
1.11. The management of spasticity by Physical Therapy 
Physical therapy may help children with cerebral palsy to learn better ways 
to move and maintain their balance. It may help children learn to walk, use 
their wheelchair, stand by themselves, or go up and down stairs safely. 
Children may also work on skills like running, kicking and throwing a ball 
or learning to ride a bike (Jones, 1987). Appropriate muscle tone is 
necessary to increase mobilization, prevent postural abnormalities, provide 
independence in daily living activities and accelerate walking speed. 
Various methods including neurodevelopmental therapy, physical exercise, 
electrical stimulation, orthoses and splints, biofeedback and cold 
applications, are used for the management of spasticity. Physical therapy 
includes daily stretching exercises to maintain the full range of motion for 
the affected muscles. In mild spasticity, this may be the only treatment 
needed, while in severe spasticity, it is a part of the full therapy plan (Cherry 
(1980), Kluzik, Fetters and Coryell (1990), Whyte and Glenn (1990), 
Girolomi and Champell (1994), Barry (1996), Levitt, (1995)). 
See appendix 1 for more details about Physical Therapy. 
1.11.1. Neurodevelopmental Therapy 
Neurodevelopmental Therapy (NDT) is based on the principles of 
normalization of postural tone, inhibition of abnormal reflexes, and the 
facilitation of appropriate developmental reflexes, equilibrium responses, 
and postural reactions (Bly, (1991), Bobath and Bobath, (1984)).  The aim 
of treatment is to improve corrective and balance reactions and muscle tone, 
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to decrease excessive muscle tone and to improve posture (Bobath, (1980) 
Perin, (1989) Valvono and Long, (1991) Leach, (1997)). 
1.11.2. Therapeutic Exercises 
Resistive exercises and both passive and active stretching, can be used with 
children with cerebral palsy after Botulinum toxin type A injections. The 
goals of these exercises include maintaining or regaining the range of 
motion in order to prevent contractures and maximize functions and enhance 
motor skills. Joint and soft tissue mobilization can be effective additional 
measures to enhance mobility once the spasticity is decreased by Botulinum 
toxin type A (Cherry (1980), Humphrey (1985), Harris and Lundgren 
(1991), Leach, (1997), Levitt, (1995)). 
1.11.3. Use of splints, plaster casts, and orthoses 
The use of casts has become increasingly popular as an adjunct to more 
traditional methods of managing spasticity (Smith and Harris (1985), 
Hanson and Jones (1989)). 
Physiotherapy combined with the use of splints and plaster casts can prevent 
the development of fixed contractures. These treatments may preserve the 
optimal length of muscle and the range of motion. They may improve gait 
and weight bearing and also improve functional hand use (Bertoti, (1986), 
Smelt (1989), Yasukawa, (1990)). The application of plaster casts is an 
effective treatment method in the short-term management of spasticity and 
is especially valuable when it is started early before the onset of contractures 
(Nuzzo (1980), Bakheit, (2001)).  The main disadvantage of plaster casts is 
that they limit the functional use of the limb and the immobilisation may 
cause disuse muscle atrophy (Bakheit, 2001). Orthotic intervention in 
ambulatory children with spastic cerebral palsy is intended to prevent 
deformity, achieve a stable base, improve dynamic efficiency of gait and aid 
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achievement of motor function (Buckon, Thomas, Huston, Moor, Sussman 
and Aiona, 2001).  Orthoses are designed to provide joint stability, to hold a 
joint in a functional position and to keep tight the stretched muscles (Flett, 
2003). 
Ankle foot orthoses (AFOs) are commonly prescribed for children with 
cerebral palsy to improve their walking abilities and to prevent the 
development of deforming contractures.  They also allow for greater ease in 
performing tasks like stair climbing and rising from the floor (Rethlefsen, 
Dennis, Forstein, Reynolds, Tolo and Antonelli, 1995).  Dorsiflexion will 
allow stretching of the Achilles tendon, which may result in reduced 
spasticity of the triceps surae muscle (Middleton, Hurley and Mcllwain, 
1988). 
1.11.4. Cryotherapy 
The effect of the cryotherapy is usually modest lasting one hour, because of 
this cryotherapy has limited clinical value in the management of spasticity.  
The immersion of the spastic limb into cold water (t=7ºC) or the application 
of ice packs onto the muscle for 20 to 30 minutes usually results in 
noticeable reduction in the muscle tone (Bakheit, (2001), Kathleen, (1997)  
1.11.5. Electrical Stimulation  
Electrical Stimulation of the neural structures has been shown to reduce tone 
in spastic muscles.  Clinical improvement in spasticity and reduction in 
painful muscle spasms may occur following spinal cord stimulation, 
transcutaneous electrical nerve stimulation and cerebellar stimulation.  
However, this form of treatment is not widely used (Seib, Price, Reyes and 
Lenhmanan, 1994).  The effect of electrical stimulation is usually transient. 
In some patients the beneficial effect may last six hours or more (Bakheit et 
al, 2001, Leach, 1997). 
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1.11.6. Neurosurgical treatment of spasticity 
A number of neurosurgical procedures have been used to treat cerebral 
palsy. These include implantation of cerebellar or dorsal column stimulators 
and performing of dorsal rhizotomies (Park & Owen, 1992).  In children 
who have adductor contractures, the use of selective anterior branch 
obturator neurotomies may be beneficial. Stereotactic surgery is also used 
but has limited success (Henry, 1997). Spellman and Van Manen reviewed 
28 patients with cerebral palsy, with a mean of 21 year’s postoperative 
follow-up. They found good results in patients with moderate to severe 
dyskinetic cerebral palsy but poor results in those patients with quadriplegia 
or diplegia with spasticity (Henry, 1997). 
Selective posterior rhizotomy is a relatively new neurosurgical procedure 
designed to reduce spasticity in cerebral palsy children (Berman, Vaughan 
and Peacock, 1990) Contraindications include muscle weakness especially 
postural muscle (Henry, 1997). 
1.11.7. Orthopaedic surgery 
Most of the surgery performed on patients with spasticity takes place at the 
muscles or the tendons.  Orthopaedic surgeons can lengthen, release or 
transfer a contracted or spastic muscle (Henry, 1997). Common surgical 
procedures for the correction of equinus deformity in cerebral palsy have 
included gastrocnemius lengthening and achilles tendon lengthening.  It is 
not clear which of these methods is more effective for increasing the 
excursion of the ankle joint (Etnyre, Chambers, Scarborough and Cain, 
1993). 
A previous study compared the effects of different methods of surgical 
correction of equinus gait in children with spastic cerebral palsy. This study 
showed that surgical intervention resulted in significant improvement of 
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velocity, cycle time, and stride length (Etnyre et al, 1993) Overall, the aims 
of surgery are to reduce established deformity, improve cosmesis, improve 
gait pattern and reduce the energy cost of walking (Flett, 2003). 
1.11.8. Drug therapy 
Neuromuscular blockade can be used to interrupt the function of the nerve, 
the neuromuscular junction, or the muscle.  This blockade may be achieved 
by chemical alteration of peripheral muscle activity, thus weakening the 
treated muscles by selective paralysis, denaturing of muscle fibres, or partial 
denervation (Koman, James, Mooney and Beth, 1996). 
Neuromuscular blockade balances agonist-antagonist forces by diminishing 
stretch reflexes through neural destruction and blocking of nerve transmition 
with 4% to 6% phenol, alcohol or local aenesthetic. 
1.11.9. Alcohol 
Ethyl alcohol nonselectively denatures protein and disrupts myoneural 
junctions. It causes retrograde Wallerian degeneration of peripheral nerves. 
It is used for peripheral nerve blocks and intrathecal blocks (Koman et al, 
1996). 
1.11.10. Phenol 
Like alcohol, phenol denatures the protein in the injected area (Koman et al, 
1996). Destructive treatments using phenol nerve blocks are inappropriate in 
the management of children who have a maturing nervous system (Ubhi et 
al, 2000). Complications after phenol usage include skin and muscle 
necrosis and muscle atrophy, paraesthesias, wound infection, and 
commonly, post-injection pain. 
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1.11.11. Local anesthetic agents 
Local anesthetics block both afferent and efferent axons. The onset of action 
is within minutes and duration of action varies between one and several 
hours. A short-acting anesthetic can also serve as preparation to casting or 
as an analgesic for intramuscular injections of other antispastic treatment. 
Unfortunately, such medications have limited usefulness in improving 
muscle tone in children with cerebral palsy. 
1.11.12. Baclofen 
Baclofen, an agonist of γ-aminobutric acid-β receptors (GABA), is effective 
in the treatment of spasticity and is currently the most widely used 
antispasmodic drug (Ordia, Fischer, Adamski and Spatz, 1996). Baclofen 
can be administered orally or intrathecally. It is better known for its efficacy 
in reducing spasticity in adult subjects. It is most effective for treating 
spasticity of spinal rather than central cerebral origin (Flett, 2003). The main 
adverse effects of baclofen are neuropsychiatric and include respiratory 
depression, excessive sedation, fatigue, dizziness, convulsions, mental 
confusion, and hallucinations (Katz, 1988). 
1.11.13. Diazepam 
Diazepam is the most commonly used benzodiazepine in the treatment of 
spasticity.  In clinical practice, diazepam is frequently used as an adjunct to 
baclofen in treating spasticity and is less commonly used on its own. 
Adverse effects of its use include sedation and cognitive impairment. In 
addition, there is the potential for dependence to develop.  A withdrawal 
syndrome is associated with the benzodiazepines and abrupt cessation of 
diazepam has been associated with seizures (Kita and Goodkin, 2000). 
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1.11.14. Tizanidine 
Tizanidine is an imidazole derivative and is a centrally acting α2-adrenergic 
agonist that inhibits the release of excitatory amino acids in spinal 
interneurones. Tizanidine has potent muscle relaxing properties in animal 
models of spasticity and it suppresses polysynaptic reflexes in the spinal cat. 
In placebo controlled trials, tizanidine has been shown to reduce muscle 
tone and frequency of muscle spasms in both patients with muscle spasm 
and spinal cord injury.  Although tizanidine was found to reduce spasticity 
without altering muscle strength, it has shown no consistent positive effect 
on functional measures (Coward (1981), Kita and Goodkin, (2000)). 
1.11.15. Dantrolene 
In contrast to baclofen and diazepam, dantrolene acts directly on muscle and 
reduces tone by inhibiting the release of calcium from the sarcoplasmic 
reticulum (Whyte and Robinson, 1990). Placebo controlled trials of 
dantrolene show effective reductions of muscle tone and hyper-reflexia.  
Spasticity was slightly better controlled with dantrolene than with diazepam.  
Because its site of action is peripheral, the most common adverse effect of 
dantrolene is muscle weakness.  For this reason, dantrolene may be most 
appropriate for those patients who are non-ambulatory with severe 
spasticity. Other adverse effects include drowsiness, diarrhoea and malaise 
(Kita and Goodkin, 2000). 
1.11.16. Gabapentin 
Gabapentin was first introduced in 1994 as a new treatment option for 
patients with partial seizures. It is structurally similar to GABA. It is easily 
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absorbed, reaching peak plasma concentrations in 2 to 3 hours. It is not 
protein bound.  It does not undergo metabolic degradation, and is excreted 
unchanged in the urine.  It is well tolerated in dosages up to 3600 mg/day. 
Recent studies and reports have suggested it might be effective as another 
tool in treating spasticity but further studies will be necessary to confirm 
efficacy (Dunevsky and Pere, 1998). 
1.11.17. Botulinum Toxin-A in the treatment of cerebral palsy. 
The toxin is produced by Clostridium botulinum and its ingestion can 
produce botulism, a rare and often fatal paralytic illness. Injection of 
Botulinum toxin type A into muscle causes chemical denervation and focal 
paralysis (Flett, 2003). Botulinum toxin type A is easy to administer. It 
diffuses readily into the muscle. It should be painless and it can be given 
without anaesthesia (Bakheit, 2001). The main indication for Botulinum 
toxin type A use is abnormally increased dynamic muscle tone.  The action 
of Botulinum toxin type A is known to be relatively long lasting and when 
used in conjunction with other conservative non-surgical treatment, it can be 
used for years without necessarily losing efficacy (Flett, 2003). 
The clinical effects of botulinum toxin have been recognised since the end 
of the 19th century (Davis and Barnes, 2000). Botulinum toxin type A has 
many clinical uses varying from cosmetic to clear clinical applications. 
Scott et al first used Botulinum toxin type A in 1973 as therapeutic 
treatment for the correction of strabismus. It has been used in many other 
conditions including improve upper extremity function (Wall, Chait, 
Temlett, Perkins, Hillen and Becker, (1993); Bakheit.et al, (2001)). 
Botulinum toxin type A has been used to reduce the spasticity by blocking 
neuromuscular transmission.  The net effect of neuromuscular blockade is 
complete or partial paralysis of the target muscle(s) while leaving antagonist 
   
Abeer Felmban 2008  29 
muscle(s) unaffected (Koman et al, 1996). The first clinical trials of 
Botulinum toxin type A in patient with cerebral palsy was carried out in 
1987 in the United States (Koman, Mooney, Smith, Goodman and 
Mulvaney, 1993). Since then many groups have investigated if Botulinum 
toxin type A treatment can be used in cerebral palsy try to improve walking 
(Koman, Smith, Tingey, Mooney, Slone and Naughton (1999), Ubhi et al, 
(2000), Koman et al, (1993), Cosgrove, Corry, and Graham (1994), 
Sutherland, Kaufman, Wyatt and Chambers (1999), Bottos et al, (2003), 
Flett et al (1999), Koman, Mooney, Smith, Goodman and Mulvaney (1994), 
Corry, Cosgrove, Duffy, Taylor and Graham, (1999)). 
Botulinum toxin type A also used as an adjuvant therapy in the management 
of dynamic contractures or spasticity (Wall, Chait, Temlett, Perkins, Hillen 
and Becker (1993); Koman et al, (1993); Cosgrove et al, (1994); Flett et al, 
(1999); Sutherland et al, (1999); Yang et al, (1999), Ubhi et al, (2000), 
Linder et al, (2001), Baker, Jasinski and Maciag (2002), Fragala, O’Neil, 
Russo and Dumas (2002)).  
Botulinum toxin type A injections have also been used to improve gross 
motor function in children with cerebral palsy (Yang et al, (1999), 
Reddihough et al, (2002)) and to increase muscle length (Thompson et al, 
(1998), Eames, Baker, Hill, Graham, Taylor and Cosgrove, (1999)). BTX-A 
has also been used to facilitate positioning and hygiene (Koman et al, 1993), 
to delay surgery, (Flett, (2003); Graham et al, (2002); Ubhi et al, (2000)), 
and to facilitate or replace bracing (Koman et al, 1996). In addition, it used 
as a diagnostic aid to determine the efficacy of surgery (Koman et al, 1993). 
The use of Botulinum toxin type A is inappropriate or inadvisable in the 
management of fixed contractures and in the presence of certain specific 
neuromuscular diseases in which a patient is being treated with medications 
that may exaggerate the response to neuromuscular blocking agent, in 
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muscle(s) that did not respond to alcohol or phenol injections and in the 
presence of antibodies to Botulinum toxin type A (Koman, 1994).  
1.12. Pharmacology of Botulinum toxin type A 
Now that the efficacy and safety of Botulinum toxin has been demonstrated, 
there has been continuing interest in its use. Of the 8 immunologically 
distinct serotypes (types A, B, C1, C2, D, E, F and G), the only types 
currently in clinical use are Botulinum toxin type A and Botulinum toxin 
type B (Flett, 2003). Botulinum toxin type A is a large molecule with a high 
specific binding coefficient. It spreads in tissues through local diffusion.  
Therefore, distant clinical effects and functional involvement of adjacent 
muscle groups are not apparent at doses lower than 6 U/Kg of Botulinum 
toxin type A body weight (Scott, 1981). 
Botulinum toxin type A acts by interfering with presynaptic acetylcholine 
release at motor nerve terminals. It does not destroy nerve endings, nerve 
terminal or neuromuscular junctions (Wall et al, 1993). Injection of 
Botulinum toxin type A into selected muscles, therefore, produces dose-
dependant chemical denervation resulting in reduced muscular activity 
(Borodic, Ferrante, Pearce and Smith, 1994). Its effect is reversible (Scott, 
1981).   
Nerve sprouting and muscle re-innervation lead to functional recovery 
within 2 to 4 months (Rosales, 1996). There is evidence that partially 
functional neuromuscular junctions are re-established within 4 weeks 
(Angaut-Petit, Molgo, Comella, Faille and Tabit, 1990).  The periods of 
clinically useful muscle relaxation is usually 12-16 weeks (Graham et al, 
2000). (Duchen and Strich, 1968). Botulinum toxin type A appears to 
denervate fast-twitch muscles (e.g. gastrocnemius) for longer periods than 
slow-twitch muscles (e.g. soleus) (Koman et al, 1996). 
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1.13. Dose of Botulinum toxin type A 
There is no consensus in either paediatric or adult practice about the 
“correct” dose of Botulinum toxin type A to treat spasticity.  The dose is 
generally determined by the size of the muscle to be injected.  The aim is to 
achieve a clinical response without excessive weakness or systemic side 
effects (Carr, Cosgrove, Geringrass and Neville, 1998). A dose of 20-120 U 
of botulinum toxin type A(or the equivalent dose of Dysport) for large 
muscles and 2.5-40 U for smaller ones seems to be effective in the treatment 
of both spasticity and rigidity (Gordon, 1999). 
The accepted safe maximal dosage of botulinum toxin type A is 6 U/Kg 
body weight. In previous studies of Botulinum toxin type A as a treatment 
for cerebral palsy, the minimum dose that appeared to be required for focal 
muscle weakness 1 to 2 units of toxin per kilogram of body weight per 
major muscle group injected (Koman et al, 1993). 
One study has investigated the dose-response relationship of Botulinum 
toxin type A in the treatment of children with cerebral palsy (Carr, 1998). 
The effects of high (200 units per leg) and a low-dose (100 units per leg) 
doses were compared in 33 patients with CP. The results of this study 
indicated that doses of 200 Botulinum toxin type A distributed in 4 to 5 
muscles per leg are more effective and equally safe compared to 100 units 
distributed per leg in treating spastic gait pattern in CP. Longitudinal gait 
parameters improved more significantly only in patients with high dose 
treatment.  Additionally, analysis of variance showed dose dependency of 
Botulinum toxin type A on gait velocity and stride length.  The authors 
found a dose dependent response in knee flexor muscle tone, walking speed, 
and stride length without increase in systemic effects. Some clinicians 
recommend a maximum of 900 units of Dysport and 300 units of Botulinum 
toxin type Ain the older child (Carr, 1998). 
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Some studies have suggested that the highest doses of Botulinum toxin type 
A not only resulted in more adverse events, but they were also associated 
with less therapeutic responses and in some cases, functional deterioration 
(Bakheit et al, 2001). The total dose of toxin per treatment session, rather 
than that calculated on the basis of body weight, correlated with the 
incidence of adverse events and functional improvement or deterioration. 
This would be explained by the fact that the number of neuromuscular 
junctions in a muscle may be more important for the clinical response to the 
toxin than its absolute body weight (Bakheit et al, 2001). 
1.14. BTX-A combined with Physical Therapy  
Physical therapy programme after Botulinum toxin type A injection remains 
central to treatment. It has been suggested that targeted motor training may 
prolong the benefit of Botulinum toxin type A (Graham, et al, 2000). Most 
studies recommend physical therapy after Botulinum toxin type A treatment 
(Fragala et al, 2002). However the most effective physical therapy 
programme is not known. Intensive physiotherapy treatment is currently the 
standard management following Botulinum toxin type A in cerebral palsy 
children in the hope of providing improved long-term benefit (Ubhi et al, 
2000). 
1.15. Effect of Botulinum toxin type A on muscle tone and walking 
The basic use of Botulinum toxin type A is as an adjuvant therapy in the 
management of dynamic contractures or spasticity (Jefferson, 2004). Koman 
et al first described the use of Botulinum toxin type A in children with 
cerebral palsy in an open-label study of 27 children with dynamic 
deformities. They noted that the Botulinum toxin type A action appeared to 
last longer in more active patients. They also found a reduction in spasticity 
within 12 to 72 hours after injection. It lasted for 3 to 6 months without 
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major adverse effects. These authors postulated that adjuvant therapy with 
Botulinum toxin type A might delay orthopaedic surgery (Koman et al, 
1993). 
The previous study demonstrated that very low doses of Botulinum toxin 
type A (0.5-1 U/Kg of body weight / muscle) combined with rehabilitation 
therapy (stretching exercises, therapeutic facilitation exercises, and plastic 
ankle and foot orthoses) decreased spasticity and improved gait in cerebral 
palsy children.  The long-term effect of this combination of treatments 
suggest that the initial effects were likely to be the result of a direct 
Botulinum toxin type A blockade of neurotransmission but that sustained 
effect resulted from long-lasting compensatory mechanism (Suputtitada, 
2000). 
Cosgrove et al investigated the changes in sagittal plane kinematics using 
electrogoniometer in a group of 26 patients who had dynamic 
contractures of the lower limb interfering with positioning or walking.  
Patients received Botulinum toxin type A injections to the gastrosoleus, 
tibialis posterior and hamstring muscles.  A reduction in muscle tone 
occurred within 3 days of the injections and lasted from 2 to 4 months 
(Cosgrove et al, 1994). Their study was the first to report that gains in 
dorsiflexion after calf injection.  Improvements were less in older 
subjects, probably because of the gradual development of fixed 
contractures.  In the study, improvement was noted in such parameters as 
ankle dorsiflexion in stance and swing and knee extension in stance and 
swing following injection of the calf muscles and hamstrings respectively 
(Cosgrove et al, 1994). Sutherland, Kaufman, Wyatt hgand Chambers, 
(1996) investigated the effect of treating 26 cases of dynamic equinus 
with injection of Botulinum toxin type A into the gastrocnemius.  They 
found increased walking velocity, increased step length and increased 
stride length at following compared with baseline values. During swing, 
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there was an increase in ankle dorsiflexion; this active movement 
mediated by the ankle dorsiflexors, allowed ground clearance in the 
swing phase of the gait cycle.  Koman et al, (1993) injected the paraspinal 
and lower limb muscles. They found decreases in tone and improvement 
in positioning and gait.  Sutherland et al, (1996) reported gait 
improvement in foot rotation, step length, and dorsiflexion after calf 
injection.  Ubhi et al, (2000) reported improvement in the physician 
rating scale in 48% of children treatment with Botulinum toxin type A 
compared to 17% of those treated with placebo. The improvement of 
equinus foot position in 50-60% of patients without significant morbidity. 
The Botulinum toxin type A injection into the hamstring muscles produces 
improvement in knee extension in gait without significantly reducing knee 
flexion.  This increased muscle excursion may improve stretch of the 
relaxed muscle leading to its lengthening. The hip range of movement was 
also increased significantly at 12 weeks. Improvement of hip flexor activity 
may partly account for the significant increase in speed after the Botulinum 
toxin type A that arose as an increase in cadence and step length (Corry et 
al, 1999). 
1.16. Effect of Botulinum toxin type A on muscle length 
Eames and colleagues (1999) studied the change in gastrocnemius muscle 
length following Botulinum toxin type A injection in 39 children and 
correlated the pre-treatment dynamic component of spasticity with the 
magnitude and duration of the response. They found greatest change in 
muscle length two weeks following Botulinum toxin type A.  One year after 
the injection 30% of injected muscles were longer than baseline. Botulinum 
toxin type A appeared to act on the dynamic element of a contracture and 
produced relatively small changes in absolute muscle length.  Botulinum 
toxin type A injection in both short and adequate length muscles produced 
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muscle lengthening (Thompson et al, 1998). Botulinum toxin type A 
provides a useful way of controlling excessive muscular contraction in the 
spastic muscles injected.  It follows that it is most effective in patients with 
dynamic muscle shortening which is localized to a few muscles (Graham et 
al, 2000). These observations clearly establish a link between the dynamic 
component of muscle shortening and the response to Botulinum toxin type 
A in terms of increase in muscle length during gait (Eames et al, 1999). 
Botulinum toxin type A does cause a detectable lengthening of 
gastrocnemius muscle in ambulant children.  The magnitude of this response 
varies and is related directly to the dynamic component present immediately 
before an injection. Repeated injections display similar correlation, the 
dynamic component being the important factor than the number of the 
injections. Children with hemiplegia and diplegia show similar response, but 
because children with diaplegia tend to show a greater degree of dynamic 
component, they tend to respond better to the injections. For most children, 
Botulinum toxin type A does not cause a long-term lengthening of 
gastrocnemius muscle, but does act to delay any shortening of muscle 
(Eames et al, 1999). 
1.17. Effect of Botulinum toxin type A on joint Range of Motion 
(ROM) 
Koman et al, (1993) and Cosgrove et al, (1994)) confirmed increases in the 
range of passive as well as active movements. For example, two open –label 
studies showed that reduction in calf muscle spasticity improved the passive 
ankle dorsiflexion. 
Active ROM measured at the ankle shows significant increases after 
Botulinum toxin type A treatment, whereas passive ROM does not change 
(Ubhi et al, 2000). One possible explanation for the lack of effect of 
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Botulinum toxin type A on passive movement is that Botulinum toxin type 
A affects the “dynamic” spastic component as opposed to the range of 
passive movement, which encapsulates resistance, produced by muscle or 
joint connective tissue (Ubhi et al, 2000).  
Fragala et al, (2002) studied impairment, disability and satisfaction 
outcomes after lower-extremity Botulinum toxin type A injections in seven 
children with cerebral palsy.  All the children demonstrated an increase in 
passive range of motion and decrease in spasticity in at least some of the 
injected muscles.  Six of the seven children demonstrated improvements in 
disability and parent satisfaction outcomes. 
1.18. Effect of Botulinum toxin type A on energy expenditure 
Ubhi et al, (2000) and Corry et al, (1999) carried out controlled trials of the 
effect of Botulinum toxin type A on energy expenditure during walking 
following Botulinum toxin type A injections into the hamstrings of children 
with cerebral palsy and crouch gait. The results were variable, but in some 
children there was a significant improvement in knee extension on 
kinematic studies and a significant decrease in energy consumption. 
1.19. Use of Botulinum toxin type A in the upper limb 
Upper limb spasticity frequently causes difficulties with activities of daily 
living. Severe hypertonia of upper limb muscles is a common complication 
in patients with an upper motor neurone lesion.  Botulinum toxin type A has 
been used to reduce spasticity to the wrist and fingers in patients who have 
suffered a stroke (Bakheit et al, 2001). 
Bakheit et al, (2001), Wall et al. (1993) were the first to report the use of 
Botulinum toxin type A in the upper limbs of five children with cerebral 
palsy. Injection into the adductor pollicus and rigid splinting led to 
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improvement in hand function. All cases were shown to improve in terms of 
both function and appearance. Friedman, Diamond, Johnson and Daffner 
(2000) found a significant decrease in upper limb spasticity when the elbow 
flexors were injected.  Improvements were found with elbow and wrist 
extension and flexion at 1-3 months after the injection with Botulinum toxin 
type A in cerebral palsy children.  
1.20. Effect of Botulinum toxin type A on functional activities 
Linder et al, (2001) studied the effect of Botulinum toxin type A on motor 
function, using the Gross Motor Function Measure (GMFM), in twenty-five 
children with cerebral palsy and spasticity. They recorded a significant 
improvement of gross motor functions after twelve months of treatment. 
The improvement occurred in both ambulatory and non-ambulatory 
children. 
Other previous studies also demonstrated that treatment with Botulinum 
toxin type A led to reduction in spasticity and improvement in functional 
performance in standing and walking (Botos et al, (2003), Ubhi et al, 
(2000)). 
1.21. BTX-A use for post operative pain reduction 
Many surgeons use Botulinum toxin type A during operations to reduce 
painful post-operative spasms and to protect the soft tissues from 
involuntary movement and spasms until healing occurs.  Severe post-
operative pain and spasm is often present after adductor-release surgery to 
treat or prevent hip dislocation in children with spastic cerebral palsy. 
Barwood, Bailiew, Boyd, Brereton, Low, Nattrass and Graham, (2000) 
showed that there may be an important clinical role for Botulinum toxin 
type A in reducing post-operative pain and analgesic requirement after hip 
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adductor release surgery in children with cerebral palsy. These authors 
found Botulinum toxin type A reduced the mean pain scores in 74% of cases 
(Barwood et al, 2000). 
1.22. Botulinum toxin type A use in the treatment of drooling in 
children with C.P 
In 2000 the first trial results, in adults with Parkinson’s disease showed 
Botulinum toxin type A to be an effective treatment for drooling.  No side 
effects were observed.  The authors conclude that Botulinum toxin type A is 
an effective treatment for the common problem of drooling saliva in chronic 
neurologic disease (Pal, Calne, Calne and Tsui, 2000). Likewise Dogu, 
Aaydin, Sevim, Umit and Aral, (2004) showed an improvement in the mean 
rate of saliva secretion in the first week after Botulinum toxin type A 
injection into the parotid gland.  Vaile and Finlay, (2006) suggested that 
Botulinum toxin type A inhibits saliva production.  In a study of 45 school-
aged children, Botulinum toxin type A injections significantly reduced 
salivary flow rate in the majority of children suffereing from cerebral palsy 
with severe drooling, demonstrating high response rates up to 24 weeks 
(Jongerius, Rotteveel, Limbeak, Gabreëls, Hulst and Hoogen, 2004). 
1.23. Botulinum toxin type A use in the treatment of 
blepharospasm and dry eye 
Botulinum toxin type A injections were effective in relieving blepharospasm 
but were not successful in treating dry eye syndrome. In the patients 
suffering from blepharospasm and dry eye Botulinum toxin type A is an 
effective treatment for reducing spasms (Horwath, Bergloeff, Floegel, Haller 
and Schmu, 2003). 
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1.24. Correlation between the effect of Botulinum toxin type A and 
age 
The data on the relationship between the responses to Botulinum toxin type 
A and the age of patients are contradictory. Thompson et al, (1998) reported 
that there was no correlation between the patient’s age and the response to 
Botulinum toxin type A injection. However Cosgrove et al, (1994) found an 
inverse relationship between the therapeutic response and the patient’s age. 
Similarly, Graham et al, (2000) and Ubhi et al, (2000) found that treatment 
at an early age before the development of contractures produces better 
results and may prevent deformity, thus giving long term benefit and delay 
surgery.  Eames and colleagues et al, (1999) have suggested that the age 
effect may be because of a change of the child’s problems from dynamic to 
a fixed defect overtime as contractures develop. Graham (2000) found early 
treatment is preferable to give maximum response. Fragala et al, (2000) also 
found that young children benefited from Botulinum toxin type A injection 
more than older children.  
1.25. Comparison of Botulinum toxin type A treatment with 
plasters casts 
Flett et al, (1999) compared the effect of Botulinum toxin type A injection 
into the calf with the effect of serial casting. They found that the effects of 
the Botulinum toxin type A last longer than the effects of casting.  
Desloovere, Molenaers, Jonkers, Cat, De, Borre, Nijs, Eyssen, Pauwels and 
De Cock, (2001) found significant changes in the walking patterns of both 
groups with the most significant changes at the ankle joint. Children who 
received casts after injections demonstrated a slightly more pronounced 
benefit, mainly in the proximal joints. Botulinum toxin type A injections 
were of similar efficacy to serial fixed plaster casting in improving dynamic 
calf tightness in ambulant or partially ambulant children with cerebral palsy. 
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Botulinum toxin type A injections and serial casting have become an 
increasingly integral part of treatment for children with cerebral palsy over 
the past 10 to 15 years.  The combined therapy shows a significantly greater 
increase in passive range of motion of the ankle joint in comparison to 
treatment with Botulinum toxin type A alone (Glanzman; Kim; 
Swaminathan and Beck, 2004). Similarly, patients who received both serial 
casts and Botulinum toxin type A show more sustained improvements in 
Gross Motor Function Measure scores (Bottos, 2003). Glanzman et al, 
(2004) found the combined treatment gave greater increases in passive range 
of motion of the ankle joint in comparison with Botulinum toxin type A 
alone.  
 
1.26. GMFM as an outcome measure for the evaluation of 
Botulinum toxin type A treatment 
The GMFM technique has been used in a variety of clinical and research 
situations. Its results are sensitive and reliable.  Graham et al, (2000) 
reported that the GMFM is the most useful validated objective outcome 
measure. It is more appropriate for assessing children in the mid-range of 
disability.  In children with mild disability the GMFM may not be sensitive 
enough to detect change.  Similarly, assessment of children with severe 
disability and generalised spasticity with GMFM may not be very accurate. 
Evidence of the responsiveness of the GMFM to change includes the 
findings that the mean GMFM scores of the children with cerebral palsy 
changed over 12 months and that the mean change scores were related to 
age and severity of motor disability (Russell et al, 2000). 
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In an open label prospective study Linder et al. (2001) demonstrated the 
value of the GMFM in the assessment of cerebral palsy children treated with 
Botulinum toxin type A and followed up for one-year. Bottos et al. (2003) 
also found a significant improvement of gross motor function in children 
treated with Botulinum toxin type A and plaster casts.   
However, Baker et al demonstrated a clear improvement in the dynamic 
component in patients with diplegic cerebral palsy after treatment with 
Botulinum toxin type A, but not in the overall GMFM scores.  It is also 
possible that the GMFM is not sensitive enough to detect the functional 
improvements that were subjectively reported. The GMFM is designed to 
assess whether patients can perform various functions but does not assess 
how well each function is performed.  It is, therefore, unable to detect 
improvements in the quality of function (Baker, Jasinski and Tymecka, 
2002). 
Reddihough, King, Coleman, Fosang, McCoy, Thomason and Graham, 
(2002) in a randomized study found that there were no statistical differences 
between the Botulinum toxin type A and control groups, at 3 and 6 months 
post injection. However, in another study functional outcomes assessed by 
the GMFM showed a statistically significant improvement after Botulinum 
toxin type A use (Jefferson, 2004).  
1.27. Adverse effects of Botulinum toxin type A 
Botulinum toxin type A is a safe anti-spasticity agent but adverse effects of 
Botulinum toxin type A can occur locally as a result of larger than necessary 
doses in a single muscle producing significant transient focal weakness, or 
systemically because of more than enough total body dose to several 
muscles (Jefferson, 2004). 
   
Abeer Felmban 2008  42 
Ptosis is the most common problem after injections for blepharospasm and 
hemifacial spasm (Jitpimolmard, Tiamkao and Laopaiboon, 1998).  
Significant adverse events associated with Botulinum toxin type A 
injections are rare.  Approximately 20% of patients, or families, report 
concerns over muscle weakness, cramping, pain or problem in coordination 
(Koman et al, (1993); Ubhi et al (2000); Koman, Brashear, Rosenfeld and 
Chambers (2001); Papadonikolakis et al, (2003)). 
Rosalind, (2004) found that the adverse events of Botulinum toxin type A 
could occur locally as a result of excessive doses in a single muscle, but 
they occur infrequently and generally mild in nature.  Pain around the 
injection site is the most commonly reported complaint, frequent falls from 
balance problems, and generalized weakness may also occur (Ubhi, 2000) 
and (Mall et al, 2006). 
Other authors including, Sutherland (1999), Linder (2001), Papadonikolakis 
et al (2003), and Sarioglu, Serdaroglu, Tutuncuoglu and Ozer (2003) did not 
observe any side effects in the studied population.  
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1.28. Aims of the study 
 
Cerebral palsy is large clinical problem. One of the main problems in 
reviewing the literature is the use of several assessment scales and many 
treatments used alone or combination.  
The aim of this study is to examine whether the combination of 
physiotherapy with Botulinum toxin type A treatment improve the clinical 
outcomes as assessed by GMFM and ROM for patients with cerebral palsy 
more than Botulinum toxin type A injections alone. 
 
 
   
Abeer Felmban 2008  44 
Chapter 2 
 
Methods 
2.1. Study design  
This project used an open label study design. Both the clinical staff and the 
patient’s family were aware of the treatment delivered. Ultimately, it is not 
possible to blind either group to the nature of the treatment delivered since it 
is immediately obvious whether muscles have been paralysed. 
This was a prospective study. Patients were allocated to receive Botulinum 
toxin type A alone or Botulinum toxin type A and physiotherapy. The 
experiments were conducted at The Rehabilitation Centre of The Prince 
Sultan Military Hospital in Al Hada and in the Centres of the Disabled 
Childrens’ Association in Mecca and Jeddah, in Saudi Arabia. The same 
protocols were followed at each centre. In all, 47 children participated in the 
study. These three centres treat about 325 children and so the sample 
recruited represents a significant proportion of the available patient 
population. 
The children in the study had cerebral palsy, diplegia, spasticity of the ankle 
planter flexors and significant abnormal gait because of lower limb 
spasticity predominantly affecting the calf muscles. This study assessed of 
the effects of Botulinum toxin type A alone and in combination with 
intensive physical therapy in the treatment of these children. The study 
extended over 12 months. 
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The design of the experiment was reviewed and approved by the local 
review committee. The oldest children in the study were 14 years and so 
were too young to give consent. The patients’ parents were fully informed 
of the nature and purpose of the study. Their parents gave written consent to 
participation and at least one parent attended all treatment and testing 
sessions.
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Figure 2.1. Scheme of study 
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injection  
GMFM 
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BTX-A  
18 Patients Group 1-BTX-A alone. 
Details of demographic in table 2.1,  
and injection details in table 2.4 
46 Patients with 
Cerebral Palsy 
Diplegia 
 
Second & Third 
Assessment at 
week 4,6 after 
BTX-A  
28 Patients Group 2 BTX-A+ Intensive PT. 
Details of demographic in table 2.2,  
and injection details in table 2.3. 
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The children were assigned to one of two groups: Group 1 received 
Botulinum toxin injections twice at six month intervals, their ankles were 
placed in plaster casts for 2 weeks after the first injection and they were 
fitted with medical shoes when the casts were removed. Group 2 received 
similar treatment with the addition of intensive physical therapy for 2 weeks 
after the removal of the casts.  Additional information on the nature of these 
interventions will be given in sections 2.7. 
The assignment to group 1 and 2 could not be done randomly. The children 
in group 2 had to live in the accommodation of the Rehabilitation Centre for 
the two weeks of intensive physical therapy. Thus, the allocation to groups 
was done by the social and domestic factors influencing their families. This 
results in group 1 containing 18 children and group 2 containing 28 
children. The characteristics of the two groups were reasonably balanced for 
gender and body weight and baseline GMFM scores. These data are 
reported in section 2.3. Measurements were made one week before the first 
injections and at 4, 6 and 52 weeks later. See figure 2.1. 
2.2 Ethical Approval 
The design of the experiment was reviewed and approved by Prince Sultan 
Hospital and Al-Hada Armed Forces Hospital and Rehabilitation Centre in 
Saudi Arabia. Inspection of the clinical records identified 47 children as 
potential subjects. Since the children were too young to give consent, each 
patients’ parents were informed of the purpose of the study.  Their parents 
gave informed written consent before treatment started.  At least one parent 
was present throughout the four scheduled visits. The consent forms are 
shown in appendix 2. These are translations of the original Arabic 
documents. 
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One child dropped out of the study after second assessment because of 
severe allergy. This was not associated with the experiment. Four children 
from group 2 did not attended at final assessment for GMFM at 52 weeks. 
2.3. Subjects 
46 children, 25 boys and 21 girls were recruited for the study. They all had 
spastic diplegia and dynamic equinus foot deformity. They were between 
25-154 months at the start of the study. Details of anthropometric data of 
patients, their height, weight, and age are shown in tables 2.1. and 2.2.  
2.3.1. Inclusion criteria for the study 
Parental consent was obtained. 
The patients had cerebral palsy, diplegia and spasticity of the ankle plantar 
flexors, significant gait abnormalities due to dynamic equinus with an 
inability to achieve heel strike because of lower limb spasticity 
predominantly affecting the calf muscles. The patient should be ambulatory. 
This includes children using walkers. 
2.3.2. Exclusion criteria for the study:  
1. Evidence of contracture of gastrocnemius/soleus defined as 
significantly reduced range of motion at the ankle during passive 
stretches.  
2. Severe athetoid movement in the target leg. 
3. A significant difference between the length of the right and left 
legs causing a gait asymmetry. 
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4. Obvious atrophy of the calf muscles of the leg to be treated in the 
study. 
5. Child is waiting for surgery or has had previous surgery of the 
foot, leg, or ankle. 
6. Other conflicting concurrent treatment, such as plaster casts, 
orthoses. 
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ID. No. Gender Treatment  Weight (Kg) Height (cm) Age (month) 
35 F BTX-A 15 107 74 
23 F BTX-A 11 84 29 
44 M BTX-A 16 105 70 
40 M BTX-A 16 109 74 
37 M BTX-A 17 107 77 
30 M BTX-A 16 108 78 
28 F BTX-A 17 107 80 
41 M BTX-A 15 98 86 
17 M BTX-A 18 110 80 
32 F BTX-A 15 99 97 
9 F BTX-A 30 104 109 
20 F BTX-A 44 139 129 
5 F BTX-A 46 145 154 
25 M BTX-A 13 88 45 
36 M BTX-A 13 106 74 
45 M BTX-A 13 107 79 
46 F BTX-A- 15 108 96 
10 M BTX-A- 38 111 104 
Table 2.1.  
The characteristic of children in group 1. The table shows the anthropometric details of 
patients: their ages, (in months) heights in cm, and weights in kg.  The middle column 
shows the type of treatment Botulinum toxin type A only. 
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ID. No. Gender Treatment Weight (Kg) Height (cm) Age (month) 
31 M BTX-A+PT 16 105 69 
27 M BTX-A+PT 12 86 28 
4 F BTX-A+PT 16 98 84 
7 F BTX-A+PT 27 105 82 
21 M BTX-A+PT 11 84 25 
42 M BTX-A+PT 11 86 27 
33 M BTX-A+PT 11 84 28 
11 F BTX-A+PT 11 85 32 
26 F BTX-A+PT 12 87 25 
43 F BTX-A+PT 13 84 36 
38 F BTX-A+PT 12 85 37 
39 M BTX-A+PT 12 86 43 
29 M BTX-A+PT 12 85 45 
3 F BTX-A+PT 17 85 45 
6 F BTX-A+PT 12 84 46 
15 F BTX-A+PT 13 85 48 
34 F BTX-A+PT 13 85 33 
18 F BTX-A+PT 14 95 56 
1 M BTX-A+PT 13 84 59 
8 F BTX-A+PT 14 85 60 
2 M BTX-A+PT 16 86 66 
14 F BTX-A+PT 17 85 67 
19 M BTX-A+PT 15 93 72 
22 M BTX-A+PT 18 106 73 
12 M BTX-A+PT 20 110 91 
13 M BTX-A+PT 17 109 94 
24 F BTX-A+PT 43 144 106 
16 F BTX-A+PT 40 135 132 
Table 2.2.  
The characteristic of children in group 2. The table shows the anthropometric details of 
patients: their ages (in months) heights in cm, and weights.  The middle column shows 
the type of treatment Botulinum toxin type A + Physical therapy. 
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Figure 2.2.  
The picture shows the investigator working with one of the children.  
The child is lying on a bed in a prone position. The knee of the target leg is flexed to 90 
degrees.  The skin mounted EMG electrode-amplifier can be seen fixed over the soleus 
muscle.   A manual and an electrogoniometer measurement of the range of motion of the 
ankle are taken simultaneously. 
 
2.4 Physical Examination 
The week before the Botulinum toxin type A injects were made, each child 
was examined by an orthopaedic surgeon and a physical therapist. This was 
done to define a treatment plan to identify which muscles will receive 
Botulinum toxin type A injections and to calculate the appropriate doses. In 
addition, the passive range of motion of the hip, knee, and ankle joints of 
both limbs were measured. 
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2.5. Dosing and injection procedure  
All the Botulinum toxin type A injections were made by Dr Shakfa, the head 
of the Orthopaedic Surgery Department of the Prince Sultan and Al-Hada 
Armed Forces Hospital and Rehabilitation Centre at Saudi Arabia. 
Botulinum toxin type A product used in this study was Botulinum toxin type 
A (Allergan, USA). 
All injections were prepared by following a standard procedure.  Each vial 
of contains a powder containing 100 units. This was reconstituted by 
dissolving it in 1 ml of normal saline. The powder dissolves readily and it is 
not necessary to shake the vial (Bakheit, 2001).  The dose administered was 
6 units/kg of body weight per injection site.   
Where a child receives multiple injections, the dosage of Botulinum toxin 
type A per muscle or the number of sites targeted was restricted by a total 
permissible dose. The dose calculation takes into account the mass of the 
child and the number of muscles targeted (Preiss, Condie, Rowley and 
Graham, 2003).  In this study, the maximum allowed dose was 200 units per 
treatment session. 
The orthopaedic surgeon identified the target muscles using anatomical land 
marks without electromyography guidance. The soleus and gastrocnemius 
muscle were palpated whilst being stretched passively. The choice of 
muscles selected for injection depended on the degree of spasticity. The 
injections were performed using appropriately sized syringe under antiseptic 
conditions.  The needle was inserted through the fascia into the proximal 
third of the muscle and the drug was injected. Local anaesthetics were not 
used before administering the Botulinum toxin type Ainjections in this 
study. Koman et al, (1993) found that unbuffered lidocaine was more 
painful than a toxin injection alone.  
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Figure 2.3.  
The picture shows the investigator and the orthopaedic surgeon.  The child during 
injection of Botulinum toxin type A.  One of the parents was present throughout the 
injection and injection was performed under antiseptic condition, without local 
anaesthesia. 
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ID. 
No. 
R Hip 
Adductor 
L Hip 
Adductor 
R Knee 
Flexor 
L Knee 
Flexor 
R. 
Gastro 
L. 
Gastro 
R. 
Soleus 
L. 
Soleus 
2 . . . . 50 50 10 10 
3 . . . . 40 40 10 10 
4 . . 20 20 20 20 10 10 
6 20 20 . . 30 30 . . 
7 . . 25 25 50 50 25 25 
8 . . . . 40 40 10 10 
11 . . . . 30 30 20 20 
12 25 25 20 20 20 20 10 10 
13 . . 25 25 30 30 20 20 
14 . . . . 30 30 20 20 
15 . . . . 40 40 10 10 
16 20 20 50 50 20 20 10 10 
18 . . . . 30 30 20 20 
19 . . . . 40 40 10 10 
21 20 20 . . 30 30 10 10 
22 . . . . 30 30 20 20 
24 . . . . 50 50 10 10 
26 20 20 . . 20 20 10 10 
27 25 25 15 15 30 30 . . 
29 . . 15 15 30 30 10 10 
31 . . . . 35 35 15 15 
33 20 20 . . 20 20 10 10 
34 25 25 25 25 20 20 10 10 
38 15 15 . . 30 30 . . 
39 . . 20 20 30 30 10 10 
42 20 20 . . 20 20 10 10 
43 25 25 25 25 30 30 . . 
Table 2.3.  
Botulinum toxin type A dose according to treatment Botulinum toxin type A + Physical 
therapy, group 2. The choice of muscles selected for injection depends on the degree of 
spasticity and the expected short-term goal of the physiotherapist.  The used dose for 
each child was at 6-unit/Kg--body weight but not more than 200 units. 
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ID. 
No. 
R Hip 
Adductor 
L Hip 
Adductor 
R Knee 
Flexor 
L Knee 
Flexor 
R 
Gastro 
L. 
Gastro 
R. 
Soleus 
L. 
Soleus 
5 . . . . 50 50 10 10 
9 35 35 25 25 30 30 10 10 
10 . . 40 40 40 40 20 20 
17 . . . . 35 35 15 15 
20 . . . . 50 50 .  
23 . . . . 40 20 25 15 
25 . . . . 30 30 20 20 
28 . . . . 30 30 10 10 
30 35 35 25 25 30 30 10 10 
32 35 35 25 25 30 30 20  
35 . . . . 40 40 10 10 
36 30 30 15 15 25 25 15 15 
37 . . 30 30 30 30 10 10 
40 35 35 25 25 30 30 10 10 
41 35 35 25 25 30 30 10 10 
44 . . . . 40 40 10 10 
45 30 30 15 15 25 25 15 15 
46 . . 25 25 30 30 10 10 
Table 2.4.  
 
Botulinum Toxin-A dose according to treatment Botulinum Toxin-A only, group 1. 
The choice of muscles selected for injection depends on the degree of spasticity and 
the expected short-term goal of the physiotherapist.  The used dose for each child 
was at 6-unit/Kg- body weight but not more than 200 units. 
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Figure 2.4.  
This picture shows an example of the medical shoes fitted to all the children in the study 4 
weeks after the Botulinum toxin –A injection.  
 
Figure 2.5.  
This picture shows an example of the casts fitted to all the children in the study 2 weeks after 
the Botulinum toxin –A injection.  
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2.6. The outcome measures 
The primary outcome measure was the gross motor function measurement 
(GMFM). The secondary outcome measures were range of motion at the left 
ankle joint as assessed by electrogoniometers and stretch reflex changes as 
assessed by electromyography during stretches of the ankle extensor 
muscles.  
Each of these will be described in turn. 
2.6.1. Gross Motor Function Measurement  
The GMFM questionnaire is a standardised observational instrument 
designed and validated to measure the change in gross motor function over 
time in children with cerebral palsy (Russell, 2002). 
The GMFM test includes 88 items grouped in five dimensions:  
(A) Lying and Rolling  
(B) Sitting  
(C) Crawling and Kneeling  
(D) Standing  
(E) Walking, Running and Jumping   
Each item of the test is scored on a 4-point scale and percentage score is 
calculated for each dimension.  The total score is obtained by calculating the 
mean of the five dimension scores. The full GMFM scale is shown in 
Appendix 2 at the end of thesis.  
   
Abeer Felmban 2008  60 
The guidelines contained in the GMFM manual used for scoring of each 
item were followed. These were: 
0 = does not initiate  
1 = initiates  
2 = partially completes  
3 = completes  
NT = not tested  
Each of these scores is defined as: 
(0) “Does not initiate” applies to the child who is requested to attempt 
an item and he/she is unable to commence any part of the activity.  
(1) “Initiates” refers to less than 10% task completion.  
(2) “Partially completes activity “ >10% but <100% of the task 
completed. 
(3) “Completes” describes 100% task completion.  
“Not tested” was used when an item had not been administrated or when a 
child refused to attempt an item which he/she was expected to complete 
partially (Russell et al, 1994).  
The total GMFM score and dimension scores collected at each evaluation.  
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2.6.2. Electronic Goniometer 
A twin axis electrogoniometer (SG 110 Ankle dorsiflexion/plantarflexion 
Biometrics Ltd, Nine Mile Point Ind. Est., Gwent, NP11 7HZ, UK) was 
used to detect the movement of the ankle joint during tests. The goniometers 
were sensitive to the movement in the dorsiflexion –plantarflexion plane.  
Any relative movement between the arms of the goniometer changes its 
output voltage proportional to the movement applied. The output voltage 
was amplified, digitised by a CED micro 1401 (Cambridge Electronic 
Design, Cambridge, UK) interface and recorded in the computer during the 
test.  
The goniometer was fixed on the lateral side of the patient’s ankle joint.  
The proximal end-block was placed parallel to a line between the lateral 
malleolus and the fibula head. The distal ankle end-block was aligned with 
the plantar surface.   
2.6.3. Calibration of Electrogoniometers 
A calibration was performed on the electrogoniometer during the 
assessment session. The electrogoniometer was attached to the limb as 
described above. Patients were barefoot and dressed in shorts to facilitate 
the correct positioning of the goniometer. The ankle joint was held at five 
positions at 10-degree steps between 60 and 120 degrees of dorsiflexion. 
The positions were determined with reference to a manual goniometer (See 
figure 2.5 and 2.6.). 
The electrogoniometer signals were filtered to remove 50 Hz components 
before being digitised at 100Hz by CED 1401 micro A-D converter. The 
output was recorded with Spike 2. Data were saved for analysis.  
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The graph in figure 2.7. shows typical calibration data. The 
electrogoniometer has linear relationship with the ankle joint position.  
Therefore the equation can be used to translate output voltages values into 
ankle angles.  
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Figure 2.6.  
The child lay on bed in prone position, with the target leg flexed at 90 degrees.  EMG electrode 
fixed on the soleus muscle, and the skin was cleaned with an alcohol wipe.  Range of motion 
measured by Electronic Goniometer fixed on the lateral side of the left ankle.   Data were 
analysis using the spike 2 software systems. 
 
 
 
 
 
Figure 2:7.  
A raw data of EMG.  The channels show: 1) EMG activity of the soleus muscle.  2) Driver 3) 
Ankle joint movement recorded by electrogoniometer 4) Pressure to stretch ankle joint from 
neutral position to dorsiflexion position 5 times  
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Figure 2.8. 
The calibration of the electrogoniometer used to measure ankle joint position 
 
2.6.4 Electromyography Recording 
 
Electromyography (EMG) is widely used to evaluate muscle activity 
(Basmaijan, 1985).  In this project surface electromyography was used to 
record activation of the muscles under investigation. This was preferred to 
needle electromyography in the hope that it would be better tolerated by the 
children. Needle EMG can work well when movement is restricted and 
forces are low. This could not be guaranteed in this study and the 
experimenters wanted to minimise discomfort in the children. Needle EMG 
allows more restricted spatial sampling of motor unit needle the needle tip 
and this can give clearer records of single motor unit activity. However, the 
surface EMG gives a broader sample of many motor units in the muscle and 
this wider sample will allow a better representation of whole muscle 
activity. 
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A small skin mounted pre-amplifier with integrated electrodes, measuring 
7mm in diameter, was used for recording the electromyography (EMG). 
This recording configuration eliminated connecting wire and so movement 
artefacts were kept to a minimum.  The EMG electrode with its integrated 
preamplifier can be seen in figure 2.8.  The skin at the recording sites was 
prepared very carefully before attaching the electrodes.  It was cleaned with 
alcohol to decrease the impedance and to improve the EMG recording.  
When the skin dried, the electrodes were coated with conductive gel and 
attached by tapes. This ensured good signal/noise characteristics.  The 
electrodes were placed over the belly of the soleus muscles, longitudinal to 
the predicted path of the muscle fibres as shown in figure 2.9.  
   
Abeer Felmban 2008  66 
 
 
Figure 2:9.  
The patient lay on bed in prone position, with the target leg flexed at 90 degrees.  EMG 
electrode fixed on the soleus muscle, and the skin was cleaned with an alcohol wipe.  ROM 
measured by manual goniometer and electrogoniometer.  Both of them were fixed on the 
lateral side of the left ankle. 
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Figure 2:10.  
The EMG pattern after high pass filter band stop filter. 
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2.6.5 General EMG Processing Procedures 
The raw EMG data were not always clear. There were frequent movement 
artefacts because the children did not always lie still during tests. In 
addition, sometimes there was low EMG activity. This was always likely 
after Botulinum Toxin-A injections had paralysed muscles.  
 
The Spike2 software (version 3.15) has a number of digital filters and these 
were used to remove artefacts and to enhance the EMG signal.  EMG was 
filtered by using high pass digital filter and then by band stop filter.  
The filtered EMG could then be rectified and smoothed.  Typically, a 
smooth function with a 0.05 time constant was used. In addition, full wave 
rectification helped the analysis (see figure 2.10.). 
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Figure 2.11.  
The figure shows the EMG pattern after high pass filtering and after subsequent 
rectification. 
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The onset of EMG activity was determined by setting a notional threshold 
five times larger than the mean value of the background EMG. Horizontal 
cursors were used. 
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Figure 2.11.  
The figure shows the EMG pattern after high pass filtering and after subsequent 
rectification. 
 
2.6.6. Dynamometer (Pressure gauge)  
 
The pressure applied was monitored with a pressure transducer.  The 
pressure needed to stretch the calf muscles from the rest position in flexion 
to the maximum in dorsiflexion was applied at a constant rate.  The change 
in angle from the initial position to the angle at peak pressure will be 
estimated for each of the five stretches.  
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2.7. Statistical Analysis 
A computer program was used to interpret scores for the GMFM-66. This 
scoring program is called the Gross Motor Ability Estimator (GMAE), the 
GMAE program has a self-contained tutorial. GMFM-66 scores are obtained 
by entering the GMFM item scores into the program individually for each 
child.  The option to enter the GMFM scores individually into the program 
was designed for clinical evaluation of children and to track their progress 
over time (Russell, 2002).  
 
During experiments, all values were collected as numerical outputs by 
GMFM, or angle of motion. Data were saved as Excel files in the first 
instance.  Following this, data were transferred to the Minitab version 14 for 
further statistical analysis.  The data were analysed using a one-way analysis 
of variance (unstacked). Results were considered to be significant at P 
<0.05. 
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Chapter 3 
Results 
3.1. Introduction  
 
This chapter contains results from experiments performed in The 
Rehabilitation Centre of The Prince Sultan Military Hospital in Al Hada and 
in the centres of The Disabled Children’ Association in Mecca and Jeddah. 
These centres treat children who live in the eastern area of Saudi Arabia in 
the cities of Jeddah, Taif and Makkah.   
 
The results are divided into four main sections: 
1. Characteristic features of children with cerebral palsy in 
institutionalised care. 
2. GMFM measurements in children included in the study.   
3. Measurements of the range of motion at the ankle joint in these 
children. 
4. Measurements of stretch reflex characteristics in a sample of these 
children. 
 
 
3.2 Characteristic features of children with Cerebral Palsy. 
The experimental procedures were reviewed and approved by The 
Rehabilitation Centre of The Prince Sultan Military Hospital in Al Hada and 
in the centres of The Disabled Children’ Association in Mecca and Jeddah. 
Proxy consent was obtained from the parents, who attended all sessions.  
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The author comprehensively assessed 163 children. In addition, all the 
selected children were evaluated in physical therapy department at The 
Rehabilitation Centre of The Prince Sultan Military Hospital in Al Hada.  
The physical therapy assessment forms used in this study are provided in 
Appendix 3.  
 
Children were recruited from Prince Sultan Hospital and Al-Hada Armed 
Forces Hospital, Disabled Children Association Jeddah and Makkah Centre 
and Rehabilitation Centre. The Ministry of Labour and Social Affairs of the 
Kingdom of Saudi Arabia supervises these centres. 
 
Recruiting children from several sites increased the number of suitable 
subjects for inclusion in the study. However, it also posed logistical 
problems. In an attempt to standardise treatments, Dr Shakfa and the 
investigator referred children to Prince Sultan Hospital and Al-Hada Armed 
Forces Hospital where they were all assessed before receiving Botulinum 
Toxin-A injections. In addition, all the children who received intensive 
physical therapy were treated by a single team of physiotherapists at The 
Disabled Children’ Association Centre in Makkah. This ensured consistent 
treatment but it meant that the assignment of children to the two 
experimental groups was not fully randomized. The details of the 
assignment were given in chapter 2 section 2.1. The effects of this process 
are analysed in section 3.3. Briefly, there were no significant statistical 
differences caused by the assignment process.  
 
The costs of the treatment were divided between the Prince Sultan Hospital 
and Al-Hada Armed Forces Hospital and Rehabilitation Centre and the 
Ministry of Labour and Social Affairs. The Botulinum Toxin-A injections 
for each child cost approximately £300, a total of £14100 for the 47 
children. The costs of the additional physiotherapy sessions were borne by 
the Ministry. 
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One hundred and sixty three children were comprehensively assessed by a 
physical therapy examination in each centre and hospital. The characteristics 
of these children are summarised in table 3.1.  
 
Approximately equal numbers of male and female children were assessed.  
None of the children were assessed as spastic monoplegic. However, the 
other five types of cerebral palsy were observed. 
 
The largest group of children was classified as spastic diplegic. This group 
accounted for 60% of children assessed.  There were significant numbers of 
hemiplegic and paraplegic children, 19% and 15% respectively in the group. 
There were smaller numbers of dyskinetic, hyperkinetic, triplegic and ataxic 
cases. This pattern reflects the expected frequencies of these types of 
cerebral palsy. The data on the aetiology of the cases shows the expected 
pattern, where prenatal problems predominate. Figure 3.1 and 3.2  
 
The assessment of ambulatory status was done by visual inspection in the 
clinic and with reference to their clinical records. The ambulatory status was 
very varied. 34% of the children were capable of walking independently.  
25% of the children used a walker.  Children who walked supported by their 
parent or with crutches represented 6% and 5% respectively. 27% of the 
children could not walk and relied on a wheelchair. Only 3% of the children 
depended on baby wheelchairs. 
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A Sex Number % 
 Male 85 52% 
 Female 78 48% 
B Cerebral Palsy Classification   
 
Spastic diplegia 98 60% 
 
Spastic hemiplegia 31 19% 
 
Spastic quadriplegia 24 15% 
 
Dyskinetic hyperkinetic 7 4% 
 
Spastic triplegia 2 1% 
 
Ataxia 1 1% 
C Aetiology   
 
Prenatal 75 46% 
 
Postnatal 55 34% 
 
Perinatal 33 20% 
D Ambulation Status   
 
Independent 55 34% 
 
Wheelchair 44 27% 
 
Walker 41 25% 
 
Holding by parents 10 6% 
 
Crutches 8 5% 
 
Baby wheelchair 5 3% 
E Gait Characteristics   
 
Toe-to-toe 65 40% 
 
Unable to walk 58 36% 
 
Occasional heel-to-toe 31 18% 
 
Toe-to-Heel 8 5% 
 
Ataxic Gait 1 1% 
F Included   
 
No 116 71% 
 
Yes 47 29% 
Table 3.1.  
Characteristic features of the 163 children assessed for this study. The assessment of the children 
status was done by visual inspection in the clinic and with reference to their clinical records 
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Figures 3.1 to 3.3 show the data tabulated above.  
0%
10%
20%
30%
40%
50%
60%
Diplegia Hemiplegia Quadriplegia Hyperkinetic Triplegia Ataxia
 
Figure 3.1.  
Classification of Cerebral Palsy replotted from the data in table 3.1. 60% of children were 
classified as spastic diplegic. There were 19% and 15% hemiplegic and paraplegic. There 
were smaller numbers of dyskinetic, hyperkinetic, triplegic and ataxic cases  
 
 
Figure 3.2.   
Aetiology of 163 Cerebral Palsy children, 75 prenatal, 55 postnatal and 33 perinatal.  
Replotted from the data in table 3.1. 
Prenatal 46%        Postnatal 34%           Perinatal 20%
Prenatal  
Postnatal
Perinatal
   
Abeer Felmban 2008  75 
 
0%
5%
10%
15%
20%
25%
30%
35%
40%
Toe-to-toe Unable to walk Occasional heel-
to-toe
Toe-to-Heel Ataxic Gait
 
Figure 3.3.  
Descriptions of the gait in the children reviewed. Replotted from Table 3.1  
 
 
Further classification of the children who were able to walk showed that the 
most frequent pattern used was toe-to-toe walking. The next largest group 
was those who occasionally manage heel to toe walking. 
Using the inclusion and exclusion criteria listed in tables 3.2.and 3.3, only 
46 children satisfied the inclusion criteria and entered the study. This was 
29% of the children initially assessed. A list of reasons for exclusion is 
summarized in Table 3.3. The main reasons excluding children was they 
were unable to walk, 42% of those excluded and children have history of 
surgery of the left leg, foot, or ankle, 29% of those excluded. 
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 Number Percentage 
Fixed contracture 25 22% 
Surgery 17 5% 
Unable to walk 14 12% 
Quadriplegia 10 9% 
Sever mental retardation 8 7% 
Previous BTX-A injection 8 7% 
Hemiplegia 8 7% 
Athetosis 8 7% 
Hypotonic 5 4% 
Parents refused due to physician advice 5 4% 
Younger than 2 years 3 3% 
Parents refused 3 3% 
Older than 13 years 2 2% 
   
Total 116  
Table 3.2. 
A list of reasons why children were excluded from the study. The main reasons excluding 
children was they were unable to walk, 42% of those excluded and children have history 
of surgery of the left leg, foot, or ankle, 29% of those excluded. 
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3.2.1 Lower limb surgery 
Forty-six children were excluded from the study because they had had 
surgery to correct deformities in their lower limbs. These deformities 
usually resulted from contractures of the calf muscles. Table 3.3 shows the 
details of the surgeries.  Bilateral calf surgery was the most frequent 
followed by unilateral calf surgery.  
  Frequency % 
Bilateral Calf Muscle 12 26% 
Unilateral Calf Muscle 8 17% 
Bilateral Hamstrings 7 15% 
Bilateral Adductor 4 9% 
Unilateral Calf &Hamstrings 4 9% 
Bilateral Calf & Hamstrings 3 7% 
Bilateral Calf & Adductor 2 4% 
Bilateral Hamstrings & Adductor 2 4% 
All 1 2% 
Back 1 2% 
Left tibialis anterior 1 2% 
Neurotomy 1 2% 
Table 3.3.  
The numbers of children who had previous surgery to their lower limbs to correct 
deformities in their lower limbs. These deformities usually resulted from contractures 
of the calf muscles 
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3.2.2. Visual and auditory impairments. 
The sensory impairments of the children were also recorded. These data 
came from the children’ clinical records. Their vision was usually normal, 
and only 14.7 % of the children had some vision abnormality. These 
problems included poor vision, nystagmus and strabismus. There was a 
similar pattern with auditory impairments with 6% having some auditory 
problem. Only 2 children used hearing aids. 
3.2.3 Speech disorders 
Speech disorders were more frequent than visual or auditory problems. 30.4 
% of the children had delayed development of language skills due to mental 
retardation. 12.7 % had dysartheria. This is a neurogenic speech disorder. 
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Figure 3.4.  
Ambulation status of the 163 children reviewed. The assessment of ambulatory status was   
done by visual inspection in the clinic and with reference to their clinical records. 34% of the 
children were capable of walking independently.  25% of the children used a walker.  Children 
who walked supported by their parent or with crutches represented 6% and 5% respectively. 
27% of the children could not walk. Only 3% of the children depended on baby wheelchairs 
Replotted from Table 3.1 
 
  
 
Mild retardation
25%
Normal
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Severing mental 
retardation
7%
 
Figure 3.5.  
Mental states of the 163 children reviewed. Replotted from Table 3.1.  
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In summary, 47 children (26 boys and 21 girls) with cerebral palsy were 
recruited for the study. This represents 29% of the children screened. The 
total number of children treated in these centres is about 325.  Thus the 
study includes a significant proportion of the total clinical population. 
 
The characteristics of 47 children who participated in the project are shown 
in tables 3.4 and 3.5.  Table 3.4 shows the details of children who received 
the Botulinum Toxin-A treatment (Group 1). Table 3.5 shows the details of 
children who received the Botulinum Toxin-A treatment and physical 
therapy (Group 2). 
 
Approximately 10% of the physical therapy and measurement sessions were 
stopped because the child involved did not cooperate or became distressed. 
These instances are reported in the relevant data tables, where it is recorded 
as ‘data missing’. In a small number of cases the parent terminated the 
session. 
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Group 1: Botulinum Toxin-A Treatment  
ID. No. Gender Age (month) Weight kg Height  Ambulation Mental Status 
5 F 168 26 135 Independent Normal 
20 F 131 23 109 Independent Normal 
30 M 80 16 85 Independent Mild retarded 
35 M 76 15 85 Independent Normal 
40 M 76 16 86 Independent Mild retarded 
44 M 70 16 85 Independent Normal 
9 F 108 18 110 Walker Mild retarded 
23 F 31 12 109 Walker Normal 
28 F 81 17 85 Walker Mild retarded 
32 F 96 17 106 Walker Mild retarded 
41 F 88 20 85 Walker Mild retarded 
10 M 106 30 106 Walker Mild retarded 
17 M 96 20 85 Walker Mild retarded 
25 M 46 28 98 Walker Normal 
36 M 76 13 88 Walker Normal 
37 M 78 17 85 Walker Normal 
45 M 79 14 84 Walker Normal 
46 M 96 18 93 Walker Normal 
Table 3.4.  
Demographic data of children in Group 1. The table shows the details their heights, 
weights and gender.  The columns on the right show their ambulation status. The 
children either walked independently or with the help of a walker. Their mental status 
is also shown. 
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Group 2: Botulinum Toxin-A and physical therapy treatment  
ID. No. Gender Age (month) Weight kg Height Ambulation Mental Status 
1 M 60 18 139 Independent Normal 
2 M 68 15 84 Independent Mild retarded 
3 F 47 17 99 Independent Mild retarded 
8 M 60 15 145 Independent Normal 
15 F 48 18 111 Independent Normal 
16 F 132 19 144 Independent Normal 
18 F 58 13 104 Independent Normal 
19 M 72 12 87 Independent Normal 
22 M 72 18 84 Independent Mild retarded 
24 F 108 43 107 Independent Normal 
27 M 30 30 105 Independent Normal 
29 M 46 11 110 Independent Normal 
31 M 70 17 84 Independent Mild retarded 
39 M 45 12 105 Independent Normal 
4 F 84 18 84 Walker Normal 
6 F 48 11 108 Walker Mild retarded 
7 F 84 27 95 Walker Normal 
11 F 34 11 107 Walker Mild retarded 
12 M 94 20 86 Walker Mild retarded 
13 M 96 18 85 Walker Normal 
14 F 69 17 86 Walker Mild retarded 
21 M 24 13 107 Walker Normal 
26 F 36 29 84 Walker Normal 
33 M 30 10 86 Walker Normal 
34 F 48 13 108 Walker Mild retarded 
38 F 39 16 98 Walker Normal 
42 M 29 11 105 Walker Normal 
43 F 36 14 107 Walker Normal 
Table 3.5.  
Demographic data of children in Group 2.  The table shows details of their heights, 
weights and gender.  The columns on the right show their ambulation status. Their mental 
status is also shown. 
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The allocation to the two groups was not fully randomized since it depended 
on the decisions of the parents about where their child should be treated. 
However, the two groups are well matched in terms of body sizes. There is 
no significant difference in the mean body weight and height of the children 
in the two groups. The mean weight of group 1 was 20 kg and the mean 
weight of group 2 was 16 kg.  The mean height Group 1 was 108 cm and the 
mean height of group 2 was 94 cm.  When compared with T tests the P-
values were 0.253 for body weight and 0.100 for height.  
 
The issue of the effect of the allocation on GMFM is addressed more fully 
later in figures 3.6. 3.7. and 3.8. section 3.3. The advice of Dr Aitchison of 
the Statistics Department of Glasgow University was sought and followed 
throughout this section. 
 
 
3.3 The effect of botulinum toxin- A in spastic cerebral palsy children 
 
Forty-six children were screened over a 52 -week period. 26 males and 21 
females were recruited into the trial. The variables that were ROM at the 
ankle recorded via electrogoniometry, electromyography (EMG) of soleus, 
and gross motor function measurement (GMFM). 
 
3.3.1 Group 1  
These children came from a clinical centre in a village in western area Saudi 
Arabia in the Al- Taif region. Their families refused to stay at the Disabled 
Children’ Association in Makkah or in Jeddah. They were given Botulinum 
Toxin-A injections, their ankles were fixed with casts and they were fitted 
with medical shoes.  
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3.3.2 Group 2 
These children also came from the western part of Saudi Arabia. Their 
families chose residential care in Makkah and Jeddah. These children 
received the same treatment as Group 1 and intensive physical therapy.  
Tables 3.6 and 3.7 show details of the children in both groups and their 
GMFM scores before treatment started and at intervals of 4, 6 and 52 weeks 
later.  
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ID. No. Gender 
Weight 
kg 
Height 
cm 
Age 
(Month) 
1  
GMFM 
2  
GMFM 
3  
GMFM 
4  
GMFM 
46 F 15 108 96 61 61 62 63 
10 M 38 111 104 45 47 48 50 
36 M 15 107 74 72 75 76 78 
35 F 11 84 74 67 70 72 n/a 
5 F 16 105 154 74 75 77 78 
37 M 16 109 77 62 64 66 68 
45 M 17 107 79 59 60 61 62 
25 M 16 108 45 60 63 65 72 
30 M 17 107 78 48 49 52 n/a 
9 F 15 98 109 50 51 52 52 
32 F 18 110 97 52 53 54 54 
28 F 15 99 80 50 51 51 53 
23 F 30 104 29 53 54 54 55 
41 M 44 139 86 72 73 76 n/a 
44 M 46 145 70 70 71 73 76 
20 F 13 88 129 50 51 52 52 
40 M 13 106 74 51 52 52 52 
17 M 13 107 80 54 56 56 58 
Mean 58.3 59.8 61.1 61.6 
Max 74.0 75.0 77.0 78.0 
Min 45.0 47.0 48.0 50.0 
SD 9.1 9.3 9.8 10.0 
Table 3.6.  
The characteristic of children in Group 1. The table shows the details of  children, their 
heights, weights and gender. 
The columns on the right show the GMFM Scores at 1 before treatment, 2 after 4 weeks, 
3 after 6 weeks and 4 after 52 weeks.  n/a: data not available. 
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Mean 60.1 64.2 67.9 70.9 
Max 74.2 77.5 79.1 89.7 
Min 41.6 46.3 48.7 47.9 
SD 10.5 10.9 10.6 12.8 
Table 3.7.  
The characteristic of children in Group 2. The table shows the details of children, their heights, 
weights and gender.  The columns on the right show the GMFM Scores at 1 before treatment, 2 after 
4 weeks, 3 after 6 weeks and 4 after 52 weeks.  n/a: data not available. 
 
 
 
 
ID. 
No. Gender Weight kg Height cm 
Age 
(Month) 
1  
GMFM 
2  
GMFM 
3  
GMFM 
4  
GMFM 
15 F 16 105 48 57 58 62 76 
21 M 12 86 25 70 71 74 85 
2 M 16 98 66 55 57 58 59 
1 M 27 105 59 54 56 58 60 
11 F 11 84 32 48 53 57 n/a 
22 M 11 86 73 40 43 45 51 
27 M 11 84 28 37 44 46 49 
12 M 11 85 91 55 57 61 65 
14 F 12 87 67 56 60 65 68 
8 F 13 84 60 48 54 55 56 
29 M 12 85 45 57 57 63 66 
24 F 12 86 106 62 64 69 76 
6 F 12 85 46 60 65 70 76 
29 M 17 85 43 67 68 70 72 
13 M 12 84 94 46 49 53 54 
19 M 13 85 72 63 73 76 81 
31 M 13 85 69 46 49 51 53 
26 F 14 95 25 70 77 79 81 
18 F 13 84 56 65 72 75 79 
4 F 14 85 84 71 76 77 81 
38 F 16 86 37 71 73 76 80 
3 F 17 85 45 46 46 55 48 
43 F 15 93 36 73 76 79 81 
34 F 18 106 33 69 70 78 90 
42 M 20 110 27 42 47 49 50 
33 M 17 109 28 57 66 71 74 
7 F 43 144 82 74 77 79 83 
16 F 40 135 132 69 72 75 81 
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The data in tables 3.6 and 3.7 is replotted in subsequent figures. Figure 3.6 
is a box plot of the GMFM scores of both groups one week before 
treatment. The distribution of scores is similar in both groups. There seems 
to be more variability in group 2 than group 1. This may be due to group 2 
having a larger sample size. The box plots are fairly symmetrical and this 
supports the suggestion that the data are normally distributed. A two sample 
t-test showed that there was no significant difference in GMFM score before 
the treatment began (P=0.950). In addition, the 95% CI for the difference 
contains zero.  The results are shown below in table 3.8. 
 
 
Group
B
a
s
e
lin
e
 G
M
F
21
75
70
65
60
55
50
45
40
35
Boxplot of Baseline GMF vs Group
 
 Figure 3.6.  
Box plot of baseline GMFM scores in Group 1 and Group 2 one week before 
treatment. The distribution of scores is similar in both groups. There seems 
to be more variability in group 2 than group 1. This may be due to group 2 
having a larger sample size. 
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Two-sample T for Baseline GMF 
 
Group No. Mean StDev SE Mean 
1 18 58.33 9.36 2.2 
2 28 58.1 10.9 2.1 
 
Difference = mu (1) - mu (2) 
Estimate for difference:  0.190476 
95% CI for difference:  (-5.912570, 6.293523) 
T-Test of difference = 0 (vs not =): T-Value = 0.06 
P-Value = 0.950  DF = 40 
Table 3.8. 
Output for two sample t-test comparing GMFM in groups 1 and 2 scores before treatment 
begins 
 
The box plot in figure 3.6 does not correct for other variables such as the sex 
of the child, their height, weight and age. Further analysis was done to 
discover if the data should be corrected for these variables. Box plots of the 
ages, weights and heights for both groups are shown in figure 3.7. 
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Figure 3.7.  
Box plots of the age, weight and height of the children in Groups 1 and 2.  
 
The two groups seem well matched for weight but less so for age and 
height.  
 
Scatter plots were produced to investigate if any of these variables had an 
effect on the baseline gross motor function. These are shown in figure 3.8. 
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Figure 3.8.  
Scatter plots of GMFM scores before treatment starts plotted against the age, weight and 
height of the children in both group 1 and 2. Regression lines are plotted for each group. 
 
 
The plots in figure 3.8 show considerable overlap of the data points for 
group1 and 2. The regression lines are very similar in slope and intercept. 
This indicates that no correction is required and that two-sample t-test are 
appropriate. The result of these tests is shown in table 3.9. No significant 
effects were detected and this confirms that there is no real evidence of any 
significant difference in baseline GMFM between the 2 groups. Thus, 
retrospectively, it is good to note that the ‘treatment allocation’ was fair 
even if it was non-random. 
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3.4 Gross Motor Function Measurements after Intervention 
3.4.1 Group 1 
 
The GMFM scores of the 18 children in  group 1 were measured before 
Botulinum Toxin-A injections and at four, six and 52 week later. The 
GMFM scores are shown in table 3.6. All the children were assessed before 
the injections and again at weeks 4, 6 and 52. Three children could be not 
assessed at the one-year follow up. This was due to their parent’s reluctance 
to return to the clinic rather than to any adverse event. 
 
It is clear from the data in the table 3.6 and figure 3.9 A and B that these 
children show an improvement in GMFM scores over the period of the 
study. The mean GMFM score one week before Botulinum Toxin-A 
injection was 58.3 ± 9.4. By 4 weeks after the injection it was 59.8 ± 9.6. By 
6 weeks after the injection it was 61.1 ± 10.9 and at 52 weeks after injection 
it was 61.5 ± 10.3 
 
However, the differences are not significant when tested statistically using 
an ANOVA. When the mean scores before treatment are compared with 
those at 4 week, the P Value is 0.650. When compared with the scores at 6 
weeks, the P Value is 0.407. After 52 weeks the P Value is 0.358. These 
data are recorded in table 3.10.  
 
Clinically, there is an improvement in some children in-group 1.  Figure 3.9 
B shows the data for each child at the four points of measurement. There is a 
clear trend upwards in the data. 15 children had increased GMFM scores 
after Botulinum Toxin-A injection. It is also clear that in this figure and 
from the data in the table there is a big range of GMFM scores.  
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A  GMFM before GMFM at 4 weeks 
 
Mean  58.3 59.778 
 
St.Dev 9.4 9.589 
 
P Value 0.650 
 
  
B  GMFM before GMFM at 6 weeks 
 
Mean 58.3 61.1 
 
St.Dev 9.4 10.1 
 
P Value 0.407 
 
   
C  GMFM before GMFM at 52weeks 
 
Mean 58.3 61.5 
 
St.Dev 9.4 10.3 
 
P Value 0.358 
 
 
Table 3.9. 
A summary of the results of ANOVA test comparing the 
magnitude of the GMFM scores pre and post Botulinum Toxin-
A injection in group 1 
The results of ANOVA tests of GMFM scores in group 1 
comparing GMFM scores before treatment with A 4 weeks after 
injection. 
B 6 weeks after injection. 
C 52 weeks after injection 
The results show that the mean GMFM scores were not 
significantly improved after Botulinum Toxin-A injection. 
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Figure 3.9.  
Panel A shows the GMFM scores for all the children in group1. 
Panel B shows the interval plot of the mean GMFM ± SD scores one week 
before, 4 weeks, 6 weeks and 52 weeks after Botulinum Toxin-A injection 
for the 18 diplegic children in group 1. 
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3.4.2 Group 2 
 
The GMFM scores of the 28 children in group 2 were measured before 
Botulinum Toxin-A injections and at four, six and 52 weeks later.  The 
GMFM scores are shown in table 3.7. 26 children of the 28 children 
increased their score after Botulinum Toxin-A injection. However, one 
child’s score decreased at 52 weeks. This was probably a consequence of a 
fracture in the head of femur. This injury was unrelated to the study. In 
addition, one other child did not return to the clinic for the final assessment 
at 52 weeks. This was due to the parent’s reluctance to return to the clinic 
rather than to any adverse event. 
 
Clinically, there is an improvement in most of the children in group 2. Their 
GMFM scores are plotted in figure 3.10 A and B. It is clear from the data in 
the table 3.7 and figures 3.10 A and B that these children show an 
improvement in GMFM scores over the period of the study. The mean 
GMFM score one week before Botulinum Toxin-A injection was 58.1 ± 
10.9.  Four weeks after the injection it was 61.8 ± 11.0 and by 6 weeks after 
the injection it was 65.1 ± 11.0. By 52 weeks after injection it was 69.4 ± 
13.00.  
 
The results of ANOVA tests of GMFM scores are shown in table 3.14. The 
improvement in mean GMFM between the initial assessments and 4 weeks 
after Botulinum Toxin-A injection is not statistically significant (P =0.219). 
However, the improvements in mean GMFM were statistically significant at 
6 weeks (P =0.019) and at 52 weeks (P=0.001). This improvement contrasts 
sharply with the lack of significant change for group 1 which was reported 
in the previous section.  
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A  GMFM before GMFM at 4 weeks 
 
Mean 58.14 61.79 
 
St.Dev 10.92 11.01 
 
P Value 0.219 
 
   
B  GMFM before GMFM at 6 weeks 
 
Mean 58.14 65.21 
 
St.Dev 10.92 13.00 
 
P Value 0.019 
 
   
C  GMFM before GMFM at 52 weeks 
 
Mean 58.14 69.44 
 
St.Dev 10.92 13.00 
 
P Value 0.001 
 
Table 3.10.  
A summary of the results of ANOVA test comparing the magnitude of the 
GMFM scores pre and post Botulinum Toxin-A injection in group 2 
The results of ANOVA tests of GMFM scores in group 2 comparing 
GMFM scores before treatment with A 4 weeks after injection. 
B 6 weeks after injection. 
C 52 weeks after injection 
The results show that the mean GMFM scores were significantly improved 
at 6 and 52 weeks after Botulinum Toxin-A injection in this group of 
children 
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Figure 3.10.  
Panel A shows the GMFM scores for all the children in  Group 2. 
Panel B shows the interval plot of the mean GMFM ± SD scores one 
week before, 4 weeks, 6 weeks and 52 weeks after Botulinum Toxin-A 
injection for 28 diplegic children. 
The increase in mean scores is statistically significant after 6 and 52 
weeks.   
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3.4.3 Comparison of GMFM in Group1 and Group 2 
The previous sections have described the changes in GMFM in the two 
groups of children over the year after the injection of Botulinum Toxin-A. 
In summary, Group 1 showed no significant changes in GMFM over the 
year whilst group 2 showed a significant improvement in mean GMFM at 6 
and 52 weeks. This section will compare the performance of the two groups. 
The GMFM scores of the 46 children in the both groups were measured 
before Botulinum Toxin-A injections and at 4, 6 and 52 week later.  The 
GMFM scores are shown in table 3.5.and 3.6. The raw GMFM scores for 
each child are re-plotted in figure 3.11.  
One week before Botulinum Toxin-A injection the mean GMFM scores 
were 58.3 ± 9.4 in group 1 and 58.1 ± 10.9 in group 2.  At 4 weeks after the 
injection the mean scores were 59.8 ± 9.6 in-group 1 and 61.8 ± 11 in group 
2. By 6 weeks the mean score for group 1 was 61.1± 10.1 and 65.2 ± 1 in 
group 2. Finally after 52 weeks it was 61.5 ± 10.3 in group 1 and 69.4 ± 13 
in group 2. These data are plotted in figure 3.12. It is clear by eye that the 
mean values are almost identical before the Botulinum Toxin-A injections. 
Data shown in table 3.8 confirms that the means scores are not significantly 
different.  The mean scores do not change significantly over the 52 weeks in 
Group 1. However, the improvement in mean GMFM increases significantly 
in group 2.  
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Figure 3.11.  
Individual profile plot showing GMF score from baseline to the 52nd week of the study. 
Group 1 is plotted on the left and group 2 is plotted on the right.  
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Figure 3.12.  
Box plots of GMFM scores from baseline to the 52nd week of the study.  Group 1 is plotted 
on the left and group 2 is plotted on the right.  
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The difference in GMFM scores in the two groups were analysed using 
analysis of covariance (ANCOVA). This approach was recommended by Dr 
Aitchison of the Statistics Department. The results are shown below in 
tables 3.11. to 3.13. 
 
Analysis of Variance for GMF 4 weeks, using Adjusted SS for Tests 
Source                DF  Seq SS         Adj SS  Adj      MS            F                 P 
Baseline GMF     1   4628.5           4637.2           4637.2     1003.91        0.000 
Group                  1         52.9           52.9             52.9         11.45            0.002 
Error                  43       198.6          198.6             4.6 
Total                  45     4880.0 
S = 2.14922   R-Sq = 95.93%   R-Sq(adj) = 95.74% 
Term             Coef  SE Coef      T      P 
Constant        2.967    1.853   1.60  0.117 
Baseline GMF  0.99272  0.03133  31.68  0.000 
Bonferroni 95.0% Simultaneous Confidence Intervals 
Response Variable GMF 4 weeks 
All Pairwise Comparisons among Levels of Group 
Group = 1  subtracted from: 
Group   Lower  Center  Upper  ---------+---------+---------+------- 
2      0.8875   2.197  3.507  (---------------*----------------) 
                              ---------+---------+---------+------- 
                                     1.60      2.40      3.20 
Table 3.11.  
Results of a comparison of mean GMFM scores in groups 1 and 2 at 4 weeks after injection. 
The results of the ANCOVA show that the difference is significant (p< 0.001). 
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Analysis of Variance for GMF 6 weeks, using Adjusted SS for Tests 
Source               DF  Seq SS      Adj SS        Adj  MS             F         P 
Baseline GMF   1    4750.5          4768.4         4768.4        879.03     0.000 
Group                1    207.4           207.4           207.4           38.22      P<0.001 
Error                 43   233.3          233.3            5.4 
Total                 45   5191.2 
S = 2.32908   R-Sq = 95.51%   R-Sq(adj) = 95.30% 
Term             Coef  SE Coef      T      P 
Constant        4.508    2.008   2.24  0.030 
Baseline GMF  1.00667  0.03395  29.65  0.000 
Bonferroni 95.0% Simultaneous Confidence Intervals 
Response Variable GMF 6 weeks 
All Pairwise Comparisons among Levels of Group 
Group = 1  subtracted from: 
Group  Lower  Center  Upper  ---+---------+---------+---------+--- 
2      2.931   4.350  5.770  (----------------*-----------------) 
                             ---+---------+---------+---------+--- 
                              3.20      4.00      4.80      5.60 
Table 3.12.  
Results of a comparison of mean GMFM scores in groups 1 and 2 at 6 weeks after injection. 
The results of the ANCOVA show that the difference is significant (p< 0.001). 
 
 
 
Analysis of Variance for GMF 52weeks, using Adjusted SS for Tests 
Source               DF   Seq SS     Adj SS       Adj MS        F           P 
Baseline GMF   1     5428.1       5270.8      5270.8         332.87    0.000 
Group                1     446.2          446.2        446.2          28.18      P<0.001 
Error                 39    617.6         617.6        15.8 
Total                 41    6491.9 
S = 3.97928   R-Sq = 90.49%   R-Sq(adj) = 90.00% 
Term             Coef  SE Coef      T       P 
Constant        0.643    3.612   0.18  0.860 
Baseline GMF  1.11753  0.06125  18.24  0.000 
Bonferroni 95.0% Simultaneous Confidence Intervals 
Response Variable GMF 52weeks 
All Pairwise Comparisons among Levels of Group 
Group = 1  subtracted from: 
Group  Lower  Center  Upper  --+---------+---------+---------+---- 
2      4.215   6.810  9.405  (----------------*-----------------) 
                             --+---------+---------+---------+---- 
                             4.5       6.0       7.5       9.0 
Table 3.13.  
Results of a comparison of mean GMFM scores in groups 1 and 2 at 52 weeks after injection. 
The results of the ANCOVA show that the difference is significant (p< 0.001). 
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Thus there was no significant difference in the mean GMFM scores before 
treatment started. The scores in group 1 (Botulinum Toxin-A alone) did not 
change significantly over the 52 week. The scores in Group 2 (Botulinum 
Toxin-A and intensive physical therapy) did increase significantly at 4, 6 
and 52 weeks. The children in Group 2 had significantly higher GMFM 
score at 4, 6 and 52 weeks.  
Figure 3.12 shows clearly that the data from group 1 shows an initial rise in 
GMFM scores from before the study. It is small and does not change further 
over the 52 weeks after first treatment. In group 2 however, the initial rise 
continues throughout the study. The individual data plotted in figure 3.11. 
show that the improvement is not constant for each child throughout the 
study. 
The causes of the different improvements in group 1 and 2 were investigated 
further. The ultimate aim was investigate if the improvement was larger in 
children with low GMFM scores at baseline. Plots of the starting GMFM 
scores at the scores at later times are given in figures 3.13, 3.14 and 3.15. 
These also show a line of equality line indicating ‘no change’ in GMFM.  
Figure 3.13 shows a scatter plot of baseline GMFM score against GMFM 
score at 4 weeks for groups 1 and 2. Firstly, it is easy to see that all the 
points lie on or above the line of equality i.e. all children are unaffected or 
improve. 
The points representing group 2 lie further above the line of equality i.e. 
group makes a greater improvement. This repeats graphically the results of 
the ANCOVA tests reported above showing that group 2 scores were 
significantly greater at week 4. Regression lines are fitted to each set of data 
and all points lie close to this indicating that children with low initial scores 
improve by a similar amount to those with higher initial scores. The 
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regression line for group 2 lies above that for group 1 and this shows a 
slightly greater improvement in group 2 across the range of baseline 
GMFM. 
Figure 3.14 shows a similar plot for data at 6 weeks. Group 2 points lie 
further away from group 1 as indicated by the plots of means scores shown 
above in figure 3.12. The children with higher initial scores in group 1 now 
appear to make a greater improvement than lower scoring member of group 
1.  
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Figure 3.13.  
Scatter plot of baseline GMFM score vs. GMFM score at 4 weeks. Children in group 1 
are shown as triangles and those in group 2 are shown as circles. 
All points lie on or above the line of equality i.e. all children are unaffected or improve. 
The points representing Group 2 lie further above the line of equality i.e. group makes a 
greater improvement.  
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Figure 3.14.  
Scatter plot of baseline GMF score vs. GMF score at 6 weeks. Children in group 1 are 
shown as triangles and those in group 2 are shown as circles. 
The points representing Group 2 lie further away from group 1. The children with 
higher initial scores in group 1 now appear to make a greater improvement than lower 
scoring member of group 1 
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Figure 3.15.  
Scatter plot of baseline GMF score vs. GMF score at 52 weeks. Children in group 1 are 
shown as triangles and those in group 2 are shown as circles. 
The points representing Group 2 lie further away from group 1. The children with 
higher initial scores in group 1 now appear to make a greater improvement than lower 
scoring member of group 1 
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Figure 3.15 is a similar plot again for data at 52 weeks. It can be seen that 
the children in group 2 have improved much more than those in group 1. 
This reflects the earlier results in mean data. However it is now clear that 
those with the highest initial scores made the biggest improvements. No 
child in group 1 finished with a lower GMFM score. However, the children 
with the lowest initial score often lie very close to the line of equality i.e. 
they did not improve much. The biggest improvements in group 1 lie in the 
children with the higher initial scores though their gains are smaller than 
high scoring children in group 2.  
 
The GMFM scores in groups 1 and 2 do not appear to improve in a uniform 
manner with respect to the initial GMFM score i.e. the children who started 
with ‘higher’ baseline GMFM scores show more of an increase at each time 
point than those with ‘lower’ baseline GMFM scores. This complicates any 
formal statistical analysis. It is important to allow for this when choosing a 
statistical model. However, whilst this problem remains for statisticians, it 
may be relevant in considering which treatments to recommend for 
individual children. Those with low baseline scores will probably benefit 
least from either intervention.  
 
3.5 Range Of Motion Measurements after Intervention 
In addition to the GMFM measurements described before, the range of 
motion at the ankle of each child was measured before Botulinum Toxin-A 
injections and at 4 and 6 weeks after injection. Electro-goniometers were 
used to measure the range of motion (ROM). The author used traditional 
manual goniometers to calibrate the electro-goniometers. Details are given 
in chapter 2.  
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3.5.1 Range of Motion in Group 1 
These children were treated with Botulinum Toxin-A only. Their ROMs are 
shown in table 3.14. Figure 3.16. A shows a plot of the data for each child at 
the three points of measurement.  
The means of the ROM are shown in figure 3.16 B. There is a clear trend 
upwards in the data. The children had an increased ROM after Botulinum 
Toxin-A injection. It is also clear that in this figure and from the data in the 
table there is a big range of ROM degrees. The mean ROM degrees one 
week before Botulinum Toxin-A injection was 17.4 ± 5.7 degrees, 4 weeks 
after the injection it was 21.2 ± 8.0 degrees. At 6 weeks after the injection it 
was 23.9 ± 5.6 degrees 
The data were analyzed using a one-way analysis of variance (Unstacked) 
ANOVA. The differences in mean ROM before the injections and at 4 week 
after the injection were found to be not significant (P = 0.127). However, 
when the initial values are compared with those at 6 weeks, the differences 
were found to be significant (P = 0.003).The summary of these results is 
given in table 3.16.  
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ID. No. Gender 
Weight 
kg 
Height 
cm 
Age 
(month) 
ROM 
Week -1 
ROM 
Week 4 
ROM 
Week 6 
25 M 13 88 45 12 15 25 
33 M 11 84 28 14 17 20 
10 M 38 111 104 26 34 31 
37 M 17 107 77 25 14 27 
12 F 20 110 91 17 29 26 
23 F 16 105 29 13 8 15 
32 F 15 99 97 22 20 22 
9 M 30 104 109 16 33 27 
17 M 18 110 80 23 35 27 
28 F 17 107 80 8 14 14 
5 F 46 145 154 17 21 22 
30 M 16 108 78 19 19 30 
34 F 13 85 33 7 14 14 
42 M 11 86 27 17 22 27 
20 F 44 139 129 23 26 26 
Mean 17 21 24 
Max 26 35 31 
Min 7 8 14 
SD 6 8 6 
Table 3.14.  
The range of motion at the ankle joint of the children in Group 1. The table shows the 
details of children, their heights, weights and gender.  The columns on the right show 
the ranges of motion. 
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 Figure 3.16.  
Panel A shows the range of motion at the ankle the children in Group 1 week before, 
4 weeks and 6 weeks after Botulinum Toxin-A injection. Data for 18 diplegic 
children. 
 
 
 
 
 Group 1 
 
-1 week vs 
4 weeks 
-1 week vs 
6 weeks 
Mean 17.4° 21.2° 23.9° 
St.Dev 5.7° 8.0° 5.6° 
P Value  0.127 0.003 
 
Table 3.15.  
A summary of the results of ANOVA tests comparing the mean ROM pre and post 
Botulinum Toxin-A injection in group1.  The results show that the mean ROM was 
statistically significant in group1 after Botulinum Toxin-A injection 6 weeks. 
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3.5.2 Group 2 
A similar analysis was done for the ROM in the children in group 2. Their 
data are shown in table 3.16. Figure 3.17. A shows a plot of the data for 
each child at the three points of measurement all goes up. 
The means of the ROM data are shown in figure 3.17. B. In this case there is 
a very clear trend upwards in the data. The mean ROM degrees one week 
before Botulinum toxin type A injection was 15.5 ± 5.0 degrees, 4 weeks 
after the injection it was 25.6 ± 7.2 degrees. At 6 weeks after the injection it 
was 27.9 ± 10.4 degrees 
The data were again analyzed using a one-way analysis ANOVA. The 
difference in mean ROM before the injections and at 4 week after the 
injection was found to be significant (P<0.001). The result was still 
significant at 6 weeks (P<0.001). The data are summarised in table 3.18. 
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ID. No. Gender 
Weight 
kg 
Height 
cm 
Age 
(Month) 
ROM  
Week -1 
ROM 
Week 4 
ROM  
Week 6 
22 M 18 106 73 7 18 14 
19 M 15 93 72 22 27 34 
15 F 13 85 48 9 32 33 
21 M 11 84 25 9 22 33 
13 M 17 109 94 18 24 14 
27 M 12 86 28 17 4 26 
2 M 16 86 66 18 22 28 
1 M 13 84 59 17 21 11 
11 F 11 85 32 10 15 23 
14 F 17 85 67 15 27 24 
29 M 12 85 45 27 9 27 
8 M 14 85 60 6 21 24 
16 F 40 135 132 19 49 58 
7 F 27 105 82 20 34 35 
3 F 17 85 45 18 29 33 
31 M 16 105 69 15 25 25 
18 F 14 95 56 19 32 39 
26 F 12 87 25 17 22 18 
38 F 12 85 37 14 18 22 
4 F 16 98 84 16 22 34 
6 M 12 84 46 12 30 21 
11 F 11 85 32 16 22 38 
Mean 16 24 28 
Max 27 49 58 
Min 6 4 11 
SD 5 9 10 
Table 3.16.  
The range of motion at the ankle joint of the children in group 2 who had Botulinum toxin 
type A injection with additional physical therapy. The table shows the details of children, 
their heights, weights and gender.  The columns on the right show the ROM Scores. 
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   Figure 3.17.  
Panel A shows the ROM scores for all the children in Group 2.   
28 diplegic children. The improvement form baseline is significant at 4 and 6 
weeks.  
 
 
 
 Group2 
 
-1 week vs 
4 weeks 
-1 week vs 
6 weeks 
Mean 15.5° 25.6° 27.9° 
St.Dev 5.1° 7.1° 10.4° 
P Value  <0.001 <0.001 
 
Table 3.17.  
A summary of the results of ANOVA test comparing the magnitude of the ROM pre 
and post Botulinum toxin type A injection in group 2. The results show that the mean 
ROM was statistically significant in group 2 4 and 6 weeks after the Botulinum toxin 
type A injection. 
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3.5.3 Comparison of ROM in Group 1 and Group 2. 
The previous sections have described the changes in ROM in the two groups 
of children over the year after the injection of Botulinum toxin type A. In 
summary, group 1 showed no significant changes in mean ROM after 4 
weeks but there was significant improvement after 6 weeks. Group 2 
showed a significant improvement in mean ROM at 4 and 6 weeks. This 
section will compare the ROM of the two groups. 
The results of testing these data with an ANOVA are shown in table 3.18. 
The mean ROMs in group 1 and group 2 were not significantly different 
before the Botulinum toxin type A injection (P-Value =0.290). Four weeks 
after Botulinum toxin type A the difference in means had increased but this 
difference was still not significant.  (P =0.085). The same result was found 
after 6 weeks (P =0.173). These data are plotted in figure 3.19. 
A good clinical response to Botulinum toxin type A injection in soleus and 
gastrocnemius muscle was shown by a decrease in toe walking in the 
children in both groups. This observation was noted by the parents and 
several clinicians, but not formally investigated.  
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 Group 1 Group 2 
    
A Mean 17.4° 15.5° 
 
St.Dev 5.7° 5.1° 
 
P Value 0.290 
 
   
B Mean 21.2° 25.6° 
 
St.Dev 8.0° 7.2° 
 
P Value 0.085 
 
   
C Mean 23.9° 27.9° 
 
St.Dev 5.6° 10.4° 
 P Value 0.173 
 
Table 3.18.  
A summary of the result of ANOVA tests comparing the magnitude of the 
ROM pre and post Botulinum toxin type A injections in group 1 and group 2. 
A One week before Botulinum toxin type A injection 
B Four weeks after Botulinum toxin type A injection 
C Six weeks after Botulinum toxin type A injection 
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Figure 3.18.  
This shows the mean ROM scores for Group 1 and group 2 one week before, 
4weeks and 6weeks after BTX-A injection for 46 diplegic patients 
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3.6 Electromyography Data 
The main aims in this section were to investigate how effective the 
Botulinum toxin type A injections were in paralysing the muscles and to 
investigate the effects on the stretch reflexes in soleus. 
The surface EMG was recorded over soleus when the child was in a prone 
position with their knee flexed at 90º. The details of the EMG technique 
were described in section 2.8.4 of chapter 2. The EMG was recorded during 
ankle dorsiflexion, before the Botulinum toxin type A injection and at weeks 
4 and 6 later. 
There were remarkably few sessions where EMG could not be investigated. 
A typical set of recordings is shown in figure 3.19. The upper panel shows 
soleus EMG before during and after a dorsiflexion of the ankle joint. This 
recording was made before the Botulinum toxin type A injections. The 
lower panel shows similar recordings in the same child 4 weeks later. In this 
case, no surface EMG can be seen. The summary data showing the overall 
responses is shown in table 3.19. 
One child in group 1 and three children in group 2 could not be investigated 
because of problems with hyperactivity. It was not possible to make EMG 
recordings in these cases. One child in group 2 withdrew because of an 
allergic skin reaction, which was not related to the conductive gel or tapes 
used. All other 17 children in group 1 and 25 child in group 2 were 
investigated. 
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Soleus EMG was recorded at the initial session in all 18 children in-group 1.  
The individual EMG responses are shown in tables 3.20 and 3.21. 
11 children of this group had no surface EMG activity at week 4 (61%) and 
5 children still showed no EMG activity at week 6 (28%). In group 2, all the 
children showed surface EMG activity at the initial session. 8 children 
(28%) had no EMG at week 4 and 3 children had no EMG activity at week 6 
(11%). Thus the doses of Botulinum toxin type A used appear to give 
abolition of EMG activity for 4 week in about half the children, (See 
Chapter 2, Section 2.5, tables 2.3 and 2.4.). The EMG activity was still 
absent in 8 children at six weeks after the injection.  
 Group 1 Group 2 
A 18 children treated with Botulinum 
toxin type A  
28 children Botulinum toxin type A + 
intensive physical therapy 
B 7 (38%) had EMG at -1, 4 and 6 
weeks 
17 (60%) had EMG at 1, 4 and 6 weeks. 
C 6 had EMG at -1, 6 and not week 4 5 had EMG at 1, 6 and not week 4. 
D 5 had EMG at -1 and not week 4, 6. 3 had EMG at -1 and not week 4, 6.  
Table 3.19.  
This shows the frequency of EMG activity 1-week before Botulinum toxin type A injection 
and at 4 and 6 weeks later. Group 1 received only Botulinum toxin type A whilst group 2 
received Botulinum toxin type A and additional physical therapy. 
There is no data for 3 children in group 2. There is no data for 1 child in group 1 at week 4.  
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ID. 
No. Gender 
Weight 
kg 
Height 
cm 
Age 
(month) 
EMG 
week-1 
EMG 
week 4 
EMG 
week 6 
35 F 15 107 74 EMG EMG EMG 
44 M 16 105 70 EMG EMG EMG 
37 M 17 107 77 EMG EMG EMG 
28 F 17 107 80 EMG EMG EMG 
17 M 18 110 80 EMG EMG EMG 
20 F 44 139 129 EMG EMG EMG 
46 F 15 108 96 EMG EMG EMG 
9 F 30 104 109 EMG No Data EMG 
23 F 11 84 29 EMG No EMG EMG 
40 M 16 109 74 EMG No EMG EMG 
30 M 16 108 78 EMG No EMG EMG 
36 M 13 106 74 EMG No EMG EMG 
45 M 13 107 79 EMG No EMG EMG 
41 M 15 98 86 EMG No EMG No EMG 
32 F 15 99 97 EMG No EMG No EMG 
5 F 46 145 154 EMG No EMG No EMG 
25 M 13 88 45 EMG No EMG No EMG 
10 M 38 111 104 EMG No EMG No EMG 
Table 3.20.  
The EMG at the Soleus muscle of the ankle joint of the children in Group 1. The 
table shows the details of children, their heights, weights and gender.  The columns 
on the right show the presence of absence of EMG. 
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ID. 
No. Gender 
Weight 
kg 
Height 
cm 
Age 
(month) 
EMG 
week-1 
EMG 
week 4 
EMG 
week 6 
27 M 12 86 28 EMG EMG EMG 
4 F 16 98 84 EMG EMG EMG 
21 M 11 84 25 EMG EMG EMG 
33 M 11 84 28 EMG EMG EMG 
43 F 13 84 36 EMG EMG EMG 
39 M 12 86 43 EMG EMG EMG 
29 M 12 85 45 EMG EMG EMG 
3 F 17 85 45 EMG EMG EMG 
6 F 12 84 46 EMG EMG EMG 
15 F 13 85 48 EMG EMG EMG 
34 F 13 85 33 EMG EMG EMG 
18 F 14 95 56 EMG EMG EMG 
1 M 13 84 59 EMG EMG EMG 
19 M 15 93 72 EMG EMG EMG 
22 M 18 106 73 EMG EMG EMG 
13 M 17 109 94 EMG EMG EMG 
16 F 40 135 132 EMG EMG EMG 
42 M 11 86 27 EMG No EMG EMG 
11 F 11 85 32 EMG No EMG EMG 
26 F 12 87 25 EMG No EMG EMG 
38 F 12 85 37 EMG No EMG EMG 
2 M 16 86 66 EMG No EMG EMG 
31 M 16 105 69 EMG No EMG No EMG 
7 F 27 105 82 EMG No EMG No EMG 
8 F 14 85 60 EMG No EMG No EMG 
14 F 17 85 67 No Data No EMG No EMG 
12 M 20 110 91 No Data No Data No Data 
24 F 43 144 106 No EMG No EMG No EMG 
Table 3.21.  
The EMG at the Soleus muscle of the ankle joint of the children in group 2. The table 
shows the details of children, their heights, weights and gender.  The columns on the 
right show the presence of absence of EMG. 
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3.7 The Stretch Reflex Responses  
Stretch reflexes were elicited by manipulation of the ankle joint by the 
author. She followed a sine wave generated by the Spike 2 software to 
improve consistency in the amplitude and duration of stretch and relaxation 
phases. The amplitude of ankle movements was recorded using and 
electrogoniometer and the pressure applied was recorded (See chapter 2 
sections 2.8.4 and 2.8.6.). 
Figure 3.19. shows soleus EMG recorded during stretches of the muscle. 
The upper panel shows the pressure applied to the foot to dorsiflex the 
ankle. The upper trace shows the EMG recorded concurrently. The lower 
panel shows similar stretches applied to the same ankle of the same child 4 
weeks after Botulinum toxin type A injections. There is no sign of EMG 
signal indicating the absence of stretch reflexes. In practice it was very 
difficult to produce consistent stretches over the three experimental days. 
This was a result of day-to-day variation in the author’s technique and 
variable co-operation from the children.  
In the present study, data from 6 children has been identified as suitable for 
analysis because they show consistent stretches of soleus over the 3 
sessions.  
The first level of analysis eliminated data from children where there was 
voluntary EMG before the stretch was applied or there were unwanted body 
movements. Effectively, these children did not co-operate with instructions 
to relax. A second level of analysis looked at the consistency of the 
amplitude and velocity of the five applied stretches. Figure 3.20 shows a 
recoding of EMG during five repeated dorsiflexions an example of good 
data the top panel shows the responses before Botulinum toxin type A 
injections. The two lower panels show recording from the same very 
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cooperative child 4 and 6 weeks later. Figure 3.21. shows a recoding of 
EMG during five repeated dorsiflexions an example of bad data recorded. 
 
A 
 
 
 
B 
 
 
 
 Figure 3.19.  
Panel A shows the EMG activity in the soleus muscle during ankle dorsiflexion 
one week before Botulinum toxin type A injection.  
Panel B shows the EMG in the soleus muscle of the same child during ankle 
dorsiflexion four weeks after injection of Botulinum toxin type A. The EMG 
was silent or substantially reduced from pre-injection values 
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Figure 3.20. 
In each panel the upper trace shows soleus EMG and the lower trace shows the 
pressure applied to dorsiflex the ankle. 
Panel A shows the EMG activity in the soleus muscle during repeated ankle 
dorsiflexion one week before Botulinum toxin type A injection. Panel B shows 
the EMG four weeks after injection. 
Panel C shows the EMG six weeks after injection. 
This is an example of good data recorded from a cooperative child 
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Figure 3.21. 
In each panel the upper trace shows soleus EMG and the lower trace shows the 
pressure applied to dorsiflexion of the ankle. 
Panel A shows the EMG activity in the soleus muscle during repeated ankle 
dorsiflexion one week before Botulinum toxin type A injection. Panel B shows the 
EMG four weeks after injection. 
Panel C shows the EMG six weeks after injection. 
This is an example of poor data recorded from uncooperative child 
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The examples shown in figure 3.20. illustrate that the stretch reflexes vary in 
amplitude even in the most favourable conditions when consistent stretches 
are applied. The commonly observed pattern was that the amplitude of the 
reflex declined over the series of stretches.  
It was observed that the 4th stretch in the sequence elicited the most 
consistent reflexes. This was probably because the children were more 
relaxed.  
Consistent data were found for the 4 most cooperative children and these are 
described below.  
Examples for Group 1  
One set of suitable data was identified in this group.  The EMG activity in 
soleus and strong stretch reflexes before the Botulinum toxin type A 
treatment. Figure 3.22 shows data from this child. The top panel shows a 
strong stretch reflex in the integrated EMG elicited by the ankle 
dorsiflexion. The middle panel shows recording made 4 weeks after the 
Botulinum toxin type A injection. A similar stretch elicits a smaller stretch 
reflex. In this case the reflex is preceded by a period of EMG activity which 
could be either involuntary or a voluntary preparation for the anticipated 
dorsiflexion. The bottom panel shows the response to a stretch applied 6 
weeks after the Botulinum toxin type A injection. The EMG shows a very 
large period of activity some seconds after the stretch is applied. This is too 
slow developing to be a classical stretch reflex.  
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Figure.3.22.  
Panel A shows the integrated EMG activity one week before 
Botulinum toxin type A injection. The lower trace is the pressure 
applied to dorsiflex the ankle. The stretch reflex elicited was big.  
Panel B shows similar data form the same child four weeks after 
injection.  The stretch reflex is smaller.   
Panel C shows similar data in the same child six weeks after injection. 
All records shown with the same amplification and time scale.  
Childs ID No. 23 
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Examples from Group 2.  
3 children were selected from this group. They cooperated well and had 
EMG activity and clear stretch reflexes on al three recording sessions. 
Examples of their data are shown in figures 3.23, 3.24, and 3.25.  
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Figure 3.23.  
Similar layout to fig 3.22: Panel A, a clear stretch reflex in the 
integrated EMG activity and pressure one week before Botulinum 
toxin type A injection. Panel B shows similar data form the same 
child four weeks after injection.  Panel C shows similar data in the 
same child six weeks after injection.  
Childs ID No. 19 
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Figure 3.24.  
Similar layout to previous figures. Panel A, integrated EMG activity 
and pressure one week before Botulinum toxin type A injection. 
Panel B shows similar data form the same child four weeks after 
injection.  Panel C shows similar data in the same child six weeks 
after injection. 
In this child the stretch reflex was modest in amplitude and similar 
on all three days. 
Patient ID No. 4 
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Figure 3.25.  
Similar layout to previous figures. Panel A, integrated EMG activity and 
pressure one week before Botulinum toxin type A injection. Panel B shows 
similar data form the same child four weeks after injection.  Panel C shows 
similar data in the same child six weeks after injection. 
 In this child the stretch reflex was large in amplitude and similar on all 
three days. 
Patient ID No. 27 
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The data in figure 3.23. shows that the child had a strong stretch reflex in 
soleus before the treatment began. The initial phasic reflex is clear and the 
tonic components are less well developed. The Botulinum toxin type A 
injection had not fully paralysed the muscle at week 4 and a smaller phasic 
stretch reflex was recorded. The tonic components of the reflex are not 
present. In this example the EMG increases slightly before the pressure is 
applied and the child may have made some preparatory muscle contraction. 
This again illustrates the difficulty of working even with the more 
cooperative children. There was little change in the stretch reflex from week 
4 to week 6.  
Figure 3.25. shows a child who displays moderate stretch reflexes on all 
three occasions. The phasic reflex is small but the tonic components last 
throughout the stretch. The Botulinum toxin type A appears to have had 
very little effect on their stretch reflexes. A similar pattern is seen in the data 
in figure 3.26. The stretch reflexes may be a slightly reduced at 4 and 6 
weeks but there is a strong sustained reflex each day. 
These figures illustrate the problems of testing stretch reflexes in clinical 
populations in a clinical environment. There are many variables even in the 
same child.  It was not possible to produce identical stretch profiles and that 
is seen in figure 3.22. In addition, some children anticipated the applied 
forces, as seen in figure 3.23.  There were frequent problems with the 
behaviour of some children who were uncooperative or were distracted 
during EMG recording. 
3.8 Adverse effects observed during the study 
Fortunately, no children were affected by allergic skin reactions to the tapes, 
gels etc. used during the study.  
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No significant side effects of Botulinum toxin type A injections were 
recorded by any of the children. Most children reported pain at the time of 
injection. The clinicians did not use a topical anaesthetic before the injection 
and the children were often apprehensive before the injection began.   
Two children showed generalized weakness during 1-2 weeks after 
Botulinum toxin type A injection. Four other children reported minor 
weakness in their legs following botulinum toxin injection. All of these 
effects were short lived and none required medical intervention. 
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Chapter 4 
 
Discussion  
4.1 Introduction  
Cerebral palsy is the commonest cause of severe disability in childhood. It 
consists of a heterogeneous group of motor disorders including spasticity, 
muscle weakness, incoordination and dystonia.  Muscle spasticity is one 
major factor that can interfere with normal walking.  
Both conservative and surgical treatments are available to a child with 
cerebral palsy in an effort to reduce spasticity and its effects in the lower 
limb.  The non-surgical interventions include: physical therapy, orthoses, 
casts and drug therapy. It is not clear which treatment or treatments are most 
effective (Flett, 2003), (Rethlefsen et al, 1995), (Middleton, Hurley and 
Mcllwain, 1988), (Koman, 1996), (Ubhi, 2000), (Gracies, Elovic, McGuire 
and Simpson, 1997), (Kita, 2000), (Davis and Barnes, 2000), (Koman, 
1993), (Wall, 1993), (Scott, 1981), (Graham, 2000)). Empirical observations 
suggest that the combination of treatment modalities may be more effective 
than the use of one treatment. 
The particular aim of the project was to investigate the use of Botulinum 
toxin type A toxin with intensive physiotherapy in children with cerebral 
palsy. Botulinum toxin type A treatment is used to improve the motor 
function in children. This study made quantitative measure of motor 
function in two groups of children. One group was treated with Botulinum 
toxin type A alone and the second group received Botulinum toxin type A 
and intensive PT. The outcomes of the two treatments were compared at 
intervals of up to 52 weeks.  
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4.2. Objective of study 
The aims of the present study were: 
1. To survey the characteristic features of children in KSA with cerebral 
palsy. 
2. To recruit two groups of children to the study. 
3. To establish baseline data for GMFM, ROM and stretch reflexes in 
these groups and to repeat the measures at intervals of up to one year. 
4. To record the clinical outcomes for the children in the two groups.  
 
The first aim was fully achieved and the survey of Saudi children with 
cerebral palsy is contained in the chapter 3 section 3.2.  The second aim was 
also achieved. One group of children was recruited from families living in 
more rural areas near Taif and the other group was recruited from families 
living in the cities of Mecca and Jeddah. In total, 163 children were assessed 
and 47 were recruited to the study.   
 
The third aim was also achieved and GMFM and ROM measurements were 
made for all these 46 children at intervals up to one year after they entered 
the study. However, it was much more difficult to get consistent data on the 
stretch reflexes. Only six examples of these are shown in the results section. 
It was difficult to make concurrent recordings of soleus EMG, ankle joint 
position and apply consistent stretches to the ankle. The children were 
frequently uncooperative during these measurements and it was rare to have 
a complete set of data over four recording sessions. The final was almost 
completely achieved. Sufficient data was collected to allow a good 
statistical analysis of the GMFM and ROM data. The stretch reflex data 
obtained is compared to case studies because of the relatively small data set. 
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4.3. Characteristics features of children with cerebral palsy in KSA  
In 2002 a major report on the prevalence and characteristics of European 
children with cerebral palsy was published (SCPE, 2002). This included 
data on 6000 children with cerebral palsy from 13 geographically defined 
populations. The overall average prevalence for this study was 2.08 cases 
per 1000 live births. The highest prevalence was found in eastern Denmark 
with (2.63/1000), Northern Ireland (2.26/1000) and the Viterbo region in 
central Italy at (2.21/1000). The lowest rates were found in France, in the 
regions of Isere (1.78/1000) and Garonne (1.66/1000) and in Scotland 
(1.62/1000). There is no obvious geographical pattern amongst the 
European data.  In north-east England in the period 1964-1993 the rate of 
has risen in spite of falling perinatal and neonatal mortality rates, and this is 
probably because of the effect of modern health care. It is probable that 
babies with a low birth weight, who would have formerly been unlikely to 
survive, now survive perinatal period with severe cerebral palsy. (Colver, 
Gibson, Hey, Jarvis, Mackie and Richmond, 2000). 
 
In the USA there are approximately 550,000 persons with cerebral palsy. 
The number of new cases has increased from 1.5-1.8 cases per 1000 live 
births in 1990 to 2.0-2.5 cases per 1000 live births in 2000 (UCP, 2002). 
The reasons for this change are unclear.  However, Dale and Stanley, (1980) 
and Volpe, (1994) found the increased survival of infants born before full 
term has translated into an increase in the clinical subtypes of cerebral palsy 
more commonly seen in ex-preterm infants, e.g. spastic diplegia. 
 
In Saudi Arabia, several studies have investigated children with cerebral 
palsy, other neurological disorders and other disabilities (Al-Naquib, (1981), 
Taha and Mahdi, (1984), El Rifai, Ramia and Moore, (1984), Al Frayh and 
Al Naquib, (1987), Al-Naquib, (1988), Al-Rajeh, Bademosi, Awada, Ismail, 
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al-Shammasi and Dawodu, (1991), Al-Triki, (1997), Ansari, (2001), Al-
Asmari, (2006), Rajab, Yoo Seung-Yun, Abdulgalil, Kathiri, Riaz, Mochida, 
Bodell, Barkovich and Walsh, (2006)). 
 
A population survey in Saudi Arabia on the prevalence of child disability 
found the rate to be 1.2 per 1000 and this accounted for 0.04% of the total 
population (Ansari et al, 2001) An independent study from Saudi Arabia 
reported a 2.5-fold increase in the occurrence of cerebral palsy in 
consanguineous families (Al-Rajeh et al, 1991). 
 
The major risk factors identified were a history of disease in a sibling and 
consanguinity of the parents. Low birth weight, typically less than 2 kilos, 
gestational age less than 32 weeks, twin pregnancy and respiratory distress 
were significantly more frequent among cerebral palsy cases than controls. 
The antenatal factors, including inherited ones, play a major role in the 
pathogenesis in Saudia Arabia (Al-Rajeh et al, 1991). Al-Turaiki, (1997) 
also found a strong relationship between handicaps including cerebral palsy 
and marriage within close relatives. 
 
The SCPE report found that only 7.8% of the total number of cerebral palsy 
cases in Europe could be attributed to postnatal causes. In the USA 10% of 
cerebral palsy cases could be attributed to postnatal causes (UCP, 2002). 
However, in Saudia Arabia in Al Riyadh 17% of the cases of cerebral palsy 
were attributed to postnatal events. 
 
Several other studies of Saudi and Iraqi populations have found that 
postnatal events were responsible for between 15 and 32% of all cases. Al-
Naquib, (1981) produced data, which showed that cerebral palsy, is more 
common in Arab populations than in Europe and the USA. The opposite 
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pattern is seen in the frequency of pre-natal causes. The USA studies find 
almost half the cases were known to have pre-natal causes but the Arab 
studies gave much lower frequencies.  
 
Al-Naquib, (1988) found the prenatal factors include a high incidence of a 
positive family history and consanguinity in cerebral palsy in Saudia Arabia. 
Thus, similar features are common to both the pre natal and postnatal causes 
Al-Turaiki, (1997). 
 
Country Saudia 
Arabia  
Saudia 
Arabia 
 Saudia 
Arabia  
Saudia 
Arabia  
Iraq USA  USA USA 
Author  Al-
Naquib 
El 
Rifai 
Taha & 
Mahdi 
Al Frayh & 
Al Naquib 
Al 
Naluib 
Holm O'Reilly 
& Nowiz 
UCP 
 
Year 1988 1984 1984 1987 1981 1982 1981 2002 
Numbers 1716 190 202 260 — 142 — — 
Prenatal 22 33 23.5 27.96 24.5 50 38.5 70 
Perinatal 9 49 48 12.68 27 33 46.4 20 
Postnatal 22 17 28.4 32.3 15.5 10 15.2 10 
Mixed 4 — 7 3.88 2.5 7 — — 
Un 
known 
43 — 13. 0 20.38 30.5 — — — 
Table 1.4.  
The etiology of cerebral palsy.  This study compared to other studies in Saudia Arabia and 
other countries. Modified from Al-Naquib, (1988). 
 
 
 
Cerebral palsy has many effects on the development of the central nervous 
system (Levitt, 1995). Some of these are widespread and affect higher brain 
functions such as the intellectual development of the children. In this study 
57 % of the children had problems with mental retardation. This ranged 
from mild to severe. Only 7% were classified with severe retardation). In 
Europe one in five children with cerebral palsy was found to have a severe 
intellectual deficit (SCPE, 2002). 
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Sensory developmental problems are also frequent.  In this study 15 % of 
the children had vision abnormalities and 6% had auditory impairments.  In 
Europe over one in ten children had severe visual impairments (SCPE, 
2002).  In England and Scotland 8.9% of cerebral palsy cases had severe 
visual disability and 12% had severe hearing disability (Pharoah et al, 
1998). The frequency of sensory impairment seems similar in these studies. 
4.4. Frequency of Spasticity 
The group of children recruited for this study was also representative of the 
cerebral palsy population in terms of the motor disability. The dominant 
motor problem in children with cerebral palsy is spasticity: 90% of the 
children in this study had spasticity predominantly in gastrocnemius and 
soleus.  This is very similar to the SCPE study, which showed that 86% of 
the children with cerebral palsy had spasticity  
The most common type of cerebral palsy in this study was spastic diplegia. 
It represented 65% of the cases.  Al-Naquib (1988) found spastic diplegia to 
be the most common form of cerebral palsy in his study of children in KSA. 
These data are similar to the European statistics. The SCPE report found 
that the European frequency was 55%.  
The next largest group are the cases of spastic hemiplegia. They represent 
29% of the cases in this study. A study by Al Frayh and Al Naquib (1987) 
found 19% of the cases to have spastic hemiplegia in sample of 260children. 
The European rate was reported to be 29% (SCPE, 2002). The studies all 
agree that spastic dyskinetias and ataxias are found at a low frequency. 
Spasticity causes many problems with mobility, poor posture and self-care. 
The main functional difficulty for children lies in impaired walking. In this 
study 70% of the children had a walking disability.  14 children did not walk 
at all. Kuban and Levition, (1994) reported around 25% of the patients with 
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cerebral palsy were unable to walk. This paper did not give the ages of the 
patients. Their patients were a mixed population identified in France and the 
UK. In Europe, 31% of children with cerebral palsy are not able to walk. In 
England and Scotland 33% of children with cerebral palsy have severe 
ambulatory disability and no independent walking (Pharoah et al, 1998).  
One important question is: is improvement in spasticity linked to improved 
walking? 
Several studies have suggested that intramuscular injections of botulinum 
toxin type A can be both safe and effective in relieving spasticity. This 
ultimately leads to better walking in children with cerebral palsy (Koman et 
al, (1993), Cosgrove et al, (1994), Koman et al, (1994), Wong, (1998), Flett 
et al, (1999), Boyed, Graham, Nattrass and Graham, (1999), Corry et al, 
(1999), Sutherland et al, (1999), Yang et al, (1999), Ubhi et al, (2000), 
Barwood et al, (2000), Bakheit et al, (2001), Linder et al, (2001), Bottos et 
al, (2003))  
Many people believe that physical therapy may help children with cerebral 
palsy to learn better ways to move and balance. It may help children learn to 
walk, use their wheelchair, stand by themselves, or go up and down stairs 
safely. Children may also work on other skills in physical therapy like 
running, kicking and throwing a ball or learning to ride a bike.  
In this study 18 and 28 children were enrolled into group 1 and group 2 
respectively. The demographic and clinical characteristics of the two groups 
were comparable at baseline. Children in both groups showed improvements 
in the joint ROM and the GMFM scores, but the improvement in-group two 
was bigger. Furthermore, between groups comparison showed a 
significantly better improvement in children who received Botulinum toxin 
type A and physiotherapy.   
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4.5. Discussion of the study design 
Ultimately, the aim of this project was to investigate the efficacy of 
Botulinum toxin type A and Botulinum toxin type A in combination. with 
physical therapy. 
The study was of the `open label `type, i.e. the clinical staff, the researcher 
and patient’s family were aware of the treatment programme used. It is 
considered that this was the only practical design. The main action 
Botulinum toxin type A is to paralyse muscles and this cannot be concealed 
from those taking part in the experiment. Whilst the children and their 
parents knew that treatment was used, it is not clear that they had sufficient 
information to introduce any deliberate bias into the study. It is possible that 
the clinical staff could have done this accidentally. The physiotherapy 
programme was standardised to ensure consistent delivery. In addition, only 
one group of children was treated at any one centre and so the clinicians 
would not have been aware of the progress made by the parallel group. The 
GMF observations made by the researcher are the ones most likely the very 
structured GMFM questionnaire and this probably represents the best 
defence against accidental bias. The introduction of a second observer who 
is blinded to the study does not always help in such cases because of the 
possibility of discrepancies in the operation of two or more observers. 
Many other studies of the efficacy of Botulinum toxin type A have used the 
same design (Koman et al, (1993), Cosgrove et al, (1994), Thompson et al, 
(1998), Koman et al, (1999), Boyd et al, (1999), Eames, Baker, Hill, 
Graham, Taylor and Cosgrove, (1999), Corry et al, (1999), Boyd et al, 
(2000), Bakheit et al, (2001), Linder et al, (2001), Fragala et al, (2002). 
Cerebral palsy is such a heterogeneous condition that it is difficult to recruit 
matched controls with similar degree of spasticity and motor disturbances 
(Wong, 1998). 
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The study did not allocate the children to the two groups in a randomised 
way. All the children at one site received one treatment and all the children 
at the other site received the alternative treatment.  The primary reason for 
this was to respect family wishes.  The parents who brought their children to 
the Centres of the Disabled Children’s Association in Mecca and Jeddah 
clinic did not wish their children to attend the residential centre at 
Rehabilitation Centre of The Prince Sultan Military Hospital in Al Hada 
where the intensive physical therapy was delivered. Ultimately, the 
allocation to treatment groups was made by the parent’s decision to enter or 
not enter the residential hospital. This could have introduced problems with 
the creation of dissimilar experimental groups.  However, the post hoc 
analysis reported in section 3.3 and figures 3.8 showed that this was not a 
significant problem. It would be better if any future study were designed to 
ensure a balanced study. One advantage of the design used was that the 
families were happy to keep their children in the study and this is seen in the 
very low drop out rate and this improved the statistical power of the study. 
One other feature of the recruitment was the decision to exclude children 
with severe disabilities. This initial decision was intended to avoid the 
problems of testing children who could not understand the instructions 
during the GMFM tests and to allow a focus on children who could walk 
independently or with assistance.  The data shown in table 3.2 shows that 
this eliminated 7% of the children who were initially screened. The post hoc 
analysis shown in figure 3.15 shows that the children with the highest initial 
GMFM scores, i.e. those least affected, benefited most from treatment. Thus 
the recruitment policy probably biased the study in favour of detecting an 
effect though this was accidental. 
In retrospect, it may be fairer to describe the sampling strategy as a 
‘stratified’ i.e. the population is divided or stratified on some characteristic 
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(the initial classification of severity) before random selection on the sample 
(Thomas, Nelson and Silverman (2005)). 
Any future developments of this study should consider using a crossover 
design where the all the volunteers get both treatments in sequence. This 
contrasts with the parallel groups design used. The crossover design can be 
used in situations where it is not possible to identify a separate comparison 
group. In effect, each subject serves as his/her own control. Also, since the 
same subject receives both treatments, there is no possibility of covariate 
imbalance. Ideally in a crossover design, a subject is randomly assigned to 
an each treatment order. 
It is worth recognising that despite their potential to provide greater 
statistical power, crossover studies have well known limitations. Persistence 
of effect of first treatment can be a problem and this could be a significant 
problem since the treatment effects seen in this study were still significant 
12 months after the treatment started and 6 months after the last injection. In 
addition, the crossover design requires each volunteer to remain in the study 
for longer periods and this can cause high dropout rates than in shorter 
duration parallel group studies. 
This was an ‘open label’ prospective study. The clinicians, physical 
therapists and parents knew which treatment was delivered. It is impossible 
to blind those involved to the nature of the treatment. 
 In addition, it is difficult to blind patients or clinicians to the nature of 
treatment since the Botulinum toxin type A produces a very obvious 
paralysis.  
However, some authors have been used a randomized controlled trial 
design, e.g. Koman et al, (1994), Flett et al, (1999), Wissel, Heinen, 
Schenkel, Doll, Ebersbach, Muller and Poewe, (1999), Sutherland et al, 
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(1999), Barwood et al, (2000), Ubhi et al, (2000), Boyd, et al, (2001) and 
Baker et al, (2002). 
This study tested 46 children. Thus size of the study sample is larger than 
most previous studies. There are two larger studies: (Reddihough et al, 
2002) with 49 children and (Koman et al, 1999) with 48 children. The 
smaller studies include Koman et al,. (1993) 26 children with dynamic 
deformities, Cosgrove et al, (1994) 26 children, Koman et al, (1994) 12 
children, Eames et al, (1999) 39 children, Flett et al, (1999) 20 children, 
Ubhi et al, (2000) 40 children and (Boyd, et al, (2001) 39 children. 
4.6. Children Age  
In this study the children were between 25-154 months. This is similar to 
other studies. Some have tested children as young as 18 months (Barwood et 
al, 2000) but the great majority concentrated on children between 2 and 15 
years (Flett et al, (1999), Ubhi et al, (2000), Linder et al, (2001), 
Reddihough et al, (2002), Bottos et al, (2003), Fragala et al, (2002), Boyd et 
al, (2001), Wong, (1998)).  
The optimal time to treat spasticity with Botulinum toxin type A appears to 
be after the age of 2 years to coincide with the child motor development and 
learning to walk. 
4.7. Dose of the Botulinum toxin A 
In present study all the Botulinum toxin type A injections were made by Dr 
Shakfa, the head of Orthopaedic Surgery department at Prince Sultan 
Hospital and Al-Hada Armed Forces Hospital and Rehabilitation Centre, at 
Saudi Arabia. All injections were prepared by following a standard 
procedure. The dose administered was 6 units/kg of body weight per child. 
There was a maximum of 200 units per child for the lower limb the dose 
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calculation takes into account the mass of the child, the number of muscles 
targeted (see Chapter 2, section 2.5).  
In this study the Botulinum toxin type A dose was too small to block the 
muscle contraction at 4 weeks. In some children the EMG in soleus returns 
by 6 weeks after Botulinum toxin type A. This is clearly seen in table 3.18. 
This return of EMG is observed in other studies (Gordon, (1999), Koman, 
(1993) Carr, Cosgrove, Geringrass and Neville, (1998) and Bakheit, (2001)). 
However, a clinical response was achieved in this study without excessive 
weakness or systemic side effects.  
There is no consensus in either paediatric or adult practice about the 
appropriate dose of Botulinum toxin type A in spasticity.  The dose is 
generally determined by the size of the muscle to be injected.  The aim is to 
achieve a clinical response without excessive weakness or systemic side 
effects (Carr et al, 1998). The doses used in this study appeared to be 
adequate for the treatment of spasticity as confirmed with the 
neurophysiological test. 
4.8. Muscle injected  
 
The choice of muscles selected for injection depended on the degree of 
spasticity in the lower limb. The orthopaedic surgeon identified the target 
muscles by manipulation of the limbs without electromyography guidance. 
The soleus, gastrocnemius, hamstring and adductor muscle were injected by 
using appropriately sized syringe under antiseptic conditions, without using 
anaesthetic before administering the Botulinum toxin type A injection (Tables 
2-3 and 2-4 in chapter 2). 
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4.9. Study duration 
The duration of the current study was 52 weeks. This comparable is with the 
other studies. Linder et al, (2001), Reddihough et al, (2002), M Bottos et al, 
(2003), Barwood et al, (2000), Fragala et al, (2002), Boyd et al, (2001) and 
Flett et al, (1999) all carried out their final assessment after 12 months Only 
three studies have longer duration follow ups.  Glanzman et al, (2004) 
waited 24 months and Wong, (1998) waited between 10-24 months. 
Sutherland et al, (1996) conducted a trial over 3 years.  
In this study the results were statistically significant at 12 months. The 
effects were also significant at 4 and 6 weeks after injection. 
Nerve sprouting and muscle re-innervation lead to functional recovery 
within 2 to 4 months (Rosales, 1996). There is evidence that partially 
functional neuromuscular junctions are re-established within 4 weeks 
(Angaut-Petit, Molgo, Comella, Faille and Tabit, 1990).  The periods of 
clinically useful muscle relaxation is usually 12-16 weeks (Graham et al, 
2000). (Duchen and Strich, 1968). 
Because nerve sprouting and muscle re-innervations lead to functional 
recovery within 2 to 4 months, this study used the measurements after 
Botulinum toxin-A injection  at 4,6 and 52 weeks. 
 
 
4.10. Outcomes of the study  
4.10.1. Gross Motor Function Measure (GMFM)  
 
The primary outcome measure in this study was GMFM. This is commonly 
used to measure gross motor performance in children with cerebral palsy. It 
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establishes the baseline performance and to detects change over time 
(Leach, (1997), Russell et al, (2000), Graham, (2000) and Linder, (2001)). 
 
In this study the GMFM technique worked well. The technique was 
sufficiently sensitive to detect changes in the motor behaviour of the 
children in group 2. In addition, it can produce a stable state in the children 
in group 1.  However, the time taken to administer the tests was a problem 
since it took approximately 45-60 minutes per session per child. It also 
depended on the ability level of the child and the child’s level of 
cooperation and understanding. In this study some data was unobtainable 
when working with uncooperative children.  These operational problems 
probably explain why only nine studies have used GMFM outcomes after 
Botulinum toxin type A injection: (Flett et al, 1999), (Yang et al, 1999), 
(Wissel et al, 1999), (Ubhi et al, 2000), (Linder et al, 2001) (Reddihough et 
al, 2002) (Boyd et al, 2001) (Bottos et al, 2003) and (Mall et al, 2006). 
 
Overall, this study worked well. The sample size, measurement techniques 
and duration were adequate to deliver statistically significant results as can 
be seen in table 3.12 and table 3.17. In addition, the study size and duration 
are similar to the largest and longest duration studies already published. 
 
GMFM is a valid measure of the motor function in children. This study 
found GMFM sensitive to change after long-term from treatment and at 4, 6 
and 52 weeks post injection it was statistically significant difference in the 
mean of the GMFM in Group1 and Group 2 after 4 weeks (P <0.002), 6 
weeks (P <0.001). and at 52 weeks (P <0.000). Both groups’ treatments 
showed evidence of improvement in GMFM over the period of the study 
and particularly at 52 weeks. The observed improvement in GMFM was 
also evident to the treating therapists and the children’s parents. 
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Group 2 had Botulinum toxin type A and physical therapy showed a 
significant average advantage in GMFM over group 1 had Botulinum toxin 
type A only at all times in the study. 
This advantage in average GMFM scores increased from 4 through to 52 
weeks with a clear and significant difference between 4 and 52 weeks 
This benefit of treatment appeared to increase the higher the child’s baseline 
GMFM, this was not statistically significant difference in the mean of the 
GMFM score in Group 1 and Group 2 before the Botulinum toxin type A 
injections (P = 0.952). 
These results substantially agree with previous studies by Yang et al, (1999) 
Ubhi et al, (2000), Linder et al, (2001) and Bottos et al, (2003).   
 
The GMFM approach is the most fully validated objective outcome measure 
of motor function. It is more appropriate for assessing children in the mid-
range of disability Graham, (2000), Linder et al, (2001) It may not be 
sensitive enough to detect changes in children with mild disability. In this 
study the biggest improvement in GMFM scores occurred in children with 
the highest initial scores. (Refer to results chapter 3 table 3.8). This is most 
likely a genuine effect because the changes will be hardest to detect in the 
children with milder disabilities. In addition, Linder et al, (2001) found 
improvements in GMFM scores were most clearly evident in children with 
moderate impairment and the result of this study agrees with Graham et al, 
(2000) and Linder et al, (2001), Graham, (2000).  
 
The present study confirmed that the combination of physiotherapy with 
Botulinum toxin type A is more effective than Botulinum toxin type A 
alone. By contrast, Reddihough et al, (2002) found there were no statistical 
differences between GMFM scores after treatment with the Botulinum toxin 
type A and PT or treatment with physical therapy alone at either 3 or 6 
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months post injection. Similar results were reported by Flett et al, (1999), 
Boyd et al, (2001) and Mall et al, (2006) they found it not significant 
between the two groups. 
 
 
4.10.2. Electromyography (EMG)  
 
The main aims of using electromyography (EMG) in this study were to 
investigate how effective the Botulinum toxin type A injections were in 
paralysing the muscles and to investigate the effects on the stretch reflexes 
in soleus.  
Electromyography (EMG) is a technique for evaluating and recording the 
activation signal of muscles. Two main types of electrodes used for the 
study of muscle behaviour are surface electrodes and needle electrodes 
inserted through the skin. Each has its advantages and its limitations. The 
most common needle electrode is the concentric electrode is record deep-1-2 
mm of needle tip, small sample single motor units 5 MU. Surface electrodes 
records up to 1 cm into the muscle, bigger volume 100 MU (Basmajian 
1985). 
Advantages of the needle its clear record, single motor unit and its useful 
with isometric experiments on the other hand its disadvantages difficult to 
ensure same position on different days, sampling problem are these 5 motor 
units like the rest of muscle and the needle in isometric experiment painful 
when muscle stretch with high forces high velocities. In this study the 
family and children were thought very unlikely to accept needle EMG 
because of local pain. 
   
Abeer Felmban 2008  145 
Surface electrodes offer the advantages giving a wider sample of motor 
units and being well tolerated movement. It was till difficult to make 
consistently good EMG recordings. The main difficulty was caused by 
children who would not relax and much spurious EMG was recorded. 
Indeed only eleven of the forty-three children had complete set of good 
EMG data for the initial tests and the repeats a 4 and 6 weeks. When good 
EMG was recorded during ankle dorsiflexions it was clear that significant 
muscle activity was present on some children at weeks 4 and 6, after the 
Botulinum toxin type A. 
I recommended that future studies continue using of EMG recording. It may be 
easier to use in ore mature children. Only two authors have published reports using 
EMG to assess spasticity, Sutherland et al, (1996, 1999) and Bottos et al, (2003). 
They found no significant differences in their EMG data.  
 
(Basmajian, 1974) EMG is widely used to investigate muscle activity.  Most 
studies of reflex function require stable EMG recording for 10 to 100 
minutes. In this study short-term EMG recordings were made. Examples can 
be seen in figures 2.5, 2.6 in chapter 2. These short term recording did allow 
investigation of how complete the paralysis was after Botulinum toxin type 
A injections. These data are in table 3.18 chapter 3. The EMG activity 
returned to normal after Botulinum toxin type A injection by 6 weeks. In 
some children, it had returned by 4 weeks. This agrees with the results of 
Gordon, (1999), Koman, (1993), Carr, (1998) and Bakheit, (2001). 
 
However, in many children, it was very difficult or impossible to make 
EMG recordings because some hyperactive children kicked and protested.  
They could not relax and much spurious EMG was recorded.  Indeed only 
eleven of the forty-three children had a complete set of good EMG data for 
the initial tests and the repeats at 4 and 6 weeks. Only two authors have 
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published reports using EMG to assess spasticity, Sutherland et al, (1996, 
1999) and Bottos et al, (2003). They found no significant differences in their 
EMG data.  
In this study EMG it not work very good with CP children. However it spent 
long time with 46 children to fixed EMG electrode.  However, it returns 
after 4 and 6 weeks in some children.  See table 3.18 in chapter 3 
 
4.10.3. Goniometry 
 
Like GMFM and EMG goniometry is well-established technique. It has 
been frequently used to study spasticity (refer to Literature review). The 
goniometry measurement shared some of the same problems with 
uncooperative children but it was easier to use than EMG. Sufficient data 
were obtained to allow statistical analysis. These are shown in table 3.13, 
3.15.in chapter 3  
The results of this study showed a significant increase in the range of 
motion at the ankle and this indicates a reduction in spasticity. This increase 
in ROM was found when the pre Botulinum toxin type A values were 
compared with the values 4 weeks later. The difference was significant in 
both groups of children. This difference was larger in group 2. This result 
agrees with Koman, (1993), Cosgrove, (1994), Koman, (1996), Sutherland, 
(1999), Suputtitada, (2000), Ubhi, (2000), Fragala, (2002) and Bottos, 
(2003). 
 
The increase in the ROM correlated with clinical improvement. Ubhi et al, 
(2000) found the range of passive ankle dorsiflexion movement did not 
change between the weeks 2 and 12 after Botulinum toxin type A injection. 
All the previous studies and this one, measure changes before and after 
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botox. Indeed in this study, the children’s parents or guardians often 
mentioned spontaneously that the spasticity had reduced within 24 hours of 
the injection. It is likely that Ubhi made all their measurements after the 
Botulinum toxin type A had taken effect. 
 
4.11. Limitations of the study  
 
The present study has some limitations. In terms of the design of the study, 
it would have been more satisfactory to achieve larger groups with similar 
ages and gender balance. In addition, for logistical reasons the assignment to 
the two groups could not be done randomly. The children in group 2 
received two-weeks of intensive physical therapy treatment. This was best 
delivered if the families lived in the residential accommodation at the 
Rehabilitation Centre. The children were available for 1 to 2 hours each day 
and the families did not have to travel to the centre. Additional benefits were 
that treatments were delivered in a consistent manner by the same therapists 
in the same setting. The children in group 1 lived at home and came to the 
clinic for assessment and treatment like fitting of shoes and casts. Thus, the 
allocation to groups was done by the social and domestic factors influencing 
the families. One very positive result of using this allocation procedure was 
that the children and parents were happy to continue in the study and the 
dropout rate was very small. Four families did not return for the final 
assessment at one year and one child withdrew from the study after the 
initial assessment. Despite the recruitment difficulties the two study groups 
were very well matched for age, gender and baseline GMFM. 
 
A second area of experimental difficulty lay in the interaction with the 
children. The clinical staffs involved were all experienced in working with 
children and the parents and at least one parent was present at all sessions. 
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However, it was frequently difficult to gain full cooperation from the child 
throughout the whole session. In an ideal world, the child would lie still on a 
bed in a prone position for parts of the assessment. The posture of limb 
would be constant and the knee of the target leg flexed to 90 degrees. The 
investigator could then apply controlled flexion movements to the ankle. 
However, some hyperactive children did not cooperate even when 
encouraged to do so by their parents. Kicking, shouting, crying and even on 
occasions vomiting confounded the tests. These movements could dislodge 
the skin mounted EMG electrode-amplifiers and the electrogoniometers. 
This caused the gaps in the experimental data as shown in table 3.18 and 
3.19 of the results section. Even if the equipment stayed in place, the 
additional muscle contractions often rendered any measurements valueless. 
However, these difficulties would not have affected the primary outcome 
measure of the study. 
One of the strongest features of the GMFM scoring was that it was much 
less affected by the child’s immediate behaviour. GMFM scores were 
almost always successfully completed and the failure rate was in 4 children 
only. 
 
 
4.12. Conclusion 
In conclusion, this study has shown that Botulinum toxin A is safe and easy 
to administer, can be given as an outpatient procedure, and results in an 
improvement in walking and increase in range of motion.  It offers an 
alternative to surgical intervention and our study supports its use with 
intensive physiotherapy programme following Botulinum toxin A injection, 
to maximise muscle lengthening and thus provide improved long-term 
benefit in children with cerebral palsy, to capitalise on the muscle relaxation 
more easily. 
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Botulinum toxin A should not be considered as a replacement for 
physiotherapy or orthotics. It should be viewed as an adjunct to current 
therapeutic strategies.  Indeed the data in this thesis make an argument for 
an increased physical therapy programme following, Botulinum toxin A 
injection to enhance the child’s motor performance. 
 
 
4.13. Recommendation  
 
1. Future studies of the effectiveness of the combined use of BTX-And 
physiotherapy in the management of spasticity in children with 
cerebral palsy should use a randomised controlled study design. This 
is the gold standard method in medical research. 
2. The use of laboratory gait-analysis may provide useful additional 
information in studies that assess the benefits of treatment in 
ambulatory children with cerebral palsy. 
3. Need to initiate data base included all cerebral palsy children in 
Saudia Arabia to know the incidence and prevalence of cerebral palsy 
in Saudia Arabia. 
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Appendix 1  
Summary description of the rehabilitation programme used 
in this project 
 
 
 
 
This is the physical therapy programme (PT) was used in this study after BTX-
A injection for 2 weeks/2 hours daily. This PT programme based on Daniels 
and Worthingham (1980), Gage, J. (2004), Hall, C. and Brody L., T. (2005). 
Also, PT programme drawing by the author. 
   
 
Introduction  
One of the important steps in ensuring a positive outcome of a rehabilitation 
program is the child or the parent’s ability to understand the therapist’s 
instructions. Many variables affect this aspect of the childcare, including 
cultural barriers, hearing impairment and clarity of instructions. The best- 
designed rehabilitation program may fail (Brody, 2005). Consequently, this 
study required the children to stay in accommodation for the duration of the 2 
week rehabilitation program.  
The children in the study had cerebral palsy, diplegia, spasticity of the ankle 
planter flexors and significant gait problems. This study assessed of the effects 
of BTX- A alone and in combination with intensive physical therapy in the 
treatment of these children.  
Definition of Physical Therapy 
Physical therapy as defined by the GPT (2001) includes: 
1. the diagnosis and management of movement dysfunction and the 
enhancement of physical and functional abilities 
2. the restoration, maintance and promotion of optimal physical function, 
optimal fitness and wellness, and optimal quality of life as it relates to 
movement and health  
3. the prevention of the onset, symptoms, and progression of impairment, 
functional limitations, and disabilities that may result from diseases, 
injuries, conditions, or disorders.  
Physical therapy, as provided by or under the direction and supervision of a 
physical therapist, includes: 
   
1. Examining patients with impairment, functional limitation, and disability 
or other health-related condition to determine a diagnosis, prognosis, and 
intervention 
2. Examination within the scope of physical therapy practice include, but are 
not limited to, tests and measures of four categories of condition; 
musculoskeletal (e.g., range of motion, muscle performance, joint 
mobility, posture), neuromuscular (e.g., reflex integrity, cranial nerve 
integrity, neuromotor development, sensory integration), 
cardiovascular/endurance, ventilation, circulation), and integumentary 
(e.g., integumentary integrity) 
3. Alleviating impairments and functional limitations by designing 
implementing, and modifying therapeutic interventions.  Interventions 
include, but are not limited to, procedural interventions such as 
therapeutic exercise; manual therapy techniques; prescription, fabrication, 
and application of assistive, adaptive, supportive, and protective devices 
and equipment; airway clearance techniques; physical agents and 
mechanical and electrotherapeutic modalities; and functional training in 
self-care, home management, work (job/school/play), community and 
leisure activities. 
4. Preventing injury, impairments, functional limitations, and disability, 
including the promotion and maintenance of fitness, health and quality of 
life in all age populations. 
5. Engaging in consultation, education, and research (APTA, 1995). 
 
Physical therapy programme after Botulinum toxin A injection 
Specific therapy programmes should be used based on every subject’s 
individual requirements for stretching or strengthening exercises and gait 
training with or without assistance. Rehabilitating after BTX-A injections 
   
should be done in a stepwise incremental way starting with non-weight-bearing 
exercises, moving to resisted exercises and to then weight bearing activities. 
1 Range of Motion Exercises - Non-Weight Bearing 
These exercises are used to increase range of motion typicallya t the ankle 
joint.  All exercises should be performed whilst the patient is sitting with their 
legs fully extended, knees straight out in front.  
1.1 Dorsiflexion 
1. Pull the child foot back toward himself by moving his ankle.  Remember 
to keep the child’s knees straight. Continue until you can no longer pull 
your foot back. 
2. Ask child to hold this position for 10 seconds 
3. Return to neutral position 
4. Repeat above steps 10 more times  
1.2 Plantarflexion 
As above but with the ankle plantarflexed by ask the child to push the child 
foot forward away from him Ask the child to hold this position for 10 seconds  
   
 
Figure 1. 
This picture shows the child position during plantarflexion 
and dorsiflexion of the ankle joint. Non-weight bearing 
exercise. 
   
 
1.3.Inversion 
1. Ask the child to turn the foot inward by moving his ankle.  Continue until 
he can no longer turn his foot inward.  
2. Ask the child to hold this position for 10 seconds  
1. Return to neutral position. 
2. Repeat above steps 10 more times. 
 
1.4 Eversion 
As above but ask the child to turn the foot outward by moving his ankle.  
 
   
 
 
 
 
 
 
 
 
 
 
1.5 The Alphabet 
3. Ask the child to sit on a chair with the foot dangling in the air or on a 
bed with the foot hanging off the edge 
4. Draw the alphabet one letter at a time by moving the ankle and using the 
great toe as a "pencil." 
 
 
Figure 2  
This picture shows the child position during eversion and 
inversion of the ankle joint. Non-weight bearing exercise. 
   
 
Figure 3 
This picture shows the child position during non-weight 
bearing exercise Alphabet. the ankle joint moving the great 
toe as pencil. 
 
   
 
2 Isometric Strengthening Exercises 
These exercises to strengthen the muscles around your ankle, this will provided 
added support to the joint. 
2.1 Eversion Isometrics 
1. While the child seated place the outside of the foot against a table leg or 
a closed door. 
2. Ask the child to push outward with his foot against the object the foot is 
touching, (the ankle joint should not move) causing a contraction of the 
child muscles. 
3. Ask the child to hold this muscle contraction for 10 seconds. 
4. Relax for 5 seconds. 
5. Repeat 5 times, increasing to 10 repetitions. 
 
2.2 Inversion Isometrics 
As above but with inversion of the ankle. 
   
Figure.4 
This picture shows the child position during inversion and 
eversion of the ankle joint against resistance. 
 
3 Resisted Strengthening Exercises 
These exercises work to strengthen the muscles around the ankle joint. This 
will provided added support to the joint. Each exercise should be performed 
with a towel or belt around the ankle providing resistance to the movements. 
To provide the own manual resistance to each movement 
3.1 Dorsiflexion 
1. Ask the child to pull his/here foot back toward him self, against the 
resistance of a belt (while keeping knees straight), by moving the ankle 
joint. 
2. Ask the child to hold this position for 10 seconds  
3. Return to neutral position 
   
4. Repeat above steps 10 more times  
3.2 Plantar flexion 
As above but with plantar flexion of the ankle. 
 
 
 
 
 
 
 
 
 
3.3Inversion 
1. Turn your foot inward by moving your ankle, against the resistance of 
the belt. 
2. Hold this position for 15 seconds  
3. Return to neutral position 
4. Repeat above steps 10 more times  
 
 
Figure 5. 
This picture shows the child position during dorsiflexion and 
planter flexion of the ankle joint against a belt resistance.  
   
 
3.4 Eversion 
As above but with eversion. 
 
 
 
 
 
 
 
 
 
 
4 Single Leg Stand 
1. Ask the child to stand upright while holding onto a stable object like a 
table or chair.  
2. Shift some of their weight onto one foot, if the child can. 
3. Hold for the position for 10 seconds. 
4. Relax and put weight back onto another foot. 
 
Figure 6. 
This picture shows the child position during inversion and 
eversion of the ankle joint against the child resistance 
   
5. Repeat 10 times also we can do these exercise with a belt resistance as 
in a figure 5. 
 
 
 
 
 
 
 
 
 
 
 
5 Full Weight Bearing Exercises 
These exercises will help put more weight on the foot as well as strengthen it.  
1. Ask the child to stand upright and place only the amount of weight on 
his leg as he can and avoid hyperextending the child knee. 
2. Relax and put weight back onto another foot. 
3. Repeat 10 times alternatively. 
 
Figure 7. 
This picture shows the child position during dorsiflexion and 
planterflexion of the ankle joint against a belt resistance 
   
 
 
 
 
 
 
 
 
 
 
 
 
6 Balance Activities 
Shortening of Achilles tendon can often result in decreased balance ability. 
Towards the end of rehabilitation performing balance activities is an important 
way to prevent future injury. 
6.1 Single Leg Stance 
1. Ask the child to stand on one foot while raising another foot off the 
ground if he/she can. 
 
Figure 8  
This picture shows the child position during full weight bearing 
exercises. The position on the left is correct. That on the right is 
incorrect.  
 
   
2. Maintain full weight bearing on one foot for 10 seconds 
3. Return to resting position. 
4. Repeat above exercise 10 more times for the other foot. 
 
 
 
 
 
 
 
 
 
 
 
6.2 Sitting balance on unstable surface 
To increase postural stability and trunk balance:  
1. Child sitting on the therapeutic ball. 
2. Ask the child to hold a ball by his/here hands with extended arms. 
 
Figure 9. 
This picture shows the child’s position during single leg stance 
   
3. Practice reaching hands forward, overhead, and to the side. 
4. Repeat 5 times  
 
Figure 10. 
This picture shows the child’s position during balance exercise on 
the therapeutic ball. 
 
 
6.3 Minitrampoline balance  
To improve stability in single leg stance  
1. Ask a child to stand on the minitramp with a stable object at hand. 
2. Let the child practice standing on one leg, make sure that a child’s knee 
is slightly bent if he/she can. 
   
3. Ask a child to jump, with hand support if he/she need. 
4. Repeat above 5 more times 
 
 
Figure 11. 
This picture shows the child position during balance exercise on 
minitrampoline. 
 
7 Single Leg Stance on a Towel 
1. Fold a towel into a small rectangle and place on the ground 
2. Ask a child to stand with his/here left heel on the towel, half on the floor. 
3. Lift the right leg off the ground standing only on the towel with the left 
leg if he/she can do it. 
   
4. Ask a child to curl the toes, pull the towel toward him all the way to the 
arch. 
5. Hold for 5 seconds 
6. Repeat above 10 more times 
 
 
 
 
 
 
 
 
 
 
 
8 Walk up and down stairs 
To increase flexibility of the plantar fascia 
1. Ask a child to stand with the toes extended against the vertical part of a 
step and the heel on the floor  
2. Ask the child to bend the knee slowly above the toes  
 
Figure 12. 
This picture shows the ankle position during exercise of the 
single leg stance on a towel 
   
3. Walk up 4 step and walk down 4 step-alternating feet. 
 
 
Figure 13.  
This picture shows the child position during walking up and 
down stairs. 
 
9 Foot orthoses 
Orthoses are useful in the management of deformity because they apply a 
sustained stretch to a hypertonic muscle/tendon group and by positioning one 
joint can gain better posture and muscle activity elsewhere. Orthoses may be 
articulated to allow movement about a specific joint, thereby allowing muscles 
to be more active. (Burtner, Woollacott, Qualls, 1999) 
The functions of foot orthoses 
1. To even the distribution of weight-bearing forces. 
   
2. To reduce stress on proximal joint. 
3. To control foot motion at the subtalar and mid-tarsal joints, including 
magnitude, end range, and rate. 
4. To balance intrinsic foot deformities if necessary. 
 
10 Walking with crutches 
When a child walks with crutches, taking some of his weight on the involved 
knee, several guidelines should be followed: 
1. Make sure the child’s weight is on his hands, not under his arms.  His 
arms should be slightly bent if his crutches fit properly. 
2. When the child walks, place his crutches out first, followed by his 
involved leg and then his uninvolved leg. 
3. Place his involved heel down first. Let his knee bend slightly and allow 
his foot to roll toward his toes as he begins to bring his uninvolved leg 
forward. 
4. As he brings his uninvolved foot through, ask a child to bend his 
involved knee, and pick it up behind him.  Straighten the involved knee 
as he brings it past his cruches to place it on the floor in front of him.  
His knee should be straight just before his heel contacts the ground. 
5. When a child using a single crutch, be sure to ask him to use it on the 
side opposite his injured knee.  
 
   
 
Figure 14. 
This picture shows the crutches and the hand positions during 
walking with assistance of crutches. 
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Consent To Participate in A research Investigation 
 
 
Biomedical and Life Sciences Department, Glasgow University 
 
 
Child Name:                                        Child ID No: 
 
Date: 
 
 
   
 
Research Title: A comparison toxin-A combined with Physical Therapy and 
Botulinum toxin-A alone in Children with of Botulinum Spastic Cerebral 
Palsy Cerebral Palsy remains a significant issue for our medial and 
educational establishments and for society as a whole.  Cerebral Palsy is the 
most common cause of childhood physical disability. The upper motor 
neuron injury that accompanies with cerebral palsy frequently results in 
muscle imbalance, spasticity, and dynamic joint deformity.    Spasticity is the 
most common symptoms seen in cerebral palsy children.  It interferes with 
function, standing balance and gait.  Currently there are a number of 
interventions, both conservative and surgical, which are being offered to the 
child with cerebral palsy in an effort to reduce spasticity and its effects in the 
lower limb.   Mediations frequently used in the treatment of spasticity-
included baclofen, benzodiazepines, tizanidine, clonidine, dantroline and 
Botulinum toxin-A. Botulinum toxin-A, the most potent biologic toxin 
known, is one of seven antigenically different toxins produced by the bacteria 
clostridium Botulinum. Botulinum toxin-A acts at the neuromuscular junction 
by inhibiting the release of acetylcholine, which leads to decrease spasticity 
in injected muscle.  There were no side effects for this injection in previous 
studies except pain and redness in injection site. You are being asked to 
participate in a research investigation as described in this form below.  All 
such investigational projects carried out in Prince Sultan Hospital and Al-
Hada Armed Forces Hospital and Rehabilitation Centre At Kingdome of 
Saudi Arabia.  The investigator will explain to you in detail the purpose of the 
project, the procedures to be used, and the potential benefits and possible 
risks of participation.  You an ask the investigator any questions you ay have 
to help you understand the project and you may expect to receive satisfactory 
answers to questions. A basic explanation of the project is written below. 
   
 
There are two main objectives in this study:  
1) To evaluate the effects of Botulinum toxin-A Spastic Cerebral Palsy 
by using gross motor function measurement, passive ankle range of 
motion. 
2) To compare of botulinum toxin-A combined with physical therapy 
and botulinum toxin-A alone in children with spastic cerebral palsy. 
 
The procedure to be used include: 
The duration of this study fifty weeks, and there are four sessions assessment.  
First before injection and the second post four weeks, third post six weeks and 
last assessment post fifty weeks.  Upper and lower limb muscle tone will be 
evaluated using special scale gross motor function measurement Passive ankle 
range of motion will be measured using electrogoniometer.  A small skin 
mounted pre-amplifier with integrated electrodes, measuring 7mm in diameter, 
was used for recording the electromyography (EMG). 
After pre injection assessment, each subject will be transferred to Prince Sultan 
Hospital and Al-Hada Armed Forces Hospital and Rehabilitation Centre in Al-
Taief at Kingdome of Saudi Arabia.  The injection will be under supervision 
neurologist consultant. After 2 weeks following the injection those children 
were given casts for 2 weeks. Post injection 2 weeks children will stay in the 
disabled children association Makkah or Jeddah centres accommodation under 
intensive physical therapy. I certify that I have read and fully understanding the 
above project.  I willingly consent to participate. 
 
   
 
 
Name of the guardian of child 
…………………………………….. 
 
Signature 
 
……………………………………… 
 
I certify that I have explained fully to the above the guardian of child the nature 
and purpose, the potential benefit and possible risk of botulinum toxin-A 
injection. 
 
Signature of Investigator  
 
……………………………………… 
 
 
   
Appendix 3 
Patient’s assessment form 
Cerebral Palsy Assessment Form 
 
 
 
Name:                                           Age:         Sex:          □ Male □Female 
Guardian:………………………Tel.No:…………………….. 
Cerebral Palsy classification: 
□Spastic                       □Dyskinetic             □Ataxic         □Mixed 
□Diplegia□                  □Hyperkinetic  
□Quadriplegic             □Dystonic 
□Hemiplegic 
Causes:  
□Prenatal (Specify if possible)                  □Perinatal (Specify if possible) 
□Postnatal (Specify if possible)                □ Full term □ Preterm 
Ambulation:  
□Independent                □Walker               □Wheelchair   
□Others  
Speech:  
□Normal            □Language delay             □Dysartheria 
□Communications device 
Vision:  
Normal                 □Poor                          □Blind                 
Eye:  
□Nystagmus 
Hearing:  
□Normal        □Mild          □Non               □Hearing aids 
Mental state:  
□Normal      □ Mild retarded      □Moderate        □Severe  
   
Previous surgery:  
□No              □Yes                                                               (If yes specify)  
Previous drug: 
□No            □Yes 
Present drug:  
□No            □Yes 
Deformity:  
□Hip          Left□       Right□ 
□Knee       Left□        Right□ 
□Ankle     Left□         Right□ 
Physio therapy programme: 
□No □Yes  Since (     ) 
□Improve             □Stable             □Worse 
If yes specify:  
□Ice □Stretching Exs           □Active Exs        □Positioning      
□Stretching Exs          
□Others (specify)                  
Gait:  
□Toe-to-toe         □Occasional heel-to-toe          □Heel-to-toe             
□Toe-to-heel 
□This patient will be included in this study. 
□This patients has been excluded from this study because of: 
□Fixed contracture      □Hemiplegic      □Previous drug     □Quadriplegic      
□Previous surgery       □Patients can not walk    □Sever mental retardation  
□Others…………………. 
Investigator:                                                      Date:                                   
                                                                                                                                         
 
   
 
 
Appendix 4 
 
The Gross Motor Function Measurement 
 
 
GMFM a standardised observational instrument designed and validated to 
measure the change in gross motor function over time in children with cerebral 
palsy.  The scoring key gives a general guideline. However, most of the items 
have specific descriptors for each score.  It is imperative that the guidelines in 
the manual are used for scoring each item.  
 
Scoring is based on a four- point scale for each item using the following key:  
0 = does not initiate  
1 = initiates  
2 = partially completes  
3 = completes  
NT = not tested 
 
   
“Does not initiate” applies when the child is unable to begin any part of the 
activity.    
“Initiates” (1) applies when less than 10% of the task is completed.  
“Completes,” (3) applies when the task is completed fully. 
“Not tested” is used when an item has not been administrated or when a child 
refused to attempt it.  (Russell et al 2002) 
The test includes 88 items grouped in five dimensions: (A) Lying and Rolling; 
(B) Sitting; (C) Crawling and Kneeling; (D) Standing; (E) Walking, Running, 
and Jumping.  
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
   
 
 
 
 
   
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
   
 
 
 
 
   
Appendix 5 
 
Tables to show in summary for the previous published work on the effect of 
BTX-A on children with cerebral palsy  
The papers are arranged in chronological sequence. 
 
   
 
Date & 
Author 
Design of the 
study 
Participants Outcome  Results Comment  
1993 
Koman et 
al 
 
Preliminary, 
open-label 
study. The 
first reported 
successes of 
use of  
BTX-A  
27 patients, 
dynamic 
deformities. 16 
ambulatory, 11 
more severe.  
1–2 U/kg BTX-
A/muscle group 
Physician 
Rating Scale 
subjective 
assessment by 
careers 
Spasticity 
significantly 
decreased after 
12-72 h after 
injection  
Delayed 
surgery. 
Reduces 
spasticity for 3–
6 months 
without major 
side effects 
Spasticity of the 
target muscles 
then gradually 
returned BTX-A 
may delay 
orthopaedic 
surgery 
1994 
Cosgrove 
et al 
 
 
Open-label 
study  
26 patients, 
BTX-A in 
gastro-soleus 
/tibialis/ 
posterior/hamstr
ings. Dynamic 
contractures 5–
28 U/kg body 
weight Dysport  
Sagittal-plane 
kinematics 
ROM  and 
electro-
goniometry 
Reduced tone , 
improved ankle 
kinematics with 
gains in 
dorsiflexion 
inversely 
proportional to 
the age of 
participant 
Fixed contractures 
develop gradually 
with age 
1994 
Koman et 
al 
 
Randomized 
double-blind 
placebo 
controlled, 
trial  
Small trial: 6 
children BTX-
A, 6 placebo  
1 U/kg BTX-
A/leg 
Physician 
Rating Scale for 
gait, muscle 
strength, 
physiotherapy 
career 
questionnaire 
83% BTX-A 
group versus 
33% placebo 
group showed 
improved gait 
BTX-An effective 
treatment for 
dynamic 
deformity; effects 
last 3–6 month. 
1996 
Sutherland 
et al 
 
Open-label 
prospective 
study  
3 years period  
26 children, 2-
16 years, 4 U/kg 
of BTX-A in L 
and R 
gastrocnemius,  
EMG,  
Gait analysis 
Significant 
improvements in 
dynamic ankle 
dorsiflexion in 
both stance and 
swing phases, 
stride length, 
and EMG of 
tibialis anterior.  
Future research 
should also 
compare BTX-A 
casting, orthotic 
devices, physical 
therapy, selective 
dorsal rhizotomy, 
and surgical 
lengthening.  
No complications  
1998 
Thompson 
et al 
 
Open-label,  
study, 
hamstring  
spasticity  
 
10 children with 
crouch gait 5–8 
U BTX-A 
/kg/muscle 35 
U/kg Dysport 
Hamstring 
length and 
excursion from 
computer model 
Increased 
muscle length 
with improved 
knee extension. 
Increased 
walking speed, 
pelvic tilt, and 
hip flexion 
Short hamstrings 
over-diagnosed in 
crouch gait 
1998 
Wong et al 
 
 
Open-label 
prospective 
study. Period 
of the study 
10-24 months  
17 children aged 
25-177 months.  
6 U/kg /child of 
BTX-A 
Video gait 
analysis,  
Electrogoniomet
ry, ambulatory 
state, modified 
Ashworth scale, 
and parental 
report.  
BTX-A is useful 
as an adjunctive 
therapy in 
ameliorating 
spasticity in CP 
children  
BTX-A is 
effective in 
younger ones. 
1999 
Boyd et al 
 
Open-label 
cohort study  
197 children 2–4 
U BTX-A 
/kg/muscle 
Response to 
BTX-A, time to 
next 
intervention 
Adverse effects 
55% later 
surgery, 45% 
repeated BTX-A 
80%, clinical 
responders with 
improved 
function 
BTX-A safe and 
effective 
   
 
1999 
Corry et al 
 
Open-label, 
study of 
hamstring 
spasticity  
 
10 children 
dynamic 
hamstring 
spasticity 5–8 U 
BTX-A/kg 6 
U/kg Dysport 
Muscle tone, 
range of 
movement, 3D 
kinematics 
Oxygen uptake 
Improved knee 
extension in 
stance; mean 
pelvic tilt 
increased. 
Energy cost of 
walking 
unchanged 
Longitudinal 
muscle growth 
occurs after BTX-
A injection 
1999 
Eames et al 
 
Open-label 
prospective 
study  
39 children, 
gastrocnemius 
injected. 8–10 
U/kg BTX-A or 
20–25 U/kg 
Dysport 
3D kinematics 
as measure of 
changes in 
gastrocnemius 
length 
Short-term 
muscle 
lengthening. 
Diplegia better 
response than 
Hemiplegia 
Need for 
orthopaedic 
surgery delayed 
1999 
Flett et al 
 
Randomised 
controlled 
trial, BTX-A 
vs serial 
casting 
One year  
20 children, 
Aged  
2-8 years  
10 BTX-A, 10 
placebo with 
dynamic calf 
tightness 4–8 
U/kg BTX-A  
Muscle tone, 
GMFM, ankle 
joint range of 
movement– gait 
Physician 
Rating Scale, 
parent 
satisfaction 
Questionnaire 
Improved gait, 
muscle tone, 
passive ankle 
dorsiflexion in 
both groups at 6 
months  
No significant 
difference in 
GMFM after 2, 
4 and 6 months. 
BTX-A and 
casting have 
similar effects, 
and costs. Parents 
preferred BTX-A. 
 
1999 
Heinen et 
al 
 
Open-label 
prospective 
study  
 
2 children with 
adductor 
spasticity No 
dose of BTX-A 
stated 
Tone, joint 
mobility, 
GMFM, parent 
questionnaire 
Improved 
function, 
positioning, gait 
and posture, 
facilitation of 
care 
Beneficial effects 
of BTX-A on 
daily activities 
1999 
Koman et 
al 
 
Open-label 
study  
 
48 patients 4–7 
U BTX-A/kg 
body weight 
Response to 
BTX-A: 
Physician 
Rating Scale, 
progression to 
surgery 
Improved gait 
and, function, 
sustained long 
term 
 
BTX-A delayed 
need for surgery 
 
1999 
Massin et 
al 
  
Open-label– 
prospective 
study  
15 children, 6 
U/kg BTX-A 
Energy cost of 
walking: oxygen 
uptake in 
response to 
exercise 
 
Reduced energy 
cost and 
improved 
endurance 
– 
1999 
Sutherland 
et al 
 
Double-blind 
placebo 
controlled 
trial  
20 children, 
gastroc soleus 
complex 
injected. 2–4 U 
BTX-A/kg body 
weight 
Gait studies with 
3D 
kinematics/kinet
ics, EMG 
Improvements 
in maximum 
dorsiflexion in 
both stance and 
gait. No 
significant 
differences in 
the EMG data in 
both groups 
Short-term 
efficacy of BTX-
A to improve 
1999 
Wissel et al 
 
Randomised 
Double blind, 
high dose vs 
low dose  
 
33 children, 
high dose: 40–
80 U BTX-A 
/muscle. Low 
dose: 20–40 U 
BTX-A/muscle 
Muscle tone, 
range of 
movement at 
knee and ankle, 
general gait 
parameters 
High dose gives 
better response,  
Greater 
functional 
benefit in 
younger 
children 
Dose-dependent 
functional 
improvement 
   
 
1999 
Yang et al 
 
Open-label 
prospective 
study  
 
38 children 28 
had BTX-A and 
10 in 
comparison 
group,  
GMFM, 
Physical Rating 
Scale  
Ashworth scale. 
BTX-A is 
effective 
treatment for 
reducing 
spasticity and 
improving gross 
motor function 
in CP children  
 
GMFM provides 
objective evidence 
regarding 
functional 
improvement after 
BTX-A 
2000 
Barwood et 
al 
 
Double-blind, 
randomised 
controlled 
trial  
clinical trail. 
12 month 
period 
 
16 patients 
undergoing hip 
adductor release 
surgery. age 
between 2-10 
years 8 U BTX-
A/kg body 
weight 
Pain scores, 
analgesia 
requirements, 
length of 
hospital stay 
Reduced: mean 
pain scores, 
analgesic 
requirements, 
length of 
hospital stay 
compared with 
the placebo,  
Significant 
proportion of 
post-op pain from 
muscle spasm 
relieved by BTX-
A 
2000 
Boyd et al 
 
Open-label 
prospective  
study 
25 children, 15 
diplegia, 10 
hemiplegia 4–9 
U BTX-
A/kg/muscle 
Muscle tone, 
ankle range of 
movement. 3D 
kinetics: ankle 
joint 
Improved 
patterns of ankle 
joint moment 
and power 
generation 
Change in 
functioning of 
muscle post BTX-
A 
 
2000 
Ubhi et al 
 
Randomised; 
double-blind, 
placebo 
controlled, 
trial  
40 children: 
aged 2-16 years 
22 BTX-A, 18 
placebo 
gastrosoleus 
injected 25 U/kg 
Dysport in 
diplegia, 15 
U/kg in 
hemiplegia 
Video gait 
analysis, 
GMFM, ankle 
dorsiflexion 
range 
Physiological 
Cost Index 
Improved gait 
and function in 
BTX-A group.  
GMFM showed 
a statistically 
significant 
improvement in 
walking after 
BTX-A after 12 
weeks. At 2,6 
weeks no 
significant 
changes.  
Effective 
adjunctive 
treatment to, 
improve spasticity 
and functional 
mobility. 
Intensive 
physiotherapy 
treatment blocks 
following BTX-A 
for long term 
benefit  
2001 
Bakheit et 
al 
 
Multicentre 
retrospective 
study  
758 patients 
undergoing. 
1594 treatments 
Dysport 
Adverse events 
from BTX-A 
Increased 
adverse effects 
with higher 
doses. 
Multilevel 
treatments give 
better response 
than single level 
Recommended 
maximum total 
dose 1000U 
Dysport 
2001 
Boyd et al 
 
Randomised 
study. 
1 year 
39 children Age 
2-5 years, 
Adductor and 
hamstring. 
Muscle, 4 –16 U 
BTX-A/kg,  
GMFM  
GMFCS 
Orthosis 
(SWASH) 
GMFM showed 
a similar 
improvement in 
both groups 
A longer-term 
follow up of a 
larger cohort may 
be required to 
determine the 
effect of the 
combined 
treatment on hip 
displacement. 
2001 
Linder et al 
 
 
Open-label, 
study, 
prospective 
study  
1 year  
25 children Age 
1.5-15.5 years, 
adductor spasm, 
or pes equinus 
12 U BTX-A/kg 
body weight 30 
U /kg Dysport 
GMFM, fine 
motor 
assessment, 
modified 
Ashworth scale, 
Improvement in 
joint mobility 
and reduction of 
spasticity, 
significant 
improvement of 
GMF Scores 
after 12 months 
GMFM 
improvement in 
younger 
children  
Improvement in 
GMFM is 
specifically 
related to BTX or 
represents at in 
part the natural 
course of motor 
development  
   
 
2002 
Baker et al 
 
Multi-centre, 
randomised 
double-blind 
placebo 
controlled 
study  
125 children 
with diplegic 
cerebral palsy 
and dynamic 
equinus 
spasticity 
during 
walking 
Patients 
randomised to 
receive 10, 20 
or 30 U/kg 
Dysport  
Electro-
goniometry, 
change in 
dynamic 
component of 
gastrocnemius 
shortening at 4 
weeks after 
injection 
Dynamic 
component of 
spasticity most 
improved in 
20U/kg group 
Recommended 
optimal starting 
dose 20 U/kg 
2002 
Fragala et al 
 
Multiple 
single-subject 
design study, 
over 12 
month period  
7 children, 3-
11 years, 9.5-
18 U/kg of 
body weight 
the dose 
depend on the 
child needed.  
PROM, 
Ashworth scale, 
Canadian 
occupational 
performance 
measure. 
(COPM-
performance 
Score), Parents 
satisfaction 
(COPM-
Satisfaction 
Score) 
All of the 
subjects 
demonstrated 
improvements in 
PROM or 
spasticity.  
Further studies 
evaluating the 
effectiveness of 
specific physical 
therapist 
intervention after 
BTX-A injection 
are also needed. 
2002 
Polak et al 
 
Double-blind  
comparison 
study  
 
48 CP 
children with 
spastic 
hemiplegia. 
High dose (24 
U/kg) versus 
low dose (8 
U/kg) 
Dysport  
 
Instrumented 
gait analysis, 
maximum ankle 
angle in stance 
and swing 
phases; 
gastrocnemius 
muscle length 
Optimal dose 
range between 
200 and 500 U 
with higher 
dose/kg more 
effective and 
longer lasting 
 
– 
2002  
Reddihough 
et al 
 
Cross-over 
study  
One year  
49 children 
with spastic 
diplegia/quadr
iplegia BTX-
A plus 
physiotherapy 
versus 
physiotherapy 
alone 
GMFM, fine 
motor 
assessment, 
modified 
Ashworth scale, 
parental 
perception 
ratings 
Unsustained 
improvements in 
gross motor 
function in both 
groups, small 
increase in fine 
motor ratings in 
BTX-A group. 
Parental ratings 
favoured BTX-
A 
Timing of formal 
assessments 
missed peak gross 
motor function 
response 
 
2003  
Bottos et al 
 
Randomised 
controlled 
trial, vs BTX-
A plus serial 
casting 
One year  
10 children, 
4-11 years, 
BTX-A 
injected 
bilaterally at 
multiple sites 
in the triceps 
sura 15-20 
U/kg in each 
muscle  
Ashworth scale, 
GMFM, fine 
motor 
assessment, 
modified, ROM 
range of motion 
measure, gait 
analysis, .EMG 
Spasticity 
decreased 
significantly at 1 
month in both, 
at 4 month, and 
12-month  
in-group 2 only. 
GMFM 
significantly 
improved at 4 
month for 
standing and 
walking.  
BTX-A reduces 
spasticity and 
improves function 
performance in 
standing and 
walking with 
casting provides 
more marked 
result. 
   
 
2004 
Glanzman et 
al 
 
Open-label 
prospective 
study  
24 month  
 
186 children 
37 treated 
with BTX-A, 
55 with 
casting, 86 
treated legs 
and 32 
received 
combined 
BTX-A with 
casting. .10-
12 U/kg of 
BTX Mean 
age 7 years  
ROM 
(goniometry), 
GMFCS, 
The combined 
group showed a 
significant 
increase in 
passive (ROM) 
of the ankle 
joint in 
comparison of 
BTX-Alone. 
Casting produced  
a significant 
increase in the 
ROM. More than 
BTX-A alone  
2006 
Mall  et al 
 
 
Multicentre, 
randomised 
double-blind 
placebo 
controlled 
study 
Study period 
3 months,  
61 children,  
aged between 
18 months –
10 years 30 
U/kg of BTX-
A. 
Ashworth scale, 
GMFM, 
GMFCS, 
GAS) Goal 
attainment 
Scale. 
GMFM failed to 
detect the 
superiority of 
BTX-A 
treatment at 
week 4 and 
week 12 
Most children 
with CP, 
reduction of 
adductor muscle 
tone with all its 
functional 
implication is 
achievable.  
 
 
